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For he was a shrub among the poplars 
Needing more roots 
More sap to grow to sunlight, 
Thirsting for sunlight, 
A low growth among the forest. 
Into the soul 
The selves extended their branches, 
Into the moments of each living hour, 
Feeling for audience 
Straining thin among the echoes; 
And out for the solitude 
Voice and soul with selves unite, 
Riding the echoes, 
Horsemen of the apocalypse; 
And crowned with one self 
The name displays its foliage, 
Hanging low 
A green cloud above the forest. 
   Christopher Ifekandu Okigbo 
    (Siren Limits II)
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The availability of an effective vaccine against Bordetella pertussis substantially reduced 
the morbidity and mortality from pertussis, however, in the last decade there appears to have 
been a substantial increase in pertussis cases as reported mainly in high income countries. 
Although it is believed that the greatest burden of pertussis, including deaths, is in low- and 
middle-income countries (LMICs), there seem to be little data available to back this up.  
 
 
This thesis set out to find data that will give some insight into the burden of pertussis in a 
low- and middle-income setting in infants and children with severe lower respiratory tract 
infection (LRTI). Given the paucity of data in LMICs, the thesis started by systematically 
searching for existing data that will give some indication of the possible extent of the 
pertussis problem in these countries. Secondly, a prospective study was conducted at a 
children’s hospital. As hospital admission is a marker of severe disease, these children were 
targeted as the appropriate population in which to meaningfully conduct a primary study on 
the burden of pertussis. In addition to quantifying the burden by describing the prevalence of 
confirmed pertussis in this group of children, the study set out to look for potential factors 
that may be associated with increased risk of pertussis.  LRTI are now commonly known to 
be associated with identification of multiple organisms in respiratory samples, this study 
aimed to also look at organisms that are detected with Bordetella pertussis; and investigate 
whether this association was in any way associated with severe disease or negative outcomes. 
Finally, this study hoped to identify clinical features that could be used to develop a more 
reliable clinical case definition of pertussis. 
 
Chapter 1 gives a background that justifies the undertaking of this study. In chapter 2 a 
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systematic review quantifies, using the best available data, the burden of pertussis in LMICs. 
Chapter 3 clarifies the methods briefly described in the rest of the manuscript. The burden of 
pertussis due to the two organisms known to cause the disease, Bordetella pertussis and 
Bordetella parapertussis, is described in some detail. In both this chapter and the earlier 
mentioned systematic review (chapter 2), the burden of pertussis is stratified by subgroups to 
identify potential risk factors. The issue of risk is formally and specifically taken up in the 
chapter that follows (chapter 5) where potential risk factors are analysed, and the independent 
impact for some of these factors is established. 
 
The last two results chapters (chapters 6 and 7) deal respectively with the conundrum of 
finding other respiratory organism in the same specimen with Bordetella pertussis and 
failure to find useful clinical criteria that can help with improved diagnosis of pertussis. 
While there is no established pattern noted between pertussis and most organisms, a few 
give signals of being independently associated with Bordetella pertussis even if the clinical 
relevance is not clear at the moment.  
 
In the final chapter of the thesis (chapter 8) I conclude the thesis by making an argument 
that although there are still knowledge gaps, the thesis gives a clear indication that pertussis 
remains a serious problem in LMICs especially for some groups that show increased risk of 
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Style and abbreviations 
 
The papers that have been included in this thesis comprise manuscripts submitted to both 
American and British journals. To maintain a sense of consistency through the thesis, all 
spellings in the manuscripts have been changed to comply with British English spellings, the 
spelling format most commonly followed in South Africa. The only exception to this has 
been in the included figures where the text within figures has been retained as submitted to 
the journals. Although all the journals to which manuscripts have been submitted use 
Vancouver referencing, they differ slightly in how the style is formatted. To maintain 
consistency throughout the thesis, a generic Vancouver style template has been adopted and 
applied throughout. In general, all the manuscripts that contribute to the various chapters 
have been reproduced in the thesis as submitted to the various journals. Each chapter 
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Epidemiology of pertussis 3 
According to the World Health Organization (WHO), there are more that 20 to 40 million 4 
annual cases of pertussis, and 300,000 associated deaths due to the disease; 90% of which 5 
are estimated to occur in low- and middle-income countries (LMIC) [1, 2]. Most 6 
morbidity and mortality is seen amongst unimmunised or incompletely immunised 7 
infants, who have more severe disease and are more likely to have complications.[3] 8 
Increasingly, pertussis is also recognised as an important cause of disease in adolescents 9 
and adults with waning immunity. Older individuals have less severe disease and fewer 10 
complications, but substantial economic costs are associated with unrecognised infection 11 
in these individuals who also serve as an important source of infection for non-immune 12 
infants. [4] 13 
 14 
Pertussis is a notifiable disease in South Africa (SA). Notification may be on clinical 15 
suspicion alone and does not require laboratory confirmation, but laboratory tests should 16 
be performed where available. At present there is no active surveillance for pertussis and 17 
the introduction of such surveillance is not currently a priority. Lack of surveillance is not 18 
a uniquely South African problem, most LMICs lack resources for surveillance.[4, 5] 19 
Only 60 cases of pertussis were notified to the Department of Health from January 2000 to 20 
September 2004, which is likely a substantial underestimate of the true prevalence of 21 
disease in South Africa. Anecdotal reports from concerned paediatricians and general 22 
practitioners indicate that the incidence of the disease is possibly much higher than the 23 




A retrospective folder review of children at the Red Cross War Memorial Children’s 26 
Hospital in Cape Town, South Africa revealed that 61 out  of  75 (81%) children with 27 
polymerase chain reaction confirmed (PCR) pertussis seen between 2008 and 2012 were 28 
never notified. [6]These were children who were ill enough to warrant an investigation by 29 
the attending physician. The epidemiology of pertussis in children presenting with less 30 
severe respiratory disease who do not warrant admission is still unknown and further 31 
study needs to be done in this regard.  32 
 33 
Pathogenesis 34 
Pertussis is an acute, communicable infection of the respiratory tract caused by Bordetella 35 
pertussis and occasionally by Bordetella parapertussis. Both organisms are strict human 36 
pathogens with most of the burden attributable to Bordetella pertussis.  Other Bordetella 37 
species have been known to cause human disease, but it is Bordetella holmesii that in 38 
addition to Bordetella pertussis and Bordetella parapertussis has been recognised as a 39 
cause of pertussis-like illness.[7] Pertussis is spread by droplets from person to person and 40 
patients are infectious from 7 days after exposure to 3 weeks after the onset of 41 
paroxysms.[8] The organism does not invade systemically but attach to ciliated epithelial 42 
cells of the airways causing ciliastasis, local tissue damage and interference with 43 
phagocytic cell functioning. Viscous secretions and sloughed cells may accumulate in the 44 
airways and cause obstruction. Complications include apnoea, bronchopneumonia, otitis 45 
media, atelectasis, pneumothorax, hypoxic seizures, encephalopathy, feeding difficulties, 46 
and vomiting. Pressure-related complications include rectal prolapse, petechiae, hernias, 47 
epistaxis, subconjunctival and intracranial haemorrhages.[4]  48 
 49 
Central to the pathogenesis are the many toxins that are produced by the organism.[9] The 50 
most important of these is the pertussis toxin that seems crucial in the pathogenesis of 51 
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severe disease and death.[10] Although Bordetella pertussis and Bordetella parapertussis 52 




Diagnosis of Bordetella pertussis illness in infants and young children is difficult as 57 
clinical presentation is variable and non-specific. Diagnosis is made on the basis of the 58 
clinical picture (mild cough, coryza and fever, progressing to paroxysmal cough, 59 
precipitated by crying, eating or drinking, “whooping”, vomiting, cyanosis, sweating, 60 
prostration and exhaustion).  61 
 62 
In the absence of access to laboratory confirmation, most low and-middle income 63 
countries rely exclusively on clinical criteria to diagnose pertussis. The two commonly 64 
used diagnostic criteria are those defined by WHO and the Centers for Disease Control 65 
and Prevention (CDC). Both WHO and CDC criteria include presence of a cough for at 66 
least 14 days characterized by one of paroxysms, inspiratory whoop or post-tussive 67 
vomiting.[11] In addition to the three clinical features CDC also includes presence of 68 
apnoea in its criteria.[12] Disease presentation may be modified by age, previous 69 
immunisation or infection, antibiotic exposure and concurrent infection with other 70 
pathogens. As a result, the presentation of pertussis is frequently atypical, especially in 71 
very young infants and adults. Supporting laboratory investigations are also important 72 
(leucocytosis and lymphocytosis, isolation of B pertussis from nasopharyngeal 73 
secretions).[13] 74 
 75 
A conference poster presentation of a review of PCR 115 confirmed pertussis cases from 76 
the area of Bloemfontein, South Africa, found a much shorter duration of cough (Median 77 
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6 days, interquartile range 3 -12days) that might not have met most clinical criteria for 78 
suspicion of pertussis disease. Lobar pneumonia was a finding in 62% of the patients in 79 
this cohort.[14] 80 
 81 
Culture of the organism, which has been regarded as the gold standard, is possible but 82 
difficult. Although culture is highly specific, it has poor sensitivity, particularly late in 83 
disease. Culture is most likely to be positive during the catarrhal phase (5 to 14 days from 84 
the onset of illness).[4] Most cases of pertussis are only recognised once they have a 85 
paroxysmal cough. Unfortunately - especially when classical case definitions based on 86 
long duration of cough symptoms are employed - the sensitivity of culture is very poor by 87 
the time the diagnosis is suspected. Sensitivity is higher in infants than in adolescents and 88 
adults and is influenced by quality and timing of specimen collection and laboratory 89 
expertise.[4] Specimens should include a properly performed nasopharyngeal aspirate or 90 
nasopharyngeal swab, ideally inoculated directly onto a suitable culture medium (e.g.: 91 
Regan Lowe medium) at the bedside. The organism is fastidious and grows slowly. 92 
Culture plates must be incubated for at least 7 days before reported negative. Culture 93 
allows for surveillance of antibiotic resistance and molecular epidemiological typing in 94 
outbreak situations.[4] 95 
 96 
PCR has greatly improved the ability to confirm pertussis cases and is increasingly used 97 
for diagnosis on clinical specimens. There are many advantages associated with the use of 98 
PCR: results are rapid, less dependent on delays in transport and even non-viable 99 
organisms may be detected. PCR targets include IS481, the common Bordetella target that 100 
includes Bordetella pertussis and IS1001 for Bordetella parapertussis. The qualitative 101 
PCR using these gene targets can be performed on a nasopharyngeal swab (Dacron not 102 
calcium alginate swabs as the latter may inhibit PCR) and/or aspirate specimens. The 103 
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IS481 target is also found in other Bordetella species such as Bordetella holmesii and 104 
Bordetella brochiseptica.[15] IS481 is therefore not specific to Bordetella pertussis. A 105 
published study demonstrated that up to 20% of patients initially diagnosed as pertussis 106 
using the IS481 target were in fact Bordetella holmesii infected[16]. If IS481, a target 107 
with high sensitivity is used to screen cases, it remains important to test the positive 108 
specimen further for the presence of pertussis toxin promoter gene sequences, as these are 109 
specific for Bordetella pertussis.[15] Ideally two targets should be used for diagnostic 110 
consensus. The sensitivity of PCR is highest earlier in the course of disease and declines 111 
with time from the onset of symptoms. PCR is more sensitive than culture and remains 112 
positive even once treatment is commenced. It is therefore still useful for persons 113 
presenting as late as three weeks since onset of illness.[17] 114 
 115 
In a prior unpublished study[18] to compare a standard nested PCR and a LightCycler-116 
based real-time assay with culture for confirming the diagnosis of pertussis, 48 children 117 
presenting to Red Cross War Memorial Children’s Hospital with clinical features of 118 
pertussis were sequentially enrolled, nasopharyngeal aspirates were collected, and 119 
inoculated onto charcoal agar for isolation of Bordetella pertussis. The identity of colonies 120 
morphologically resembling B. pertussis was confirmed by amplification of the pertussis 121 
toxin promoter gene (ptxA-Pr). A nested PCR assay targeting the IS481 sequence was 122 
performed directly on the NPA samples. In addition, a real-time PCR assay for detection 123 
of the pertussis toxin promoter gene was performed on all samples. Bordetella pertussis 124 
was cultured from five (10%) patients. However, the nested PCR assay for IS481 was 125 
positive in 31 (65%) patients, and the toxin promoter gene was present in 17 (55%) of 126 
these 31. No patient with a negative IS481 assay was culture positive or PCR positive for 127 
the toxin promoter. These initial results suggest that PCR is a more sensitive method of 128 
detecting Bordetella pertussis than culture. But it also shows that ptxA-Pr, even though 129 
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more specific for Bordetella pertussis, may lack the requisite sensitivity for case 130 
confirmation. In the absence of double assays, PCR for the IS481 target, even though less 131 
specific, may offer the best diagnostic confirmation support for clinically suspected cases 132 
of pertussis. 133 
 134 
Serological diagnosis using ELISA is available, quick and easy to perform in the 135 
laboratory. As the measured response is uses antibodies against common vaccine 136 
components, in patients recently vaccinated, it is not easy to distinguish between acute 137 
infection and recent infection on a single serum sample.[19] Acute and convalescent 138 
paired sera can be taken and the change in titres used for diagnostic purposes. Serology 139 
suffers a number of drawbacks: only anti-PT (pertussis toxin) serology has been well-140 
standardized and validated, and only anti-PT IgG ELISA testing is recommended for use 141 
in the diagnosis of pertussis. Appropriate cut-offs have not yet been determined in many 142 
instances, making interpretation, especially for unpaired testing, difficult. IgG titres need 143 
to be interpreted in the context of a diagnostic cut-off determined by local sero-144 
epidemiological surveys. A recommendation for considering anti-PT IgG titres between 145 
50—120 international units per millilitre (IU/ml) as highly suggestive of recent pertussis 146 
has been proposed by a collaboration of European laboratories, but this is based on sero-147 
epidemiological surveys in Western Europe.[20] No sero-epidemiological data exists for 148 
SA or other countries in Sub-Saharan Africa from which we could infer appropriate cut-149 
off levels; this limits the usefulness of such tests in our setting at present. 150 
Direct fluorescent antibody tests for direct antigen detection have poor sensitivity and 151 
specificity and should not be relied on.[21] 152 
 153 
The current recommendation from the South African National Institute of Communicable 154 
Disease (NICD) is that suspected cases of pertussis in South Africa (SA) should have the 155 
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following tests performed for detection of B. pertussis: 156 
• ideally: a nasopharyngeal swab or aspirate for PCR detection of B. pertussis. 157 
• a nasopharyngeal swab or aspirate for culture of B. pertussis if PCR testing is not 158 
feasible or available. [22] 159 
 160 
The advantages and disadvantages of the available diagnostic methods are summarised in 161 
Table 1 [22]. 162 
 163 
Table 1: Comparison of diagnostic methods for Bordetella pertussis 
Method Advantage Disadvantage 
Culture Highly specific – if positive it confirms the 
diagnosis. Can be done by most diagnostic 
microbiology laboratories pro- vided media 
and SOPs are available for processing. 
Relatively cheap. 
Poor sensitivity – highest in first two weeks 
(catarrhal phase) and is reduced following 
treatment. Higher sensitivity for infants than 
for adolescents and adults. Requires 
selective media and prolonged incubation (at 
least 7 days). Ideally culture medium 
should be inoculated at the bed- side. 
Molecular techniques (PCR) Highly sensitive. Can detect B. 
pertussis DNA even after treatment has 
commenced and remains positive late in the 
disease (≤3 weeks). Rapid results.      At      
present     the 
recommended diagnostic test of choice if 
available. 
Specificity can be a problem. 
False positives do occur especially if only a 
single target PCR is used e.g. IS481. Requires 
molecular expertise and equipment. Relatively 
expensive. 
Serology Relatively cheap and rapid test. Only useful if a standardized anti- 
PT IgG ELISA test is used (other antibodies 
lack sensitivity and specificity); even then, 
local cut- offs have not been determined. 
Serology can NOT be used for diagnosis of 
pertussis in children or adults who have 
received acellular pertussis vaccine in the 
previous year, if not longer. 
Not recommended alone for routine 
diagnosis. 
Direct fluorescent antibody detection (DFA Rapid results. Poor sensitivity and specificity - many false 
negatives and false positives. Slides are 
difficult to interpret and prone to reader 
error. No longer recommended 
for routine diagnosis. 
 164 
Accurate diagnosis of pertussis is important for the timely institution of optimal treatment 165 
(a macrolide antibiotic) and infection control measures, especially in-hospital, and for 166 
appropriate treatment of household contacts. 167 
 168 
Recent evidence has shown that the finding of a pathogen or pathogens in respiratory 169 
specimens does not always indicate a causal relationship. Organisms whose presence used 170 
to be regarded as being of pathogenic significance are now found in otherwise healthy 171 
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subjects using new more sensitive molecular diagnostic tests. This has highlighted the 172 
importance of the use of controls in studies looking at aetiological causes of respiratory 173 
disease.[23] 174 
 175 
Pertussis vaccine 176 
The availability of an effective vaccine against Bordetella pertussis since the 1940’s has 177 
substantially reduced the morbidity and mortality from this disease, preventing an 178 
estimated 760 000 deaths annually. In many countries the original whole cell vaccine (wP) 179 
has since been replaced by various formulations of the acellular vaccine (aP). However, 180 
despite adequate vaccine coverage in many parts of the world, pertussis continues to 181 
contribute a substantial burden of disease in un-immunised infants and increasingly 182 
recognised infection and/or disease in adolescents and adults.[24] In the last decade there 183 
appears to have been a substantial increase in pertussis cases amongst immunised 184 
populations. The reasons for this are not fully elucidated but are in part due to improved 185 
case detection and laboratory diagnostic procedures.[25] Recent evidence indicate that due 186 
to the immune responses that aP vaccines induce that involve largely Th2 responses, they 187 
may be less effective than wP vaccines that induce Th1 and Th17 responses. In addition, 188 
the duration of protective immunity induced by aP vaccines is shorter than that induced by 189 
wP.[26] South African infants were routinely immunised with the whole cell vaccine at 6, 190 
10 and 14 weeks and boosted at 18 months of age as part of the National Expanded 191 
Program on Immunisation (EPI) until April 2009 when this was changed to aP.[21]  192 
 193 
In the Western Cape Province of South Africa, vaccine coverage in 2005 was found to be 194 
80%, 77% and 48% for vaccines due by 14 weeks, 9 months and 18 months respectively. 195 
Thus, a substantial number of children did not receive their early vaccines, while a large 196 
proportion of children did not receive full courses of Diphtheria, Pertussis, Tetanus (DPT) 197 
 
24 
and measles vaccines. Children in the Boland region were significantly less likely to have 198 
received vaccines due by both 14 weeks and 9 months compared to those in the Cape 199 
Town Metro region.[27] Another study found vaccine coverage rates of 100%, 99% and 200 
94% at 6, 10 and 14 weeks respectively in the Paarl area of the Western Cape between 201 
2006 and 2008.[28] In another study, vaccine coverage had declined to 53% by the time of 202 
the pertussis vaccine booster dose at 18 months.[29] There are not available reliable and 203 
recent data – a survey is currently underway to collect this data. 204 
 205 
The relative effectiveness of the vaccine in HIV-infected and HIV-exposed but uninfected 206 
infants and children compared to HIV unexposed children is uncertain. In one 207 
Cameroonian study, levels of antibodies against pertussis fimbrial antigens were 208 
substantially lower in HIV-infected than in HIV-exposed but uninfected children and there 209 
was a high risk of low antibody levels in response to the DTwP vaccine in those HIV-210 
infected children with severe immunodeficiency (CD4 T-cell level, <25%).[30, 31] The 211 
concentrations of antibodies induced by the DTwP vaccine were lower in HIV-infected 212 
children than in uninfected children. Likewise the quality and duration of immunity to 213 
pertussis in HIV infected children once they are started on HAART is uncertain.[32] In a 214 
cohort study conducted in Khayelitsha, Western Cape Province, South Africa that 215 
included a review of antibodies against pertussis, the authors concluded that “Among 216 
South African infants, antenatal HIV exposure was associated with lower specific 217 
antibody responses in exposed uninfected infants compared with unexposed infants at 218 
birth, but with robust responses following routine vaccination.”[33] 219 
 220 
Surveillance Challenges  221 
Potential obstacles to surveillance include a lack of standardised clinical case definitions, 222 
making inter-country comparisons difficult, a lack of accurate diagnostic facilities for 223 
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confirmation of Bordetella pertussis in many developing countries (only two public health 224 
laboratories currently offer the PCR diagnostic in South Africa), inadequate recognition 225 
and reporting of cases by health care workers, particularly in adults and adolescents, and 226 
the fact that passive notification systems significantly underestimate disease burden.  227 
 228 
Rationale for the study 229 
 230 
Hypothesis 231 
We hypothesised that a substantial number of cases of severe childhood acute respiratory 232 
infection in a South African hospital were due to Bordetella pertussis and Bordetella 233 
parapertussis infection. 234 
 235 
The aims: 236 
1. To determine the burden of pertussis in infants and children with severe LRTI  237 
2. To determine factors that are associated with increased risk of pertussis in children 238 
with severe LRTI. 239 
3. To determine the prevalence and type of respiratory co-infection in children 240 
infected with confirmed pertussis 241 
4. To develop a reliable clinical case definition of pertussis. 242 
5. To conduct a systematic review of the epidemiological patterns of confirmed 243 
pertussis in low- and middle-income countries since the inception of EPI in 1974. 244 
 245 
A brief description of the cohort of participants used to answer the aims of the thesis 246 
 247 
From September 2012 the study recruited children admitted for a lower respiratory tract 248 
infection to the acute admission ward of the Red Cross War Memorial Children’s Hospital 249 
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in Cape Town, South Africa. The children were sequentially enrolled to a maximum of 250 
four children per day over a full one-year period.  Inclusion criteria were WHO-defined 251 
age-specific tachypnoea or lower chest indrawing, apnoea.  The children were less than 13 252 
years (the age limit for children coming to the hospital). Children could only be enrolled if 253 
parents were willing to sign informed consent. 254 
 255 
We excluded participants if they had a previous admission to a health care facility in the 256 
preceding two weeks. The reason for this was to minimise health care-associated infection 257 
as study wanted primarily to assess community acquired pertussis.  258 
 259 
A detailed history and clinical examination were done, especially noting the presence of 260 
cough, apnoea, duration of symptoms and use of antibiotics prior to admission. History of 261 
HIV exposure, infection and where relevant, antiretroviral treatment (ART) were 262 
recorded. Information on immunisation was abstracted from the Road to Health Card 263 
(RTHC), and the date and type of each vaccine recorded. The RTHC is a standardized 264 
national record for each child.  265 
 266 
HIV testing was done as appropriate for the age of the child and the children’s status 267 
classified accordingly. Specific descriptions of both testing and classification appear in 268 
each chapter where this is relevant. 269 
 270 
Two nasopharyngeal (NP) swabs followed by an induced sputum (IS) specimen were 271 
collected from each child and sent to the laboratory for both culture and PCR testing for 272 
pertussis. In addition, a multiplex PCR for other respiratory pathogens was also 273 
performed. As with HIV, descriptions of specific tests used, and their interpretations 274 




As we also needed to assess the risk of pertussis posed by a close family member carrying 277 
B. pertussis in their nasopharynx, the caregiver bringing the child was also enrolled for the 278 
study. As with the child, the caregiver’s previous medical history (including HIV related 279 
data) and history of recent symptoms were taken. An NP sample was taken from the 280 
caregiver to be likewise tested for pertussis. 281 
 282 
The study enrolled 460 child-caregiver pairs into the study. The data collected from these 283 
enrolled participants were used to answer Aims 1 to 4 of the thesis as stated above. Brief 284 
composition of the recruited participants is shown in Table 2. 285 
 286 









< 2 months old  41 (8.9) 
≥ 2 months old  419 (91.1) 
Median (interquartile range)  7.8 (3.6-17.8) months 
Range   3.9 weeks - 12.7 years 
   
Gender  
 
Female  202 (43.9) 
Male   258 (56.1)  
 
 
Number of samples   
 
Nasopharyngeal Swabs  460 (100.0) 










Median (Interquartile range)  28 (24 - 33) years 
Range  15 - 52 years  
 
 
Relationship to child  
 
Mother  450 (97.8) 
Father   2 (0.4) 
Grandmother  5 (1.1) 
Other  3 (0.7) 






Outline of the thesis 290 
 291 
General statement on the structure of the thesis 292 
With the exception of Chapter 1, the introduction chapter, and Chapter 7, the conclusion 293 
chapter, all the chapters in the thesis take the form of manuscripts that are either 294 
published (in the case of Chapter 3) or undergoing peer review in various journals. Each 295 
chapter contains its own literature review, methods and discussion sections, each relevant 296 
to the specific aim of the thesis addressed by that chapter. As a result, the thesis does not 297 
contain standalone literature review, methods, or discussion chapters. The thesis does 298 
however contain a systematic review and metanalysis as detailed below. In addition, the 299 
thesis has a short conclusion chapter, highlighting the findings of the thesis. 300 
 301 
Each aim is dealt with separately in its own chapter with only the data necessary to 302 
answer the aim specified for each chapter utilised as required in each instance. As a 303 
result of this approach, numerators and denominators as well as summarised data, are 304 
not always the same across all chapters, even when involving the same variables. This is 305 
not an error. As an example, Chapter 3 which answers Aim 1 of the thesis includes both 306 
Bordetella pertussis and Bordetella parapertussis confirmed cases in its numerator and 307 
all 460 children in its denominator while Chapter 4, which is concerned with the risk of 308 
pertussis due to Bordetella pertussis, and thus uses only confirmed Bordetella pertussis 309 
its numerator to allow for comparison with other studies. Similarly, in Chapter 6, the 310 
data of the few children above 9 years of age are excluded as they fell outside the ranges 311 






Chapter 1  316 
The background, rationale and outline of the thesis is presented. In the background, 317 
the burden of pertussis is briefly described in the context of its changing epidemiology, 318 
diagnostic and notification challenges, as well as vaccine coverage. South African 319 
specific data is highlighted, indicting paucity thereof. In addition, a brief summary of 320 
the methods and the participants is given. The chapter also includes an outline of the rest 321 
of the chapters in the thesis. As each chapter contains its own literature review, the 322 
chapter does not contain extensive literature review, but only what is essential to 323 
establish grounds for this research. 324 
 325 
Chapter 2  326 
The chapter contains a formal systematic review on the burden of pertussis in LMICs. 327 
The prevalence of pertussis is described stratified by geographic location, diagnostic 328 
method, age categories as well as the period over which the cases were detected. The 329 
chapter highlights the high case fatality rate in young infants as well as the increased 330 
risk of pertussis burden posed by HIV infection and in utero exposure to HIV.  The 331 
systematic review describes both laboratory-confirmed Bordetella pertussis and 332 
Bordetella parapertussis. 333 
 334 
Chapter 3 335 
In this chapter, the burden of pertussis in children admitted with acute lower respiratory 336 
tract infections as defined by WHO is described.  The chapter highlights the shorter 337 
duration of symptoms at the time of diagnosis and describes an increased yield in 338 
confirmed cases secondary to the use of a second specimen collected following induced 339 
sputum. Also noted in this study is association of high risks of pertussis with HIV 340 
exposure and infection.  341 
 
30 
Chapter 4 342 
In this chapter, factors that flagged as potential risk factors in the previous 343 
descriptive chapter are taken up and analysed further in more detail. A major 344 
finding reported in this chapter is the high risk of confirmed pertussis in children whose 345 
mothers have Bordetella pertussis isolated from a nasopharyngeal specimen. In 346 
addition, the study analyses further the association with both HIV infection as well as 347 
in-utero exposure to HIV uninfected children noted in the previous chapter by 348 
quantifying the level of risk and establishing independence of risk. Additionally, the 349 
study confirms in this African study, the well-known increased risk to pertussis 350 
associated with incomplete immunisation, early infancy and poor nutritional status. 351 
 352 
Chapter 5 353 
The manuscript deals with bacterial and viral co-infections that occur with 354 
pertussis. Here we describe the frequency of specific viral and bacterial 355 
organism that are found in the lower respiratory tract of children investigated for 356 
pertussis. The analysis includes correlating confirmed pertussis with the overall 357 
number of coexisting potential pathogens as well as assessing the association 358 
between pertussis and specific organisms. The importance of associated 359 
respiratory pathogens detected with Bordetella pertussis are analysed with 360 
respect to severity of respiratory symptoms.   361 
 362 
Chapter 6 363 
This manuscript assesses the sensitivity and specificity of clinical features compared to 364 
PCR as reference standard in the diagnosis of pertussis. The chapter shows the poor 365 
diagnostic accuracy of clinical case definitions and the limitation of these in both 366 
clinical use and surveillance of pertussis. The addition of lymphocytosis to clinical 367 
definitions is shown to be of limited value in improving diagnostic accuracy. 368 
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Chapter 7  369 
As all relevant discussions are contained in each manuscript chapter, this is a short chapter 370 
that reflects on findings and conclusions of the thesis. The chapter discusses the significance 371 
of the findings from the systematic review and the four chapters reporting results from the 372 
primary study. The resurgence of pertussis, highlighting the high mortality in young infants 373 
and identified risk factors for pertussis are reflect on. The discussion brings into focus the 374 
need for more awareness and need for improved diagnosis of pertussis. Finally, the focus 375 
falls on the need for improved immunisation programs to control pertussis, especially 376 
targeting high risk groups in the population. 377 
 378 
Appendices: The following three documents have been appended to the end of the thesis: 379 
Appendix A: Informed consent form 380 
Appendix B: Ethical approval HREC 371/2011 381 
Appendix C: Case Report Form 382 
 383 
Author contributions to included manuscripts 384 
 385 
The contributions to the manuscripts have been endorsed by my co-supervisors, 386 
Professors Heather Zar and Gregory Hussey. All six manuscripts (published or under 387 
review) have been approved by the University of Cape Town (UCT) doctoral degrees 388 
board and UCT Vice chancellor as being appropriate for inclusion in the thesis as per 389 
UCT policy. Permissions to include these manuscripts have be sought from and granted by 390 
each of the co-authors involved in each manuscript. 391 
 392 
1. The burden of laboratory confirmed pertussis in low- and middle-income countries 393 
since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a 394 
systematic review and metanalysis. Muloiwa R, Kagina BM, Engel ME, Hussey 395 
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[Under review BMC Medicine] 396 
 397 
Building on the published study protocol, I implemented the literature search strategy, 398 
extracted the data and analysed it. B. Kagina assisted with the quality assurance required 399 
for a systematic review study as per the study design and protocol. I analysed the data and 400 
drafted the first manuscript. M. Engel reviewed the statistical analysis plan and results. G. 401 
Hussey supervised all the aspects of the design and in the editing of the manuscript. The 402 
final manuscript was approved by all the authors. This manuscript addresses Aim 5 of the 403 
thesis. 404 
 405 
2. Incidence and Diagnosis of Pertussis in South African Children Hospitalised With 406 
Lower Respiratory Tract, Muloiwa R, Dube FS, Nicol MP, Zar HJ, Hussey GD. The 407 
Pediatric infectious disease journal 2016; 35(6): 611-6. 408 
 409 
I did the epidemiology study design for  the project, including the analysis plan. G. 410 
Hussey sourced the funding for the study. I managed the field data collection supervised 411 
by H. Zar. F. Dube did the laboratory analysis of the specimens under supervision of M. 412 
Nicol.  I did all the data analysis and wrote the first draft of the paper, integrating 413 
contributions from the co-authors. H. Zar and G. Hussey co-supervised the writing. All 414 
authors provided contributions to the published manuscript. This manuscript talks to 415 
Aim 1 of the thesis. 416 
 417 
3. Impact of HIV status and maternal carriage on risk of childhood Bordetella 418 
pertussis disease.  Muloiwa R, Dube FS, Nicol MP, Hussey GD, Zar HJ [Under review 419 
Plos One] 420 
 421 
I designed the analysis plan to answer the question addressed by this manuscript using 422 
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the laboratory data supplied by F. Dube under supervision of M. Nicol.  I did all the 423 
data analysis and wrote the first draft of the paper, integrating contributions from the 424 
co-authors. H. Zar and G. Hussey supervised and reviewed the manuscript. All authors 425 
provided contributions to the published manuscript. The manuscript answers to Aim 2 of 426 
the thesis. 427 
 428 
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hospitalised with lower respiratory tract infection. Muloiwa R, Dube FS, Nicol MP, 430 
Hussey GD, Zar HJ [Under review Scientific Reports] 431 
 432 
I designed the analysis plan to answer the question addressed by this manuscript using 433 
the laboratory data analysed by F. Dube under supervised by M. Nicol.  I did all the 434 
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co-authors. H. Zar and G. Hussey supervised and reviewed the manuscript. All authors 436 
provided contributions to the published manuscript. This manuscript address Aim 3 of 437 
the thesis. 438 
 439 
5. Diagnostic limitations of clinical case definitions of pertussis in infants and children 440 
with severe lower respiratory tract infection. Muloiwa R, Nicol MP, Hussey GD, Zar 441 
HJ [Under review Plos One] 442 
 443 
I designed the analysis plan to answer the question addressed by this manuscript. I did 444 
all the data analysis and wrote the first draft of the paper, integrating contributions from 445 
the co-authors. M Nicol reviewed the manuscript while the final supervision was done 446 
by H. Zar and G. Hussey. All authors provided contributions to the published 447 
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Background: An effective vaccine against Bordetella pertussis was introduced into the 40 
Expanded Programme on Immunisation (EPI) by WHO in 1974; leading to substantial 41 
global reduction in pertussis morbidity and mortality.  In Low and Middle-Income 42 
Countries (LMICs), however, the epidemiology of pertussis remains largely unknown. 43 
This impacts negatively on pertussis control strategies in these countries. This study aimed 44 
to systematically and comprehensively review published literature on the burden of 45 
laboratory-confirmed pertussis in LMICs over the 45 years of EPI.  46 
 47 
Methods: Electronic databases were searched for relevant literature (1974 to December 48 
2018) using common and MeSH terms for pertussis. Studies using PCR, culture or paired 49 
serology to confirm Bordetella pertussis and parapertussis in symptomatic individuals 50 
were included if they had clearly defined numerators and denominators to determine 51 
prevalence and mortality rates.  52 
 53 
Results:  Eighty-two studies (49 167 participants) made the inclusion criteria. All six 54 
WHO regions were represented with most of the studies published after 2010 and 55 
involving mainly upper-middle income countries ((n=63; 77%). PCR was the main 56 
diagnostic test after the year 2000. 57 
 58 
The overall median point prevalence of PCR-confirmed Bordetella pertussis was 11% 59 
(Interquartile range, 5-27%), while culture-confirmed was 3% (IQR 1-9%) and paired 60 
serology a median of 17% (IQR 3-23%) over the period. On average, culture 61 
underestimated prevalence by 85% (RR=0.15, 95% CI, 0.10-0.22) compared to PCR in 62 
the same studies. 63 
 
 38 
Higher proportions of pertussis were associated with HIV exposure [RR, 1.4 (95% CI, 64 
1.0-2.0)] and infection [RR, 2.4 (95% CI, 1.1-5.1)]. HIV infection and exposure were 65 
also related to higher pertussis incidences, higher rates of hospitalisation and pertussis 66 
related deaths.  67 
 68 
In studies reporting deaths, the case fatality rate was 6.5% (95% CI, 4.0-9.5%). Most 69 
deaths occurred in infants less than six months of age. 70 
 71 
Conclusions: Despite widespread use of pertussis vaccines, prevalence of pertussis 72 
remains high in LMIC over the last three decades. There is a need to increase access to 73 
PCR based diagnostic confirmation in order to improve surveillance. Disease control 74 
measures in LMICs must take into account the persistent significant infant mortality and 75 
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Pertussis is a highly infectious respiratory illness caused by Bordetella pertussis or 92 
Bordetella parapertussis. The World Health Organization (WHO) estimates that 90% of 93 
the 20 to 40 million annual cases of pertussis, and 300,000 associated deaths due to the 94 
disease, occur in low and middle-income countries (LMIC) [1, 2]. While there are good 95 
surveillance data to support the re-emergence of pertussis in High Income Countries 96 
(HICs), the disease trends are unknown in LMICs due to paucity of epidemiological data 97 
in these settings [3, 4]. A non-systematic review of available data for the African 98 
continent was published recently by the Global Pertussis Initiative (GPI).[5] 99 
 100 
The high HIV prevalence estimates in LMICs coupled with suboptimal vaccines uptake 101 
are modifiable risk factors that can fuel pertussis epidemics in these settings [6, 7]. The 102 
pertussis resurgence reported lately in HICs, has resulted in the review of disease control 103 
strategies in these countries [3, 8]. A review of existing pertussis control programs in 104 
LMICs is yet to be undertaken.   105 
 106 
The availability of an effective vaccine against Bordetella pertussis since the 1940s has 107 
led to a substantial global reduction in the morbidity and mortality caused by pertussis [9]. 108 
In 1974, WHO included the whole cell vaccine (wP) in the Expanded Programme on 109 
Immunisation (EPI) adopted in several countries. Although wP is still widely used in 110 
many LMICs, many HICs have replaced wP with various formulations of the acellular 111 
vaccine (aP) [10]. Epidemiological data from HICs show that despite high vaccine 112 
coverage with aP, the pertussis burden has increased in non-immunised, partially-113 
immunised infants, as well as in previously immunised adolescents and adults [3, 8, 11-114 
13]. The reported pertussis resurgence has been linked to several factors such as reduced 115 
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efficacy of aP vaccines, genetic evolution of the pertussis bacteria as well as improved 116 
diagnosis and reporting of the disease [4]. 117 
 118 
A sound understanding of trends in the burden of pertussis is required to assess the impact 119 
of current pertussis control strategies as well as to decide on future policy. We conducted 120 
a comprehensive systematic review to address the knowledge gap in the longitudinal 121 
epidemiology of pertussis in LMICs for the 45 years starting in 1974 to 2018, inclusive.  122 
Primarily, our systematic review aimed to review available published literature on the 123 
prevalence and/or incidence of laboratory confirmed pertussis in LMICs since the 124 
inception of the EPI and to determine the trend in the burden of pertussis in LMICs from 125 
1974. For secondary objectives, we sought to determine the mortality and case fatality 126 
rates ascribed to pertussis in LMICs as well as to investigate the impact of vaccine choice 127 
(wP or aP), and HIV infection and in utero exposure on the burden of pertussis in LMICs 128 




Search strategy and criteria for selecting studies 133 
The protocol for the systematic review was registered with PROSPERO International 134 
Prospective Register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO), with 135 
registration CRD42015015159. The methods employed in conducting this review have 136 
been previously published [14]. The following electronic databases were searched for 137 
qualifying literature:  MEDLINE, Scopus, Africa-Wide, PDQ-Evidence, WHOLIS, 138 
CINAHL , CENTRAL and Web of Science. Search terms used included “pertussis,” 139 
“Bordetella pertussis”, “Bordetella parapertussis,” and “whooping cough” combined with 140 
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“burden”, “epidemiology”, “incidence”, “prevalence”, and “case”. These were used 141 
together with the specific names of all LMICs as classified by the World Bank [15, 16]. 142 
The search strategy as used in MEDLINE via Pubmed is shown in Table 1. The search 143 
was carried out in April 2015, March 2018 and updated in January and April 2019. The 144 
World Bank groupings reflect the status at last search. 145 
 146 
Table 1:  Strategy used to search for literature in MEDLINE (Via Pubmed) 
Query No. Search term 
#1 Pertussis (MeSH) OR whooping cough (MeSH) 
#2 Bordetella pertussis OR B. pertussis OR Bordetella parapertussis OR B. parapertussis 
#3 #1 OR #2 
#4 Burden OR epidemiology OR incidence OR prevalence OR case* 
#5 #3 AND #4 
#6 (Afghanistan OR Albania OR Algeria OR American Samoa OR Angola OR Armenia OR Armenian Azerbaijan OR 
Bangladesh OR Belize OR Benin OR Byelarus OR Byelorussian OR Belarus OR Belorussian OR Belorussia OR Bhutan 
OR Bolivia OR Bosnia OR Herzegovina OR Hercegovina OR Botswana OR Republic of Botswana OR Brazil OR Brasil 
OR Bulgaria OR Burkina Faso OR Burkina Fasso OR Upper Volta OR Burundi OR Urundi OR Cambodia OR Khmer 
Republic OR Kampuchea OR Cameroon OR Cameroons OR Cameron OR Camerons OR Cape Verde OR Cabo Verde OR 
Central African Republic OR Chad OR China OR Colombia OR Comoros OR Comoro Islands OR Comores OR Mayotte 
OR Congo OR Republic of Congo OR Zaire OR Costa Rica OR Cote d'Ivoire OR Ivory Coast OR Cuba OR Djibouti  OR 
French Somaliland OR Democratic Republic of Congo OR DRC OR Zaire OR Dominica OR Dominican Republic OR 
East Timor OR East Timur OR Timor Leste OR Ecuador OR Egypt OR United Arab Republic OR El Salvador OR Eritrea 
OR Equatorial Guinea OR Ethiopia OR Fiji OR Gabon OR Gabonese Republic OR Gambia OR Georgia Republic OR 
Georgian Republic OR Georgia) 
#7 (Ghana OR Gold Coast OR Greece OR Grenada OR Guatemala OR Guinea OR Guinea-Bissau OR Guiana OR Guyana OR 
Haiti OR Honduras OR India OR Maldives OR Indonesia OR Iran OR Iraq OR Jamaica OR Jordan OR Kazakhstan OR 
Kazakh OR Kenya OR Kiribati OR Korea OR Kosovo OR Kyrgyzstan OR Kirghizia OR Kyrgyz Republic OR Kirghiz OR 
Kirgizstan OR Lao PDR OR Laos OR Lebanon OR Lesotho OR Basutoland OR Liberia OR Libya OR Macedonia OR 
Madagascar OR Malagasy Republic OR Malaysia OR Malaya OR Malay OR Sabah OR Sarawak OR Malawi OR 
Nyasaland OR Mali OR Marshall Islands OR Mauritania OR Mauritius OR Agalega Islands OR Mexico OR Micronesia 
OR Moldova OR Moldovia OR Moldovian OR Mongolia OR Montenegro OR Morocco OR Ifni OR Mozambique OR 
Myanmar OR Myanma OR Burma OR Namibia OR South-West Africa OR Nauru OR Nepal OR Nicaragua OR Niger OR 
Nigeria OR Pakistan OR Palestine OR Papua New Guinea OR Paraguay OR Peru OR Philippines OR Philipines OR 
Phillipines OR Phillippines OR Romania OR Rumania OR Roumania) 
#8 (Rwanda OR Ruanda OR Saint Kitts OR St Kitts OR Nevis OR Saint Lucia OR St Lucia OR Saint Vincent OR St Vincent 
OR Grenadines OR Samoa OR Samoan Islands OR Navigator Island OR Navigator Islands OR Sao Tome OR Sao Tome 
and Principe OR São Tomé OR Senegal OR Serbia OR Montenegro OR Sierra Leone OR Sri Lanka OR Ceylon OR 
Solomon Islands OR Somalia OR Somaliland OR Sudan OR South Sudan OR South Africa OR Republic of South Africa 
OR Suriname OR Surinam OR Swaziland OR Syria OR Syrian Arab Republic OR Tajikistan OR Tadzhikistan OR 
Tadjikistan OR Tadzhik OR Tanzania OR United Republic of Tanzania OR Thailand OR Tuvalu OR Togo OR Togolese 
Republic OR Tonga OR Tunisia OR Turkey OR Turkmenistan OR Turkmen OR Uganda OR Ukraine OR USSR OR 
Soviet Union OR Union of Soviet Socialist Republics OR Russian Federation OR Russia OR Uzbekistan OR Uzbek OR 
Vanuatu OR New Hebrides OR Venezuela OR Vietnam OR Viet Nam OR West Bank OR West Bank and Gaza OR Gaza 
OR Yemen OR Yugoslavia OR Zambia OR Zimbabwe OR Rhodesia) 
#9 #6 OR #7 OR #8 
#10 #5 AND #9 
 147 
The search was limited to studies published from 1974, the year that the Expanded 148 
Programme on Immunisation (EPI) was introduced, until December 2018. Titles and 149 
abstracts of the search outputs and references were screened, and the full texts of 150 
potentially relevant articles were independently assessed by two reviewers (RM and BK) 151 
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using a standardized score sheet. Disagreements on final inclusions were resolved by 152 
consensus following discussions involving a third reviewer (GH). Authors and publishers 153 
were contacted for full texts not available online or via our collaborative networks.  154 
 155 
Studies were included if the study populations were from LMICs.  While the diagnosis of 156 
pertussis is largely made on the basis of clinical parameters, it is well-known that clinical 157 
presentation may be modified by age, previous immunisation or infection, antibiotic 158 
exposure and concurrent infection with other pathogens [9]. This makes the presentation 159 
of pertussis frequently atypical, thus requiring laboratory confirmation of cases by 160 
serology, culture or polymerase chain reaction (PCR).  Therefore, laboratory confirmation 161 
by either PCR, culture or paired serological assays was also an inclusion criterion.  162 
 163 
Studies that failed to provide a numerator (number of participants testing positive) or 164 
denominator (number of participants tested for pertussis), as well as those that failed to 165 
specify the laboratory diagnostic method utilized, were excluded.  Studies on sero-166 
epidemiological and laboratory diagnostic methods in the absence of clinical disease were 167 
also excluded.  168 
 169 
Data extraction 170 
The denominator and numerator were extracted from each study to determine prevalence 171 
for each diagnostic method. We defined prevalence as proportions with confirmed 172 
laboratory diagnosis from all participants suspected and tested for pertussis. Bordetella 173 
pertussis prevalence data were stratified by WHO region, diagnostic method (culture, 174 
paired serology or PCR), clinical setting (hospital or population based) and age category 175 
of the study participants. Prevalence was further stratified by HIV status, that is HIV 176 
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infected (HIV+), HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU). 177 
HEU was used in reference to infants. 178 
 179 
Incidence data were extracted as reported by the authors.   180 
 181 
The epidemiology of Bordetella parapertussis was separately assessed.  Data on the type 182 
of pertussis vaccine (wP or aP) used, clinical diagnostic criteria (e.g. WHO, CDC, etc.), 183 
and the study design were captured.  184 
 185 
Non-English language articles were reviewed and data extracted with the assistance of 186 
online translation programs and native speakers [17, 18]. 187 
 188 
Data analysis and reporting 189 
Percentage point-estimates together with their 95% confidence intervals (CIs) were 190 
calculated to represent prevalence of laboratory-confirmed pertussis for all outcomes. The 191 
Mantel-Haenszel method was used to pool together prevalence data from individual 192 
studies using random-effects meta-analysis. Heterogeneity was evaluated both visually by 193 
assessing forest plots and formally using the χ2-based Q and I2 statistics [19]. Where a 194 
meta-analysis was not feasible, either because data were too heterogeneous or insufficient 195 
to allow for meaningful pooling, narrative reporting was used. Narratively reported 196 
frequencies were summarized using medians and interquartile ranges (IQR) of prevalence 197 
point estimates and graphically represented using forest-like plots that omitted pooled 198 
data. Instead dotted lines were used to indicate where group averages would lie without 199 
emphasizing their meaning. The Kruskal-Wallis test was used to compare point 200 




Incidence of pertussis could not be independently estimated as the requisite data was not 203 
available. Incidence was narratively reported per 100 000 as reported by the authors 204 
themselves.  205 
All statistical analyses were done on STATA software version 14 (STATA Corporation, 206 
College Station, TX). The command metaprop_one was used to generate pooled 207 
prevalence forest plots after Freeman-Tukey transformation and metan, for comparative 208 
effect forest plots showing relative risks (RR) and their 95% CI, respectively.  209 
The study utilized the guidelines for reporting systematic reviews as set down by the 210 
revised 2009 PRISMA Statement [20]. 211 
 212 
Quality of included studies 213 
An adaptation of the tool developed by Wasserman et al., was used to assess the risk of 214 
bias as well as the quality of the included studies [21]. The quality assessment criteria 215 
examined specific variables to make judgement on the studies, taking into account 216 
methodological aspects discussed by Hoy et al. pertaining to internal and external validity 217 




Characteristics of the included studies 222 
The search strategy returned 3 725 studies which reduced to 3172 after excluding 223 
duplicates.  Following screening of abstracts and titles, 275 articles were deemed 224 
potentially relevant and subjected to full-text evaluation. Eighty-two studies (n=49 167) 225 
met the final criteria for inclusion into the systematic review; Figure 1. Amongst others, 226 
studies were excluded if they did not report clinical cases such as in laboratory studies, 227 
animal studies, economic evaluation and modelling studies. The included studies 228 
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involved symptomatic individuals meeting WHO and CDC (n=52 and n=8 respectively) 229 
clinical criteria. The remaining studies (n=22) used clinical definitions derived from 230 
modifications of the criteria set by WHO or CDC. Two studies were multinational (two 231 
and seven countries in each) so that in the end the final 82 studies included, represented 232 
88 unique populations. 233 
 234 
Figure 1: Studies included in the systematic review 235 
 236 
Table 2 shows the characteristics of the included studies by WHO region. A large 237 
proportion of the studies (n=63; 77%) was published between 2010 and 2018. Sixty-eight 238 
studies (83%) involved hospital-based participants. Forty-seven studies (57%) used one 239 
laboratory diagnostic confirmatory test while 32 (39%) and three (4%) studies used two 240 
and three methods for pertussis diagnosis, respectively. 241 
Records identified through 
database searching  
(n = 3725) 
Records screened after 
duplicates removed 
(n = 3172) 
Records excluded 
(n = 2897) 
Full-text articles assessed 
for eligibility 
(n = 275) 
Full-text articles excluded  
(n = 193) 
• Cases-series/review article (41)
• No case confirmation (30)
• Used duplicate data (30)
• Wrong period or High income (13)
• Study not about pertussis (14)
• No clear numerator/denominator (27)
• No clinical disease (12)
• Full text could not be found (8)
• Other (18) 
Studies included in the 
review 
(n = 82) 
Duplicates removed 
(n = 553) 
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Table 2: Characteristics of studies included in the systematic review 
Region & Study Design Setting Diagnosis Country Vaccine Period Sample (cases) 
Africa         
Voorhoeve# (1978)[23] Surveillance Population  C, S Kenya wP 1974-77 1078 (138) 
Ramkissoon (1991)[24]  Clinical trial Population  S South Africa wP 1988 112 (3) 
Strebel (1991)[25] Surveillance Hospital  C, S South Africa wP 1989 34 (3) 
Simondon (1997)[26]  Clinical trial Population  C, P, S Senegal wP & aP 1990-95 3619 (193) 
Anukam# (2004)[27]  Cross-Sectional Hospital  C Nigeria wP 1997-00 296 (22) 
Lassmann (2008)[28] Cross-Sectional Hospital  P Gabon wP 2003-04 99 (6) 
Jusot# (2014)[29] Cross-Sectional Hospital  C, P Niger wP 2010-11 305 (34) 
Kayina (2016)[30] Cross-Sectional Hospital P Uganda wP 2013 449 (67) 
Barger-Kamate (2016)[31] Cross-Sectional Hospital P Multinational wP & aP 2011-14 3451 (52) 
Gill (2016)[32] Cohort Population P Zambia wP 2015 775 (10) 
Hallbauer# (2016)[33] Cross-Sectional Hospital P South Africa aP 2008-15 1259 (183) 
Muloiwa# (2016)[34] Cross-Sectional Hospital C, P South Africa aP 2011-12 460 (41) 
Nunes (2016)[35] Clinical trial Population P South Africa aP 2011-12 1644 (79) 
Soofie (2016)[36] Cross-Sectional Hospital P South Africa aP 2015 1839 (42) 
Zar (2016)[37] Cohort Population P South Africa aP 2012-14 284 (16) 
du Plessis# (2018)[38]  Surveillance Hospital C, P South Africa aP 2013-15 990 (76) 
Eastern Mediterranean        
Al-Bargish# (1999)[39] Cross-Sectional Hospital  C Iran wP 1996 133 (67) 
Kakar (2009)[40] Surveillance Hospital  C Afghanistan wP 2006-07 203 (7) 
Ghanaie# (2010)[41] Cross-Sectional Population  C, P Iran wP 2007-08 328 (27) 
Bokhari# (2011)[42] Cross-Sectional Hospital C, P Pakistan wP 2005-09 802 (64) 
Hajia (2012)[43] Cross-Sectional Hospital  P Iran wP 2008-11 138 (12) 
Mughal (2012)[44] Cross-Sectional Hospital  C Pakistan wP 2004-06 
 
700 (22) 
Zouari# (2012)[45] Cross-Sectional Hospital  C, P Tunisia wP 2007-11 599 (120) 
Bahari (2013)[46] Cross-Sectional Hospital C Iran wP 2008-12 156 (7) 
Nikbin (2013)[47] Cross-Sectional Hospital  C, P Iran wP 2009-10 779 (100) 
Saffar (2014)[48] Cross-Sectional Hospital  P Iran wP 2008-12 518 (43) 
Sedaghat# (2014)[49] Cross-Sectional Hospital  C, P Iran wP 2004-08 347 (30) 
Benamrouche (2016)[50] Surveillance Hospital  C, P Algeria wP 2012-13 246 (123) 
Ghorbani (2016)[51] Surveillance Hospital  P Iran wP 2011-13 3629 (239) 
Omer (2016)[52] Surveillance Hospital  P Pakistan wP 2015-16 2021(8) 
Katfy# (2017)[53] Cross-Sectional Hospital  C, P Morocco wP 2013-15 156 (88) 
 Ben Fraji# (2018) [54] Cross-Sectional Hospital  C, P Tunisia wP 2007-17 1844 (306) 
Dumaidi (2018)[55] Cross-Sectional Hospital  P West Bank  wP 2004-08 267 (130) 
Mohammadzadeh (2018)[56] Cross-Sectional Hospital  C, P Iran wP 20015-16 184 (43) 
Europe 
    
  
 
Lukić-Grlić# (1999)[57] Cross-Sectional Hospital C, S Croatia wP 1988-94 201(2) 
Daǧla (2004)[58] Cross-Sectional Hospital  C Turkey wP 2001-03 66 (2) 
Aksakal (2007)[59] Cross-Sectional Population  S Turkey wP 2004 307 (51) 
Yıldırım (2008)[60] Cross-Sectional Hospital  P, S Turkey wP 2005-06 148 (16) 
Medkova (2010)[61] Cross-Sectional Unclear C, P Russian Fed. wP Unknown 172 (81) 
Gürsel (2012)[62] Cross-Sectional Hospital  C, P, S Turkey aP 2009-10 51 (6) 
Karlı (2013)[63] Cross-Sectional Hospital  C, P Turkey aP 2008-12 40 (6) 
Uslu (2013)[64] Cross-Sectional Hospital  P Turkey aP 2012 173 (48) 
Dinu (2014)[65] Cross-Sectional Hospital  C, P, S Romania aP 2012-13 51 (14) 
Karagül (2014)[66] Cross-Sectional Hospital  C, P Turkey aP 2010-11 214 (26) 
Öksüz# (2014)[67] Cross-Sectional Hospital  C, P Turkey aP 2010-13 
 
410 (106) 
Aslan (2016)[68] Cross-Sectional Hospital  P Turkey aP 2013-14 101 (20) 
Goktas (2016)[69] Cross-Sectional Hospital  P Turkey aP 2014-15 845 (15) 
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Gökçe (2018)[70] Cross-Sectional Hospital  P Turkey aP 2013-16 172 (44) 
South-East Asia        
Singh (1987)[71] Cross-Sectional Hospital  C India wP c.1986 560 (20) 
Dahiya (2009)[72] Cross-Sectional Hospital  C, P India wP 2007-07 21 (2) 
Barger-Kamate (2016)[31] Cross-Sectional Hospital  P Multinational wP 2011-14 749 (1) 
Das (2016)[73] Cross-Sectional Hospital  P India wP 2013-14 180 (7) 
Siriyakorn (2016)[74] Cross-Sectional Hospital P Thailand wP 2010-11 76 (14) 
Hughes# (2017)[75] Cohort Population P Nepal wP 2011-14 2026 (17) 
Chinthate (2018)[76] Cross-Sectional Hospital P Thailand wP 2016-17 70 (7) 
The Americas 
    
  
 
Cooper (1983)[77] Surveillance Hospital  C, S St Lucia wP 1981 10 (2) 
Baptista (2006)[78] Cross-Sectional Hospital  C Brazil wP 2003 287 (51) 
Kowalzik (2007) Cross-Sectional Hospital P Multinational wP & aP 2001-4 181 (19) 
Sandoval (2008)[79] Cross-Sectional Population  P Mexico wP 2002-03 61 (20) 
Nieto Guevara (2010)[80]  Surveillance Hospital  C, P Panama wP & aP 2001-08 759 (178) 
Astudillo (2011)[81] Cross-Sectional Hospital  C, P Colombia wP 2006-07 133 (45) 
Leite (2012)[82] Surveillance Hospital  C Brazil wP 2006-08 652 (132) 
Ferronato (2013)[83] Cohort Hospital  C, P Brazil wP 2009-12 57 (25) 
Ochoa-Perez (2014)[84] Surveillance Hospital  C, P Mexico aP 2011-12 147 (59) 
Vaz-de-Lima (2014)[85] Surveillance Hospital  P Brazil wP 2009-12 503 (66) 
Castillo (2015)[86] Cross-Sectional Hospital  P Peru wP 2010-12 392 (155) 
Pavic-Espinoza (2015)[87] Cross-Sectional Hospital  P Peru wP 2009-10 596 (114) 
Pimentel (2015)[88] Cross-Sectional Hospital  C, P Brazil wP 2010-11 192 (10) 
del Valle-Mendoza (2015)[89] Cross-Sectional Hospital  P Peru wP 2010-13 133 (51) 
Bailon# (2016)[90] Cross-Sectional Hospital  C, P Peru wP 2012 840 (191) 
Aquino-Andrade# (2017)[91] Cross-Sectional Hospital  P Mexico aP 2011-14 286 (192) 
Phadke (2018) # [92] Cross-Sectional Hospital P Guatemala wP 2009-12 301 (11) 
del Valle-Mendoza (2018)[93] Cross-Sectional Hospital  P Peru wP 20016-17 88 (18) 
Western Pacific        
Ong (1978)[94] Cross-Sectional Hospital C Malaysia wP 1974 65 (1) 
Lin (2010)[95] Cross-Sectional Hospital  C, P China wP 2008-09 1001 (99) 
Mi (2013)[96] Cross-Sectional Hospital  P China wP 2011-12 176 (51) 
Ting (2013)[97] Cross-Sectional Hospital C, P Malaysia wP 2011 707 (275) 
Huang (2014)[98] Surveillance Population P China wP & aP 2010-12 1022 (113) 
Liu (2014)[99] Cross-Sectional Hospital  C, P China wP 2013 148 (101) 
Wang (2014)[100] Cross-Sectional Hospital  C, P China wP & aP 2012-13 313 (122) 
Hu (2015)[101] Cross-Sectional Hospital P China aP 2013-14 2536 (247) 
Moriuchi (2017)[102] Cross-Sectional Unclear P Cambodia wP 2008-16 651 (82) 
Sadiasa (2017)[103] Cross-Sectional Hospital P Philippines wP 2012-15 1152 (34) 
NB. “Sample” refers to all individuals tested for pertussis in each study; C=culture; P=polymerase chain reaction, 
S=paired serology; wP= whole cell vaccine; aP=acellular vaccine; # includes Bordetella parapertussis  
 242 
Study designs included three clinical trials, four cohort, 62 cross-sectional and 13 243 
surveillance studies. There were 71 studies published in English, four in Mandarin, three 244 
each in Spanish and Turkish, and one in Persian. Three studies by Strebel et al, Al-Bargish 245 




In total, the studies originated from 37 countries, representing all six WHO regions; 248 
Additional file 1. Nineteen (51%) of the countries represented were upper-middle income, 249 
while 11 (30%) and seven (19%) were lower-middle and low-income countries, 250 
respectively. Five countries contributed 28 (49%) of the studies (Turkey=11, Iran=9, 251 
South Africa=8, China=6 and Brazil=6). Sixty-four (78%) studies had epidemiological 252 
data for Bordetella pertussis only while 18 (22%) studies investigated for both Bordetella 253 
pertussis and Bordetella parapertussis.  The most frequently used vaccine over the period 254 
the included studies were conducted was wP in 72/88 (82%) settings either on its own 255 
(n=66) or in combination with aP (n=6). In 16 (18%) settings aP was the only vaccine in 256 
use. 257 
 258 
Data from a study by Zouari et al. was considered only for the purpose of estimating 259 
mortality but not for estimation of disease burden as its data overlapped with that of Ben 260 
Fraj et al. who reported cases over a longer period but did not report on mortality [45, 54]. 261 
 262 
Prevalence of pertussis 263 
The median prevalence of PCR- confirmed disease due to Bordetella pertussis was 11% 264 
(IQR, 5-27%; n=43 696, 64 studies). Figure 2 and Additional file 2.  PCR prevalence 265 
differed across WHO regions ranging from a median of 4% (IQR 4-10%) in South-East 266 
Asia to median of 22% (IQR 12- 40%) in the Region of the Americas; P=0.001. In one 267 
multinational study, conducted in countries in the Africa and South-East Asia regions, 268 
Barger-Kamate et al., found an increased risk for pertussis in African countries with an 269 




Figure 2. Prevalence (proportion testing positive) of polymerase chain reaction 272 




Barger-Kamate (Kenya, 2016) 
Jusot (Niger, 2014)
Soofie (South Africa, 2016)
Nunes (South Africa, 2016) 
Muloiwa (South Africa, 2016) 
Kayina (Uganda, 2015)
Lassmann (Gabon, 2008)
Barger-Kamate (Mali, 2016) 
Simondon (Senegal, 1997)
Zar (South Africa, 2016)
Barger-Kamate (Gambia, 2016) 
Hallbauer (South Africa, 2016)
Gill (Zambia, 2016)
du Plessis (South Africa, 2018) 
Barger-Kamate (South Africa, 2016) 
Barger-Kamate (Zambia, 2016)
Eastern Mediterranean region 






Nikbin (Iran, 2013) 
Mohammadzadeh (Iran, 2018)
















Region of the Americas
Ferronato (Brazil, 2013)
Bailon (Peru, 2016)
Nieto-Guevara (Panama, 2010) 
Castillo (Peru, 2015)
del Valle-Mendoza (Peru, 2018) 
Phadke (Guatemala, 2018) 
Pimentel (Brazil, 2015)






Aquino-Andrade (Mexico, 2017) 
Kowalzik (Costa Rica, 2007)
del Valle-Mendoza (Peru, 2015)
South-East Asia region
Dahiya (India, 2009)
Barger-Kamate (Thailand, 2016) 
Siriyakorn (Thailand, 2016) 
Chinthanate (Thailand, 2018) 













Study Estimate % (95% confidence interval)
0 10% 20% 30% 40% 50% 60% 70% 80%
0.6 (0.1 - 1.6)
10.4 (7.2 - 14.4)
2.2 (1.6 - 3)
4.8 (3.8 - 5.9)
6.9 (4.8 - 9.6)
14.9 (11.7 - 18.5)
6 (2.2 - 12.7)
1.4 (0.7 - 2.7)
5.3 (4.6 - 6.1)
5.6 (3.2 - 8.9)
0.6 (0.1 - 1.6)
13.8 (12 - 15.9)
1.2 (0.6 - 2.3)
6.1 (4.7 - 7.8)
2.5 (1.5 - 3.7)
1.8 (0.9 - 3.2)
48.6 (42.5 - 54.8)
6.5 (5.8 - 7.4)
6.4 (4 - 9.6)
8.6 (5.9 - 12.1)
56.4 (48.2 - 64.3)
0.6 (0.2 - 1.4)
12.8 (10.5 - 15.3)
23.3 (17.4 - 30.1)
15 (13.4 - 16.7)
0.3 (0.1 - 0.7)
8.6 (4.5 - 14.6)
50 (43.5 - 56.4)
19.8 (12.5 - 28.9)
27.4 (15.8 - 41.7)
25.5 (19.2 - 32.7)
1.7 (0.9 - 2.9)
47 (39.4 - 54.8)
11.7 (4.4 - 23.8)
7 (3.9 - 11.2)
10.8 (6.3 - 16.9)
27.7 (21.2 - 35)
30 (6.6 - 65.2)
25.6 (21.4 - 30.1)
43.8 (30.7 - 57.6)
22.5 (19.7 - 25.4)
23.4 (20.4 - 26.6)
39.5 (34.6 - 44.5)
20.4 (12.5 - 30.3)
3.6 (1.8 - 6.4)
5.2 (2.5 - 9.3)
40.1 (32.1 - 48.5)
32.7 (21.3 - 46)
50 (29.1 - 70.8)
10.9 (5.3 - 19.2)
19.1 (16 - 22.5)
13.1 (10.2 - 16.3)
67.1 (61.3 - 72.5)
10 (4.6 - 18.1)
38.3 (30 - 47.1)
9.5 (1.1 - 30.3)
0 (0 - 1.6)
18.4 (10.4 - 28.9)
10 (4.1 - 19.5)
0.1 (0 - 1)
3.8 (1.5 - 7.8)
0.8 (0.4 - 1.3)
0 (0 - 0)
0 (0 - 0)
9.7 (8.6 - 10.9)
2.9 (2 - 4.1)
68.2 (60 - 75.6)
38.3 (34.7 - 42)
28.9 (22.3 - 36.2)
9.8 (8.1 - 11.9)
53.6 (47.9 - 59.3)
12.5 (10.1 - 15.3)




The median prevalence of culture-confirmed Bordetella pertussis was 3% (IQR 1-9%); 276 
n=18 868, 44 studies).  The point prevalence was similar across WHO regions; P=0.1380. 277 
Figure 3 and Additional file 2. 278 
 279 
Figure 3. Prevalence (proportion testing positive) of culture confirmed Bordetella 280 
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 51 
Confirmation of Bordetella pertussis using paired serology showed a median of 17% (IQR 282 
3-23%; n=4 912, 9 studies). Only three WHO regions were represented and median 283 
prevalence was 3% (IQR 3-13%) in the African region and 17% (95% CI, 13-26%) in the 284 
European region, while the one country, St Lucia, representing the Region of the 285 
Americas had a prevalence of 44% (95% CI, 14-79%); P=0.1309. Additional file 2 and 286 
Additional file 3. 287 
 288 
The prevalence of confirmed Bordetella parapertussis infection using any of the three 289 
confirmatory methods was 1% (IQR, 0-2%; n=12 062, 18 studies). The Eastern 290 
Mediterranean region was noted to have the highest prevalence with a median 2% (IQR 0-291 
7%) with one study from the same region having a prevalence of 19% (95% CI  13-292 
26%).[39] . Additional file 4. 293 
 294 
Prevalence of Bordetella pertussis differed in the same population depending on the 295 
method of laboratory confirmation used.  On average, culture underestimated prevalence 296 
by 85% (RR=0.15, 95% CI, 0.10-0.22) compared to PCR in the 29 (n=14 315) studies that 297 
used both methods. (Additional file 5). 298 
 299 
Pertussis prevalence declined in the 1990’s from the levels seen in the 70’s and 80’s. A 300 
slight increase was noted since the period after 2000. Figure 4a. Huang et al., reported a 301 
26-fold increase in confirmed adult pertussis between 2010 and 2014 in China [98]. There 302 
was sufficient information in 48 studies to estimate age prevalence by age group. The 303 
lowest prevalence was noted in individuals older than 19 years with median prevalence of 304 
6% (IQR 5 -14%). After the high prevalence noted below five years of age, the risk 305 
declined in late childhood (6 to 10 years) but increased again in adolescents who showed 306 
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the highest prevalence of all groups with a median prevalence of 20% (IQR 14 - 32%). 307 
Figure 4b.  308 
 309 
Figure 4. Distribution of point prevalence (proportion testing positive) of polymerase 310 
chain reaction and culture confirmed pertussis by period (a) and age group (b) 311 
 312 
Pertussis prevalence was also stratified by the study setting (hospital versus population-313 
based) as well as by the type of vaccine used in settings where the included studies were 314 
conducted. The prevalence of pertussis in hospital-based studies had a median of 10% 315 
(IQR 4-25%) compared to population-based studies which reported median prevalence of 316 
6% (IQR 3-13%). There was an overlap in the distribution of prevalence of confirmed 317 
pertussis in populations using aP only [ Median 10% (IQR 6-28%)] compared to 318 
populations using some wP [Median 10% (IQR 3-20%)]. The overlap remained even 319 
when prevalence was stratified by diagnostic method.  In the only included clinical trial 320 
comparing the two vaccine types, Simondon et al., found aP vaccine efficacy against all 321 
confirmed pertussis to be 85% (95% CI, 66-93%) and that of wP to be 96% (95% CI, 86-322 
99%)[26]. 323 
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Incidence of pertussis 324 
Population level incidence rates of pertussis and hospitalisation were reported by some of 325 
the authors, but these could not be independently verified as the requisite population data 326 
were not available; Table 3. In addition, a majority of the authors reported point estimates 327 
incidences with no confidence intervals. Where data was available for different age groups 328 
[Voorhoeve et al, Nieto Guevara et al, Saffar et al and Ochoa-Perez et al] the incidence 329 
was always highest in infancy.[23, 48, 80, 84] The highest incidence of 15 900/100 000 330 
was reported in Kenyan infants between 1974 and 1977 before the introduction of wP. 331 
[23] In addition to Bordetella pertussis incidence, Ghanaie et al reported a separate 332 
incidence of 2 per 100 000 for Bordetella parapertussis.[41] Contacts were reported to 333 
have an incidence of 0.69/100 000 in Benamrouche et al’s study.[50]. 334 
 335 
Table 3: Population and hospitalisation incidence rates of Bordetella pertussis 
Study (Year) Incidence Age ranges Country 
Voorhoeve (1978)[23] 3800/100 000 All ages Kenya 
Strebel# (1991)[25] 187/100 000 6 months to 5 years South Africa 
Simondon (1997)[26]  119/100 000 2 months to 15 years Senegal 
Sandoval (2008)[79] 500/100 000 12 years to 15 years Mexico 
Ghanaie (2010)[41] 318/100 000 6 years to 14 years Iran 
Nieto Guevara# (2010)[80] 144/100 000 All ages Panama 
Uslu (2013)[64] 0.9/100 000 < 5 years Turkey 
Huang (2014)[98] 23.52/100 000 All ages China 
Jusot (2014)[29] 820/100 000 < 5 years Niger 
Ochoa-Perez (2014)[84] 2.3/100 000 0 year to > 18 years Mexico 
Saffar (2014)[48] 4.92/100 000 0 month to 25 years Iran 
Benamrouche (2016)[50] 1.04/100 000 All ages Algeria 
Gill (2016)[32] 520/100 000 < 1 year Zambia 
Muloiwa# (2016)[34] 526/100 000 < 13 years South Africa 
Omer (2016)[52] 247/100 000 < 1 year Pakistan 
Soofie (2016)[36] 220/100 000 < 1 year South Africa 
Giayetto (2017)[104] 4.53/100 000 All ages Argentina 
Ben Fraj (2018)[54] 134/100 000 < 5 years Tunisia 




Time-denominated rates were recorded for three community-based studies. Gill et al. 337 
reported a rate of 2.4 (95% CI, 1.2-4.2) cases per 1000 infant-months with the highest rate 338 
of 3.5 cases/1000 infant-months noted between birth and six weeks while Hughes et al 339 
reported a rate of 13.3(95% CI, 7.7-21.3) cases per 1000 infant-years.[32, 75] Nunes et 340 
al.’s data gave an overall rate of 4.9 per 1000 person-months, which differed between 341 
infants (5.7/1000) and mothers (4.3/1000) as well as by HIV status as reported below.[35] 342 
 343 
Risk of pertussis in HIV exposed and infected 344 
Ten studies, all from the Africa region, investigated the impact of HIV status on the risk 345 
of pertussis. The incidence rate of pertussis was 7.4/1000 infant-months in HEU infants 346 
and 5.5/1000 in HUU infants in the study by Nunes et al. while the rates in HIV+ and HIV 347 
uninfected mothers were 6.8 and 3.9/1000 respectively.[35] Gill et al., reported RR 1.8 348 
(95% CI, 95% CI 0.5 - 6.9) in HEU infants compared to HUU. The incidence of 349 
Bordetella pertussis-associated hospitalisation was 2.9 (95% CI, 1.8-4.5) and 1.9 (95% CI, 350 
1.3-2.6) per 1000 in HIV-exposed and HIV-unexposed infants, respectively in a study by 351 
Soofie et al. The reported 4.8% case fatality rate in Soofie et al was only due to deaths in 352 
HIV-exposed infants.[36] In the study by Hallbauer et al., there was insufficient data to 353 
estimate stratum specific rates, but HIV+ cases, who made 14% of the study sample, 354 
accounted for 22 (19%) of the 113 pertussis cases with known HIV status.[33] A gradual 355 
increase in risk of pertussis was reported in a study by Muloiwa et al in which the risk of 356 
pertussis was 5.4% in HUU, 10.9% in HEU and 15.8% in HIV+.[34] 357 
 358 
There was sufficient data to do a metanalysis comparing risk of pertussis in HUU with 359 
HEU and HIV+ in six and five studies, respectively. Compared to HUU, HIV+ and HEU 360 
individuals had a RR 1.51 (95% CI, 1.02-2.23) and RR 1.4 (95% CI, 1.01-1.92) for 361 
confirmed pertussis, respectively. Figure 5. The highest risk of pertussis was reported by 362 
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Anukam et al., in a cohort of wP vaccinated HIV infected adolescents who were not on 363 
antiretroviral therapy with RR 22.8 (95% CI, 6.9-75.1).[27]. This study was not included 364 
in the HIV metanalysis as it was an obvious outlier composed of individuals not on 365 
treatment which seemed to show excessive risk for pertussis. All other studies involved 366 
HIV+ individuals on antiretroviral therapy. 367 
 368 
Figure 5. Meta-analysis of the relative risk of pertussis comparing HIV unexposed uninfected 369 
(HUU) to HIV exposed uninfected (HEU) (a) and HIV infected (b) 370 
 371 
Deaths and case fatality rate of pertussis 372 
A total of 97 pertussis related deaths out of 1490 confirmed cases were reported in 16 373 
studies (n=14390) representing 13 countries. All deaths were associated with Bordetella 374 
pertussis with none attributed to Bordetella parapertussis. From the 16 studies, the overall 375 
proportion of deaths was 0.8 % (95% CI, 0.4-1.4%) with a pertussis case fatality rate of 376 
6.5% (95% CI, 4.0-9.5%). Figure 6. When only infants were considered (13 studies), the 377 
case fatality rate was 7.2% (95% CI, 3.6-11.8 %) in the studies reporting deaths. 378 
 379 
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Figure 6. Mortality and case fatality rate of confirmed pertussis 381 
 382 
All children who died were younger than five years and the majority were younger than 383 
six months of age. Almost all deaths occurred under one year of age with only one study 384 
(Voorhoeve et al, 1978) reporting pertussis deaths after the second year of life (n=5).[23] 385 
 386 
Quality of the included studies 387 
Using the modified tool published with the protocol for this systematic review, we found 388 
all the included studies to be of high quality.[14] This is because components of the 389 
quality index score, such as laboratory confirmation and availability of raw denominator 390 
and numerator data formed part of the inclusion criteria; which automatically excluded 391 
poor quality status. Similarly, studies had moderate to low risk of attrition and selection 392 
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This study comprehensively reports on the burden of confirmed pertussis over a 45-year 396 
period (1974-2018) in LMICs. This period starts in 1974 with the inception of EPI. 397 
Prevalence of confirmed pertussis disease differed in the same study depending on the 398 
method of laboratory confirmation with PCR showing the greatest diagnostic sensitivity as 399 
expected.[4] Most cases were due to Bordetella pertussis. Bordetella parapertussis was 400 
less common and did not have any reported fatalities associated with it. The study 401 
indicates that pertussis deaths are significantly high in LMICs with a disproportionate case 402 
fatality rate in young infants. Secondly, the metanalysis shows that HIV has a significant 403 
impact in the burden of pertussis in settings where the burden of HIV is high. 404 
 405 
Not surprisingly, the findings from our study agree with those from  some HICs: the 406 
highest incidence of pertussis was in infants and the greatest pertussis-specific mortality in 407 
children younger than 6 months.[105-107] Moreover, we also noted the increase in the 408 
prevalence of pertussis in adolescents similarly described in highly vaccinated cohorts 409 
from HICs.[108-110] The noted decline in adulthood may indicate protection following 410 
the natural boosting in adolescence. Worryingly, the pooled case fatality rate of nearly 6% 411 
exceeds the less than 4% estimated by WHO for developing countries.[2] As noted this is 412 
even higher when only infants are considered. 413 
 414 
Prevalence data presented in this systematic review suggests that LMICs may also be 415 
experiencing a resurgence of pertussis as noted in HICs. Both the GPI and WHO advocate 416 
for the strengthening of surveillance systems as a key component in the control of 417 
pertussis.[108, 111] Currently, surveillance of pertussis in LMICs is suboptimal. As a 418 
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result, there are many gaps in accurate pertussis epidemiological data which we observed 419 
in this study. The review indicates that the choice of laboratory case-confirmation 420 
influences the quantification of pertussis disease burden within the same setting. This is an 421 
important finding that suggests that use of PCR to confirm pertussis should be prioritized 422 
in LMICs. The higher sensitivity of PCR is more likely to capture the true burden of 423 
pertussis and give a better understanding of the global epidemiological pattern of the 424 
disease across different settings than any other method. In contrast, culture, recognized as 425 
the diagnostic gold standard missed on average 85% of cases identified by PCR in the 426 
studies that used both methods in this systematic review.  427 
 428 
A number of authors reported incidences although population denominators could not be 429 
independently verified as these went largely unreported. The rates were quite high 430 
compared to HICs and showed no pattern of decline over the period in which the 431 
incidences were reported. 432 
 433 
An unexpected finding was the significant overlap in the prevalence of pertussis noted 434 
with different vaccines in use. Most LMICs use wP vaccines in contrast with the 435 
predominant use of aP vaccines in HICs. In general wP vaccines are regarded as offering 436 
better protection against pertussis.[112] Despite the predominant use of wP in the 437 
reviewed studies, we noted a steady increase in confirmed pertussis since in studies 438 
reporting after 2000. This suggests that the observed resurgence of pertussis noted in HIC 439 
may only be partly explained by the change of vaccine from wP to aP in these countries. 440 
Another possible explanation for the increase may be the increase in the use of PCR for 441 
case confirmation – all the included studies conducted after 2010 used PCR as the primary 442 
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method of confirming cases. The increase in the observed prevalence coincides with the 443 
use of these molecular techniques. 444 
 445 
Although data are limited, there is strong evidence from the metanalysis showing that the 446 
risk of pertussis is increased in HIV+ and HEU individuals. The risk of pertussis was 447 
increased by 50% and 40% respectively in the two groups compared to HUU. With the 448 
exception of the study by du Plessis et al., all studies showed increased risk of pertussis 449 
incidence or prevalence associated with HIV infection or exposure.[38] In addition, there 450 
was a higher risk of hospitalisation and deaths related to pertussis in HIV exposed or 451 
infected infants.[32, 35, 36] In considering their pertussis control strategies, LMICs, 452 
which have the biggest burden of HIV, need to take into account this increased risk 453 
associated with HIV exposure and infection.[7]  454 
 455 
Our study is largely limited by paucity of data, especially longitudinal data for each 456 
included country as well as vaccine coverage in the specific population studied. In 457 
addition, case detection may have been affected by different selection criteria used as well 458 
as the variability of PCR assays used to confirm cases. Regardless, our results will 459 
encourage generation of more epidemiological studies on pertussis in LMICs, while in the 460 
meantime, assisting policy makers in disease control planning.  461 
CONCLUSIONS 462 
This study indicates an urgent need to review the existing pertussis control programs in 463 
LMICs to target children, adolescents, and HIV exposed and infected groups. In addition 464 
the study highlights the need to urgently consider measures to reduce the high infant 465 
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mortality rate, with specific consideration for maternal vaccination that has been shown to 466 
be effective in protecting young infants even in an LMIC setting.[113] In their 467 
recommendation, the GPI in addition to prioritizing surveillance, made this an urgent area 468 
of action for LMICs.[5] Encouragingly, we noted a substantial increase in the number of 469 
studies published in the last eight years of the period under review (2010-2018), possibly 470 
reflecting recent increase in interest and funding for pertussis research in LMICs.  471 
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Additional file 1: Country and year of included studies with confirmed pertussis shown 4 




Additional file 2: Distribution of point prevalence of confirmed pertussis by World 9 
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Additional file 3: Prevalence of paired serology confirmed Bordetella pertussis. Dotted 16 
lines show subgroup and whole group average estimates 17 
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Lukić-Grlić (Croatia, 1999) 







Hallbauer (South Africa, 2016) 
Muloiwa (South Africa, 2016) 
Aquino-Andrade (Mexico, 2017) 
Hughes (Nepal, 2017)
Katfy (Morocco, 2017)
Ben Fraj (Tunisia, 2018) 
Phadke (Guatemala, 2018)
du Plessis (South Africa, 2018)
Overall  (I^2 = 92.6%, p = 0.000)
0 5% 10% 15% 20% 25%
0 (0 - 0.5)
18.7 (12.5 - 26.4)
0.9 (0.1 - 3.5)
1.3 (0.3 - 3.4)
1.8 (0.6 - 3.9)
7.3 (5.6 - 9.3)
0.6 (0 - 2.3)
0.5 (0 - 2)
0.2 (0 - 1.3)
0.2 (0 - 0.8)
0.7 (0.3 - 1.4)
2.3 (1.1 - 4.2)
1 (0.2 - 3)
0.2 (0 - 0.5)
0.6 (0 - 3.5)
1.5 (1 - 2.2)
0.3 (0 - 1.8)
1.5 (0.8 - 2.4)









Additional file 5: Meta-analysis of relative detection rates of polymerase chain reaction 24 
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Abstract  53 
 54 
Background: The incidence of pertussis in children in low and middle-income 55 
countries is poorly described. This study aimed to prospectively investigate the incidence 56 
of pertussis in South African children hospitalised with lower respiratory tract infection 57 
(LRTI). 58 
 59 
Methods: Children hospitalised with LRTI in Cape Town, South Africa were enrolled 60 
over one year. Clinical data were collected. A nasopharyngeal swab (NP) and induced 61 
sputum (IS) were taken and PCR specific for Bordetella pertussis (IS481+/hIS1001-) 62 
and Bordetella parapertussis (IS1001+) was performed. 63 
 64 
Results: 460 children with median age 8 (IQR 4-18) months were studied. Bordetella 65 
pertussis was detected in 17 (3.7%) while total Bordetella spp. were identified on 23 66 
(5.0 %) of 460 NP. Adding IS testing increased the identification of B. pertussis to 67 
32/460 cases (7.0%; 95% CI 4.8-9.7%); p=0.028 and total Bordetella to 41/460 (8.9%; 68 
95% CI 4-10%); p=0.020. Shorter duration of symptoms [median 2 (IQR 2-3) days 69 
versus 5 (IQR 3-7) days; p=0.0008] was associated with detection of B. pertussis on IS 70 
versus NP. 71 
 72 
B. pertussis was detected in 15.8% (n=3/19) of HIV infected children, 10.9% 73 
(n=10/92) of HIV exposed uninfected and 5.4% (n=19/349) of HIV unexposed 74 
uninfected children. Risk of B. pertussis decreased with each additional dose of DTaP 75 
vaccine [0 doses = 17.9%; 1 dose =7.0%; 2 doses =6.9%; >3 doses =6.2%]. 76 
 77 
Conclusions: Pertussis is common in South African children hospitalised with LRTI 78 
particularly if HIV exposed or infected but decreases sequentially with vaccination 79 
doses. PCR on IS specimen provides confirmation earlier than NP while increasing overall 80 








Pertussis is an important cause of severe respiratory disease in children globally. Most 87 
cases are due to Bordetella pertussis infection with a small percentage attributed to 88 
Bordetella parapertussis.[1]  The World Health Organization (WHO) estimates that 89 
between 20 and 40 million cases of pertussis and 300 000 pertussis-related deaths occur 90 
around the world each year, 90% of which occur in children in low and middle-income 91 
countries (LMICs).[2, 3] Data are largely unavailable in LMICs, making it difficult to 92 
assess the true burden of disease and the impact of vaccination.[4, 5] 93 
 94 
Pertussis can be difficult to diagnose clinically, especially in infants. [6] Polymerase 95 
chain reaction (PCR), commonly performed on a nasopharyngeal specimen obtained by 96 
swab or aspiration, has greatly improved the ability to confirm cases.[7, 8],[9, 10] Due 97 
to lack of resources for laboratory confirmation in most LMICs, diagnosis is largely 98 
made on clinical grounds utilizing clinical case definitions such as the one 99 
recommended by WHO. [5, 11, 12]  100 
 101 
Since 2009, South Africa (SA) has introduced an acellular vaccine in a combination 102 
formulation with four other vaccines (DTaP-IPV/HIB; Pentaxim®, Sanofi 103 
Pasteur).[13]. Available data indicates that coverage for the pertussis vaccine in the 104 
Western Cape Province, where this study was done, declines from six weeks with each 105 
extra dose in the schedule.[14] 106 
This study aimed to prospectively investigate the incidence and risk factors for pertussis 107 





Materials and Methods 111 
 112 
A prospective study of the incidence and risk factors for pertussis was performed in 113 
children hospitalised with LRTI.  114 
 115 
Participants 116 
Sequential children admitted to Red Cross War Memorial Children’s Hospital (RCH), 117 
Cape Town, South Africa, from 07 September 2012 to 06 September 2013 for LRTI 118 
were eligible for enrolment. To be included, the children had to be less than 13 years of 119 
age and have WHO-defined age-specific tachypnoea or lower chest indrawing or apnoea. 120 
In addition, the children could only be enrolled after informed consent  was obtained from 121 
the parents for the children to be included. Participants were excluded if they had a 122 
previous admission to a health care facility in the preceding two weeks or if they had 123 
already been in hospital longer than 48 hours during the current admission. A maximum 124 
of four children were enrolled per working day to ensure distribution of enrolment 125 
throughout the year. The attending doctors at RCH provided clinical care. Children 126 
were followed up until they were discharged from hospital. 127 
 128 
A detailed history and clinical examination was done, especially noting the presence of 129 
cough, apnoea, duration of symptoms and use of antibiotics prior to admission. History of 130 
HIV exposure, infection and where relevant, antiretroviral treatment (ART) were 131 
recorded. Maternal HIV status at the time of pregnancy with the child was abstracted as 132 
recorded on the Road to Health Card (RTHC). In addition, caregivers who did not know 133 
their current HIV status were counselled and offered HIV testing. All children were 134 
screened for HIV infection during the study. Information on immunisation was abstracted 135 
from the RTHC, a standardised national record for each child, and the date and type of 136 
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each vaccine recorded. Vaccination status was regarded as a completed primary 137 
schedule if three or more doses were received. The status was classified unknown 138 
where RTHC was missing and up to date for age if an appropriate number of doses for 139 
the child’s age were received. 140 
 141 
HIV screening was done using an ELISA test (Architect HIV Ag/Ab Combo, Abbott 142 
Diagnostics, Wiesbaden). Children younger than 18 months who were ELISA positive 143 
had their status confirmed with an HIV PCR test (COBAS AmpliPrep/COBAS Taqman 144 
HIV-1, Roche Molecular Diagnostics, Pleasanton, CA) while those older than 18 months 145 
had a second ELISA test (Enzygnost Anti-HIV 1/2 Plus, Siemens/Dade Behring, 146 
Erlangen). HIV infection was defined as a positive PCR in children less than 18 months 147 
of age or two positive ELISA tests in older children. Children younger than 18 months 148 
who were ELISA positive, but PCR negative were classified as HIV exposed 149 
uninfected; older children were classified as HIV exposed uninfected if the mother was 150 
HIV infected at the time of the pregnancy but the child tested HIV negative. 151 
 152 
Two nasopharyngeal (NP) swabs followed by an induced sputum (IS) specimen were 153 
collected from each child. The first NP specimen was taken using a cotton wool tipped 154 
swab and immediately put into a gel Amies transport medium and sent to the laboratory 155 
for culture. The second NP specimen was taken with a nylon flocked swab 156 
(FLOQSwabsTM, Copan Diagnostics, Murrieta, CA) and immediately transferred into 157 
a nucleic acid preservation medium (PrimeStore®, Longhorn Vaccines & Diagnostics, 158 
San Antonio, TX). The IS specimen was collected after nebulization with a 159 
bronchodilator and hypertonic saline as previously described.[15] Briefly, children were 160 
fasted for 2–3 hours before sputum induction. Salbutamol nebulisation was given via a 161 
metered dose inhaler to reduce the risk of bronchospasm, after which 5 ml of 5% sterile 162 
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saline was given via an oxygen jet nebuliser at a rate of 5 l/min. After 15 min, the children 163 
were either suctioned or encouraged to cough, with suctioning performed through the 164 
nasopharynx with a sterile mucus extractor. Both specimens were frozen at minus 80oC 165 
until thawed for batched molecular diagnostic testing. 166 
The Amies swab was inoculated onto a charcoal-enriched culture medium (Greenpoint 167 
Media Laboratory, National Health Laboratory Service, Cape Town, South Africa) and 168 
incubated for a minimum of seven days. If growth was detected, the bacterial colonies 169 
were tested by PCR as described below. 170 
 171 
PCR specific for insertion sequences IS481 for Bordetella spp. and IS1001 for B. 172 
parapertussis was done with a validated commercial kit (LightMix® Kit Bordetella 173 
pertussis and Bordetella parapertussis, TIB MolBiol, Berlin, Germany) using 174 
previously published primers.[16] To exclude Bordetella holmesii (IS481 +, IS1001 -, 175 
hIS1001 +) before the diagnosis of B. pertussis infection was made, all specimens 176 
testing positive for IS481 were tested for the presence of insertion site hIS1001.[17] 177 
 178 
Controls 179 
Controls were children without symptoms or signs of respiratory illness presenting for 180 
other reasons to the same hospital or a nearby primary health care facility. Controls 181 
were matched to within 12 weeks of birth and 12 weeks of specimen collection of the 182 
cases testing positive for Bordetella spp. on the NP specimen. An average of three 183 
controls were matched to each case. One nylon flocked NP specimen was collected from 184 
each control and processed as described above. 185 
 186 
 187 




Approval for the study was granted by the Human Research Ethics Committee of the 190 
Faculty of Health Sciences, University of Cape Town, South Africa (Reference: 191 
371/2011). Written informed consent was obtained from a parent or legal guardian in 192 
their preferred language. 193 
 194 
Sample size and statistical analysis 195 
 196 
We calculated that a sample size of between 400 and 500 participants would give 197 
95% confidence intervals (CI) of 3% above and below our estimated prevalence of 198 
5%. Percentages with 95% CI were used to depict proportions of categorical variables 199 
while medians with interquartile ranges (IQR) were used to summarize all continuous 200 
variables.  201 
 202 
Cumulative frequencies of confirmed B. pertussis were described and stratified by age 203 
category, HIV status and vaccination status. 204 
 205 
A χ2 or Fisher’s exact test was used to assess the strength of association between two 206 
categorical variables as appropriate. The Mann-Whitney test was used to test the 207 
hypothesis of similarity between two groups with respect to a continuous variable. A two-208 
tailed cut-off level of significance at p<0.05 was used in all hypothesis testing. All 209 
analyses were done using Stata Statistical Software Release 13 (StataCorp LP, 210 







Study participants 216 
Over the study period, 7 792 children were hospitalised of whom 987 children had 217 
respiratory illness. Of these, 460 (46.6%) eligible participants were enrolled. The median 218 
age was 8 (IQR 4-18) months and 258 (56.1%) were male. Most children were HIV 219 
unexposed uninfected (n=349; 75.9%) while 92 (20.0%) were HIV exposed uninfected 220 
and 19 (4.1%) were HIV infected, table 1.  Among HIV infected children, one was WHO 221 
HIV stage 1 and one HIV stage 2, while 10 were stage 3 and seven were stage 4. Nine 222 
(47.4%) HIV infected children were on ART of whom four had attained viral 223 
suppression. 224 
Table 1: Baseline characteristics of the study participants, Bordetella cases and age matched NP controls 
       
Baseline character  Study sample (N=460)  Positive NP cases (n=23)  Matched Controls (N=70) 
Age       
Median (IQR) months  8 (4-18) months   8 (2.5 - 14) months  8 (5-16) months 
       
Gender  n (%)  n (%)  n (%) 
Female  202 (43.9)  13 (56.5)  33 (47.1) 
Male   258 (56.1)  10 (43.5)  37 (52.9) 
       
Pertussis doses received                
0  28 (6.1)  2 (8.7)  2 (2.9) 
1  57 (12.4)  5 (21.7)  1 (1.4) 
2  58 (12.6)  4 (17.3)  4 (5.7) 
≥ 3  308 (67)  12 (52.2)  49 (70.0) 
Unknown  9 (2.0)  0 (0.0)  14 (20.0) 
       
HIV status       
Unexposed Uninfected  349 (75.9)  17 (73.9)  68 (97.1) 
Exposed Uninfected  92 (20)  5 (21.7)  0 (0.0) 
Exposed Infected  19 (4.1)  1 (4.4)  2 (2.9) 
       
Presenting symptoms       
Cough  456 (99.1)  23 (100)  NA 
Apnoea  20 (4.5)  3 (13.0)  NA 
Fever  288 (63.7)  10 (45.5)  NA 
       
Pre-hospital antibiotic  n=173  n=10   
Penicillin  77 (44.5)  7 (70.0)  NA 
Ceftrioxone  99 (57.2)  3 (30.0)  NA 
Cotrimoxazole  4 (2.3)  0  NA 
Erythromycin  1 (0.4)  0  NA 




Immunisation status was unknown in nine children. Of 451 (98.0%) with immunisation 226 
records, 369 (85.2%) were up to date with pertussis vaccine doses for age while 308 227 
(68.3%) had completed the primary schedule. This did not differ by HIV status with 228 
237/345 (68.7%) in unexposed uninfected, 59/89(66.3%) in exposed uninfected and 229 
12/17 (70.6%) in HIV infected children respectively completing the primary schedule; 230 
p=0.891.  231 
Antibiotics were received by 173 (37.6%) children for a median duration of one day 232 
(IQR 1-1days) prior to admission. Ceftriaxone (n=99; 57.2 %) and penicillin (n=77; 44.5 233 
%) were the commonest antibiotics received. Seven children received both ceftriaxone and 234 
penicillin while one child received both ceftriaxone and co-trimoxazole. 235 
 236 
Cough (median duration 3, IQR 2-5 days) and fever were the commonest presenting 237 
symptoms, table 1. Apnoea was reported in 20 (4.4%) participants with a median age 238 
of 6 (IQR 3-16) months while those without apnoea had median age 8 (IQR 4-18) 239 
months; p=0.26. 240 
 241 
Description of microbiologic confirmation 242 
Both NP and IS specimen collection were well tolerated and obtained in most children 243 
with no severe adverse reaction noted in any participant. NP specimens were obtained 244 
in all children. In four participants IS could not be obtained as children were transferred 245 
or discharged before the specimen could be collected. In all other children (n=456; 99.1 246 
%), IS was successfully obtained. Two IS specimens were lost due to container leakage. 247 
 248 
PCR for IS481 was positive in 17 of 460 NP specimens (3.7 %; 95% CI 2.2-5.9 %) 249 
while seven (1.5%; 95% CI 0.6-3.2%) were positive for IS1001. PCR was positive for 250 
both targets in one participant. Therefore 23 (5%; 95% CI 3.2-7.4%) NP specimens 251 
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were positive for either target. Of the 454 IS specimens processed, 25 (5.5%; 95% CI 252 
3.6-8.0%) were positive for insertion site IS481 and five (1.1%; CI 0.4%-2.5%) positive 253 
for IS1001, giving a total of 30 (6.6%; CI 4.5-9.3%) IS specimens positive for either 254 
Bordetella target. 255 
 256 
NP specimens from four participants showed bacterial growth compatible with 257 
Bordetella spp. on culture but only one was positive on PCR for the IS481 locus. The 258 
same participant was also positive for IS481 on the flocked-swab NP specimen. NP 259 
specimens from all 70 controls (table 1) were PCR negative for both IS481 and IS1001 260 
insertion sites. As the other three cultures could not be confirmed as Bordetella pertussis or 261 
Bordetella parapertussis, they were not included with positive cases. 262 
 263 
None of the IS481 positive specimens were positive for the hIS1001 B. holmesii locus 264 
and so all were classified as B. pertussis positive while all the IS1001 positive specimens 265 
were classified as B. parapertussis positive. In total, 32 (7.0%; 95% CI 4.8-9.7%) 266 
participants were B. pertussis positive and 11 (2.4%; 95% CI 1.2-4.2%) were B. 267 
parapertussis positive from NP and IS specimens. Two participants were positive for 268 
both organisms. This gave an incidence of 8.9% (95% CI 6.5-11.9%; n=41/460) for 269 
either organism. The occurrence of Bordetella cases did not show any seasonal pattern 270 
although enrolled LRTI cases in general peaked between March and July 2013, figure 1. 271 
 272 
Figure 1: Recruited lower respiratory tract infection cases showing number and percentage 273 




























Figure 1: Recruited lower respiratory tract infection cases showing number and percentage of confirmed Bordetella per month
 
 85 
Children with confirmed B. pertussis had a median age of 8 months (IQR 2-21), similar 275 
to those without confirmed infection [median of 8 months (IQR 4-18); p=0.43]. A 276 
higher proportion of cases occurred in infants younger than two months of age with 277 
6/41 (14.6%) positive for B. pertussis compared to 26/419 (6.2%) in children older 278 
than two months; p=0.043.   279 
 280 
The risk of B. pertussis differed by HIV status with HIV unexposed uninfected having the 281 
lowest risk (n=19/349; 5.4%). Exposed uninfected (n=10/92; 10.9%) had an intermediate 282 
risk while HIV infected children (n=3/19; 15.8 %) had the highest risk.  283 
 284 
Risk of B. pertussis infection declined with each additional dose of the vaccine 285 
received. The highest risk was seen in children who had not received any vaccine with 286 
5/28 (17.9%) having confirmed B. pertussis. The risk was 4/57 (7.0%), 4/58 (6.9%) 287 
and 19/308 (6.2%) for children that received one, two and three or more doses 288 
respectively. Table 2. 289 
Table 2: Bordetella incidence stratified by age group, HIV and vaccine doses (N=460)      
Stratifying variable Stratum total (n) B. pertussis B. parapertussis Total Bordetella      
  
Cases n (%) Cases n (%) Cases n* (%)      
Crude 460 32 (7.0) 11 (2.4) 41 (8.9)      
Age group 
    
     
< 2 months 41 6 (14.6) 0 (0.0) 6 (8.4) 
≥ 2 months 419 26 (6.2) 11 (2.6) 35 (14.6)      
HIV status 
    
     
Uninfected unexposed 349 19 (5.4) 10 (2.9) 27 (7.7) 
Exposed unifected 92 10 (10.9) 0 (0.0) 10 (10.9) 
Exposed infected 19 3 (15.8) 1 (5.3) 4 (21.1)      
Pertussis vaccine doses 
    
     
0 28 5 (17.9) 0 (0.0) 5 (17.9) 
1 57 4 (7.0) 1 (1.8) 4 (7.0) 
2 58 4 (6.9) 3 (5.2) 7 (12.1) 
≥ 3 308 19 (6.2) 6 (2.0) 24 (7.8) 
Unknown 9 0 (0.0) 1 (11.1) 1 (11.1) 
* Two cases were positive for both organisms. NB. Positive cases includes total diagnosed on 




Stratified B. parapertussis incidences were difficult to interpret because of small number of 291 
cases. Table 2. 292 
 293 
Use of IS versus NP specimen for diagnostic confirmation  294 
Ten participants had a positive PCR for IS481 on both NP and IS. In one participant 295 
PCR for IS1001 was positive on both the NP and IS while in another IS1001 was 296 
positive on NP and IS481 positive on IS. The latter was counted as a single case of B. 297 
pertussis. In total 30 out of 41 (73.2%) Bordetella confirmed cases were detected on IS 298 
while only 23/41 (56.1%) were detected on NP (of which six were not identified on IS).  299 
 300 
Testing of IS was able to identify 25/32 (78.1%) of all confirmed B. pertussis 301 
infections compared to 17/32 (53.1%) for NP. The use of IS increased the diagnostic 302 
yield of B. pertussis by 15 (46.9%) from 17/460 (3.7%) when NP was used alone compared 303 
to 32/460 (7.0 %), when used with IS (p=0.028) and that of total Bordetella spp. by an 304 
additional 18 (43.9%) from 23/460 (5.0%) when NP was used alone compared to 41/460 305 
(8.9%)  when used with IS (p=0.020). 306 
 307 
Participants positive for B. pertussis on IS specimens only (IS+/NP-), had a shorter 308 
duration of symptoms [median 2 (IQR 2-3) days] compared to those who were B. 309 
pertussis positive on NP specimen (NP+/IS- or NP+/IS+) [median 5 (IQR 3-7) days; 310 
p=0.0008]. None of the B. pertussis cases diagnosed on IS only (IS+/NP-) had a 311 




Only 4/41 (9.8%) of confirmed cases were clinically diagnosed as pertussis. The other 316 
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cases were diagnosed as lobar or bronchopneumonia (n=15; 36.6%), bronchiolitis 317 
(n=15; 36.6%) or other LRTI (n=7; 17.1%). 318 
All participants were discharged from hospital with no in-hospital deaths occurring. 319 
Fourteen (3.0%) children were admitted to a High Dependency or Pediatric Intensive 320 
Care Units. Among these, 3/41 (7.3%) were Bordetella infected compared to 11/419 321 
(2.6%) in the uninfected group; p=0.120). 322 
 323 
The median length of hospitalisation was two days (IQR 1-4); similar in Bordetella 324 




This study has shown that pertussis is common in South African children hospitalised 329 
with LRTI with an estimated 9% of our sample having laboratory confirmed infection. B. 330 
pertussis was responsible for 75% of the cases with B. parapertussis contributing the 331 
rest. These likely represent true cases of pertussis, as they had both clinical and 332 
microbiological evidence of disease while all results obtained from controls were 333 
negative. The rate is equivalent to 526 cases of laboratory confirmed pertussis for every 334 
100 000 children hospitalised and 4154 of 100 000 children specifically hospitalised 335 
with LRTI. The lack of data on the baseline population from which the cases 336 
originated made it difficult to estimate the true population incidence.  Data from high-337 
income countries report hospitalisation incidences of between 2 and 240 per 100 000 338 
population.[18-20] Possible reasons for the high incidence of disease in our study 339 
population include incomplete primary vaccination and a high burden of HIV which 340 




Pertussis cases occurred consistently throughout the year. The proportion of confirmed 343 
pertussis cases in our study did not show any seasonal pattern although there was an 344 
overall increase in the number of respiratory cases recruited over the winter months. 345 
The increase in winter enrolment was an expected finding that reflects a trend we have 346 
consistently observed over this time of the year. A study done around the same period 347 
in the same province of South Africa reported a similar pattern of increased overall 348 
respiratory cases over the winter months.[22] A recent study found the prevalence of 349 
pertussis to be lower than 1% in children hospitalised with bronchiolitis over the 350 
winter period. Differences in both diagnostic and sampling methodology made it 351 
difficult to compare this finding with the current study.[23] 352 
 353 
HIV exposed and infected children showed higher risks for pertussis. This is of 354 
particular importance in this region with a high burden of maternal HIV with 355 
associated intrauterine exposure and infection.[24] The observed increase in pertussis 356 
cases in these groups may relate to both reduced vaccine effectiveness and passive 357 
immunity associated with HIV infection or exposure.[25-28] It is possible that these 358 
observations may have been confounded by other factors such as poverty, malnutrition and 359 
exposure to biofuels. Consistent with other studies, the risk of B. pertussis was higher in 360 
younger infants and decreased with each extra dose of vaccine received, with the lowest 361 
risk after a completed primary schedule. [18]  362 
 363 
A novel, important finding was the higher sensitivity for diagnosis of Bordetella spp. on 364 
IS specimens, with more confirmed cases on IS compared to NP specimens. The use of 365 
NP specimen on its own would have missed 47% of B. pertussis cases compared to 366 
22% missed by IS. When used in addition to the traditional NP specimen, IS 367 
significantly increased the yield by 47%. IS was successfully obtained in almost all 368 
children and was well tolerated even in very young infants. Large studies of children 369 
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with suspected pulmonary TB have reported excellent safety, tolerability and good 370 
diagnostic yield of IS, even in infants.[15, 29] These data add to the increasing evidence 371 
of the utility and safety of IS for diagnostic confirmation of the aetiology of LRTI in 372 
young children. 373 
 374 
This study also found that testing of IS is more likely to be positive early in the course 375 
of disease. Early diagnosis allows for targeted antibiotic therapy, which may reduce 376 
severity of illness and allow early prophylaxis for close contacts.[30, 31] The findings of 377 
this study suggest that IS should be the recommended specimen for testing children with 378 
suspected pertussis either on its own or in addition to NP specimen, rather than the 379 
current recommended practice of using NP specimen on its own.[9, 10] 380 
 381 
Confirming prior studies, culture had very low sensitivity, suggesting that although this 382 
method of diagnosis offers opportunity for antibiotic sensitivity testing, it is ineffective for 383 
confirming a diagnosis.[5] 384 
 385 
Limitations of this study include lack of detection of other pathogens. The finding of 386 
Bordetella infection does not preclude the possibility of co-infection that may have 387 
modified the disease presentation.[32-34] As only hospitalised cases were included in 388 
the study, the findings may not be generalizable to children with less severe forms of 389 
illness. The small number of confirmed cases limits the interpretation of stratified B. 390 
parapertussis incidence. Further studies to investigate these aspects are needed. 391 
 392 
As our study demonstrates, the difficulty in diagnosing atypical pertussis may substantially 393 
underestimate its role in severe LRTI. Accurate diagnosis is important for timely 394 
treatment, institution of infection control measures and assessment of vaccine 395 
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effectiveness.[5] Macrolides may shorten the duration of symptoms and reduce the very 396 
high secondary attack rate associated with B. pertussis.[30, 31] Although concerns exist of 397 
rapid emergence of resistance to macrolide antibiotics, empiric use should be considered in 398 
young African infants and HIV exposed or infected children hospitalised with LRTI, 399 
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Abstract  30 
Background: Risk factors for pertussis in children in low and middle-income 31 
countries are poorly understood, despite a resurgence of disease.  This study aimed to 32 
investigate risk factors for pertussis disease in African children hospitalised with 33 
severe LRTI. 34 
Methods: A prospective study of children hospitalised with severe LRTI in Cape 35 
Town, South Africa was conducted over a one-year period. A nasopharyngeal and 36 
induced sputum samples from child and nasopharyngeal sample from caregiver were 37 
tested for Bordetella pertussis using PCR (IS481+/hIS1001). History and clinical 38 
details were documented. 39 
Results: 460 children with a median age of 8 (IQR 4-18) months were enrolled.  B. 40 
pertussis infection was confirmed in 32 (7.0%). The adjusted risk of confirmed 41 
pertussis was significantly increased if infants were younger than two months [aRR 42 
2.37 (95% CI 1.03-5.42]), HIV exposed but uninfected (aRR 3.53[95% CI 1.04-12.01]) 43 
or HIV infected (aRR 4.35[95% CI 1.24-15.29]). Mild (aRR 2.27 [95% CI 1.01-5.09]) 44 
or moderate (aRR 2.70 [95% CI 1.13-6.45]) under-nutrition in the children respectively 45 
were also associated with higher risk. The highest adjusted risk occurred in children 46 
whose caregivers had B. pertussis detected from nasopharyngeal swabs (aRR 13.82 47 
[95% CI 7.76-24.62]). Completion of the primary vaccine schedule (three or more 48 
doses) was protective (aRR 0.28 [95% CI 0.10-0.75]).  49 
Conclusions: HIV exposure or infection, undernutrition as well as detection of 50 
maternal nasal B. pertussis were associated with increased risk of pertussis in African 51 
children, especially in young infants. Completed primary vaccination was protective. 52 
There is an urgent need to improve primary pertussis vaccine coverage in low and 53 
middle-income countries.  Pertussis vaccination of   pregnant women, especially those 54 





The last decade has seen a resurgence of pertussis in high-income countries to levels 58 
experienced over half a century ago.[1] Possible reasons for this include waning 59 
immunity following acellular vaccination, antigenic divergence of circulating strains 60 
from vaccine antigens as well as increased ascertainment due to improved diagnostic 61 
tools.[2-5]  62 
 63 
Introduction of the whole cell (wP) pertussis vaccine in the 1940s greatly reduced the 64 
incidence of pertussis. wP has since been succeeded by acellular vaccines (aP), mainly in 65 
high-income countries. The South Africa National Expanded Programme on 66 
Immunisation (EPI) replaced wP with a combination formulation aP (DTaP-IPV/HIB; 67 
Pentaxim®, Sanofi Pasteur) in 2009. The primary schedule comprises doses at six, ten 68 
and 14 weeks with a booster at 18 months of age.[6]. Current data indicates that vaccine 69 
coverage for the Western Cape Province, where this study was done, is 97% at six 70 
weeks, 90.8% at 10 weeks and 85.2% at 14 weeks. By 18 months of age  coverage had 71 
declined to 58.7%.[7] 72 
 73 
 Risk factors for pertussis include lack of immunisation or impaired immune 74 
responses to vaccination. Laboratory studies suggest that immune responsiveness to 75 
pertussis vaccines may be impaired by both infection and intrauterine exposure to HIV 76 
even in HIV-uninfected children. [8-11] Another factor associated with reduced immune 77 
responses to pertussis vaccine is poor nutritional status, a common problem among children in 78 
low and middle-income countries (LMIC).[12] Although household use of biomass fuels, 79 
indoor air pollution, and cigarette smoking have been associated with an increased risk of 80 
respiratory illness and bacterial carriage in children, it is unclear if these impact on the risk of 81 




With the resurgence of pertussis, adults and adolescents, who tend to exhibit milder 84 
and atypical symptoms, are now recognized as important sources of pertussis in 85 
infants. In particular, household contacts pose the greatest risk to unvaccinated or 86 
partially vaccinated infants.[14-16]  87 
 88 
We aimed to investigate risk factors for Bordetella pertussis disease in a cohort of African 89 
children less than 13 years of age hospitalised with lower respiratory tract infection (LRTI) 90 
in a high HIV prevalence setting.[17] 91 
 92 
Materials and Methods 93 
Children less than 13 years of age admitted over a one-year period (07 September 2012 to 94 
06 September 2013) for LRTI to the Red Cross War Memorial Children’s Hospital 95 
(RCH), Cape Town, South Africa, were prospectively screened for enrolment. Children 96 
with WHO-defined severe pneumonia (age specific tachypnoea or/and lower chest 97 
indrawing requiring hospitalisation) or apnoea were eligible to be included. A child 98 
was included if the legal guardian gave written consent and the child had not been in 99 
contact with a health care facility in the previous 48 hours to two weeks prior to 100 
screening for enrolment. Enrolment was limited to the first four qualifying children per 101 
working weekday. 102 
 103 
History of symptoms of the presenting illness and information on current socio-104 
demographic factors including type of housing, access to amenities such as tap water, 105 
electricity and toilet facilities, was taken from the caregiver. The mother’s level of 106 
education was recorded. Socio-economic status was categorized into quartiles on the basis 107 
of a validated weighted composite score used elsewhere that included asset ownership, 108 
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employment and education.[18] The use of household biofuels, presence of smokers in the 109 
household and the number of people sharing the bedroom with the child were established. 110 
Information on day-care attendance was also collected. 111 
 112 
The mother’s HIV status (and that of the primary caregiver if this was not the mother) was 113 
established. If the mother or caregiver was HIV infected the latest available CD4 count was 114 
recorded and used in the staging of HIV disease according to the Centre for Disease 115 
Control (CDC) classification.[19] History was taken on the presence and duration of recent 116 
primary caregiver respiratory symptoms as well as presence and numbers of other 117 
household members with similar symptoms. 118 
The vaccination status of each child was verified using the national standardized 119 
immunisation handheld record, the Road to Health Card (RTHC); specifically, the date 120 
and type of each vaccine was copied from the record. 121 
 122 
The weight of each child, as measured on admission, was used to evaluate nutritional 123 
status using WHO weight for age Z scores (WAZ). Mild under-nutrition was defined 124 
as ≤ -1 WAZ > -2, moderate under-nutrition ≤ -2 WAZ > -3 and severe under-125 
nutrition WAZ ≤ -3.[20]  126 
 127 
Each child was screened for HIV infection using an ELISA test (Architect HIV Ag/Ab 128 
Combo, Abbott Diagnostics, Wiesbaden). The diagnosis of HIV infection was made 129 
if both the ELISA and an HIV PCR test (COBAS AmpliPrep/COBAS Taqman HIV-1, 130 
Roche Molecular Diagnostics, Pleasanton, CA) were positive in children younger than 18 131 
months. A positive ELISA was confirmed with a different ELISA test (Enzygnost Anti-132 
HIV 1/2 Plus, Siemens/Dade Behring, Erlangen) in children older than 18 months to 133 
diagnose HIV infection. Children younger than 18 months who were ELISA positive, 134 
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but PCR negative were classified as HIV exposed uninfected while older children were 135 
classified as HIV exposed uninfected if the mother was HIV infected at the time of the 136 
pregnancy, but the child tested HIV negative. Caregivers who did not know their HIV 137 
status were counselled and offered HIV testing. Children or caregivers with HIV who were 138 
not accessing appropriate treatment were referred to public health facilities for further 139 
follow-up and treatment of HIV. 140 
 141 
Methods employed in the collection of respiratory specimens have been published.[21] 142 
Briefly, nasopharyngeal (NP) specimens from caregivers as well as paired NP and 143 
induced sputum (IS) specimens from children were tested by PCR for B. pertussis. The 144 
NP specimen was taken with a flocked nylon swab which was transported in a nucleic 145 
acid preservation medium (PrimeStore® MTM, Longhorn Vaccines and Diagnostics, 146 
San Antonio, TX). The IS specimen was collected after the NP was taken from each 147 
child. All specimens were frozen at minus 80oC until they were thawed for batched 148 
molecular diagnostic testing. 149 
 150 
A commercially validated duplex real-time PCR assay targeting the insertion sequence 151 
IS481 for Bordetella and  IS1001 for Bordetella parapertussis (LightMix® Bordetella 152 
pertussis and parapertussis Kit, TIB MolBiol, Berlin, Germany) was used for screening 153 
all the respiratory specimens.[22, 23] All specimens testing positive for IS481 were 154 
further tested for the presence of insertion site hIS1001 in order to exclude Bordetella 155 
holmesii (IS481 +, IS1001-, hIS1001 +) before the diagnosis of B. pertussis infection 156 
was made.[24] 157 
 158 
Ethics 159 
The study was approved by the Human Research Ethics Committee of the Faculty of 160 
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Health Sciences of the University of Cape Town; Reference: 371/2011. Written 161 
informed consent was sought and received from the legal guardian for the participation 162 
of both the child and the guardian/caregiver in the study. 163 
 164 
Analysis plan 165 
The study aimed to investigate risk factors for pertussis as a secondary outcome and 166 
was thus not specifically powered to achieve this secondary outcome. The study 167 
sample was determined to attain a 3% precision above and below a point estimate risk 168 
of 5% for the primary outcome (prevalence of pertussis).  169 
 170 
Categorical data are presented as percentages with 95% confidence intervals (CI). All 171 
continuous data are summarized as medians with interquartile ranges (IQR). A χ2 test 172 
assessed strength of association between two categorical variables with a two-tailed cut-off 173 
significance set at p<0.05.  174 
 175 
A causal model employing the current understanding of respiratory disease processes and 176 
pathogenesis of pertussis was constructed using a directed acyclic graph (DAG) to identify 177 
variables in the model required for minimal sufficient adjustment sets for estimating total 178 
independent effects of each assessed risk factor.[25]  179 
 180 
To adjust for potential confounders for each risk factor as identified by the DAG, a 181 
generalized linear Poisson regression model with robust error variance was used to 182 
estimate adjusted relative risks (aRR) and their 95% level of confidence in a 183 
multivariable analysis. For all analyses, Stata Statistical Software Release 13 184 






Baseline characteristics of children 189 
In total, 987 children hospitalised for acute LRTI were screened; 460 child-caregiver 190 
pairs were enrolled; figure 1. The median age of children was 8 (IQR 4-18) months with 191 
41 (8.9%) younger than two months of age. The median duration of symptoms was 3 192 
days (IQR 2-5 days); 173 (37.6%) received antibiotics prior to admission, Table 1. 193 
 194 
Fig 1.  Enrolment flow diagram of study participants showing  195 
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< 2 months old  41 (8.9) 





Female  202 (43.9) 
Male   258 (56.1)  
 
 
Pertussis vaccine doses   
 
0  28 (6.1) 
1  57 (12.4) 
2  58 (12.6) 
≥ 3  308 (67) 
Unknown  9 (2)  
 
 
Nutritional status (WAZ)#  
 
Normal nutrition  351 (76.3) 
Mild under-nutrition  64 (13.9) 
Moderate under-nutrition  33 (7.2) 
Severe under-nutrition  12( 2.6)  
 
 
HIV status  
 
Unexposed Uninfected  349 (75.9) 
Exposed Uninfected  92 (20) 
Exposed Infected  19 (4.1)  
 
 
Presenting symptoms  
 
Cough  456 (99.1) 
Apnoea  20 (4.5) 
Fever  288 (63.7)  
 
 
Pre-hospital antibiotic (n=173)  
 
Penicillin  77 (44.5) 
Ceftriaxone  99 (57.2) 
Cotrimoxazole  4 (2.3) 
Erythromycin  1 (0.4) 
     
# Normal: WAZ > -1, Mild: ≤ -1 WAZ >-2, Moderate: ≤ -2 WAZ > -3, 
Severe: WAZ ≤ -3, WAZ = World Health Organization weight for age Z score  
Ninety-two (20.0 %) children were HIV exposed and uninfected while infection was 202 
confirmed in 19 (4.1%) (table 1) of whom nine were on antiretroviral therapy, four with 203 
viral suppression. Of the 19 children, one was WHO HIV stage 1; another was HIV stage 2 204 
and 10 were HIV stage 3 and 4 respectively.  205 
 206 
Most children 351(76.3%) were adequately nourished with weight for age Z score > -1. 207 
Mild under-nutrition was found in 64 (13.9%), moderate under-nutrition in 33 (7.2%) 208 
and severe under-nutrition in 12 (2.6%) children; table 1. Only 60 (13.0%) of the 209 
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children had not received any form of breastfeeding, exclusive or otherwise. The majority 210 
(n=323, 77.2%) was breast-fed for the first four months of life and 77 (16.7%) for 211 
longer than four months. 212 
 213 
Most children (n=451; 98.0%) had their RTHC available and their immunisation status, 214 
including the number of vaccine doses could be verified, table 1.  Nineteen (4.2%) 215 
children were younger than six weeks and had as yet not received the first dose of 216 
pertussis vaccine. Of the 432 (95.8%) old enough to receive at least one vaccine dose, 217 
369 (85.4%) had received expected doses for age. 218 
 219 
Confirmed Bordetella pertussis in children 220 
NP specimens were obtained from all child participants. Four children were 221 
transferred or discharged out of the ward before an IS specimen could be obtained. 222 
For the remaining 456 children, IS was successfully obtained with no major adverse 223 
events, although two were later lost to container leakage. 224 
 225 
PCR for IS481 was positive in 17 NP specimens and 25 IS specimens. There was an 226 
overlap of positive NP and IS specimens in 10 participants giving a total of 32 (7.0%; 227 
95% CI 4.8-9.7%) children with confirmed B. pertussis infection. B. parapertussis 228 
(IS1001+) was detected in seven (1.5%; 95% CI 0.6-3.2%) children. B. holmesii was 229 
excluded in all the positive specimens by the absence of hIS1001.  230 
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Caregiver baseline characteristics 231 
All 460 primary caregivers took part in the study of whom 450 (97.8%) were mothers. For 232 
the remaining 10 children, the caregiver was the father in two (0.4%) instances, 233 
grandmother in five (1.1%) and another relative in the other three (0.7%) children. In 234 
451(98.0%) of the recruited pairs, the caregiver slept in the same room as the child. The 235 
median age of the caregivers was 28 (IQR 24-33) years. In the week the child presented to 236 
hospital, 171 (37.2%) of the caregivers had respiratory symptoms. The symptoms, 237 
predominantly of an upper respiratory tract infection, were present in 10 (31.3%) of 238 
caregivers whose children had confirmed pertussis and in 161 (37.7) whose children did 239 
not have pertussis; p=0.466. Baseline characteristics of the caregivers are summarized in 240 
Table 2. 241 
Table 2: Caregiver characteristics by child’s B. pertussis PCR status 







     
  n (%)  n (%) 
Gender     
Female  426 (99.6)  32 (100.0) 
     
HIV status     
Infected  88 (22.9)  13 (40.6) 
     
Presenting symptoms     
Cough  96 (22.4)  7 (21.9) 
Runny nose  107 (25)  6 (18.8) 
Wheeze  35 (8.2)  3 (9.4) 
Fever  100 (23.4)  6 (18.8) 
     
B. pertussis NP     
PCR positive   5 (1.2)  10 (31.3) 
     




HIV infection was present in 111 (24.1%) of caregivers whom 55 (49.5%) were on 243 
antiretroviral treatment. 244 
 245 
Cigarette smoking was recorded in 162 (35.2%) of the households although only 33 (7.2%) 246 
of the caregivers were themselves smokers. The use of biofuels for cooking or heating was 247 
uncommon and reported in 18 (3.9%) households. 248 
 249 
Confirmed Bordetella pertussis in caregivers 250 
NP specimens were successfully obtained from all 460 caregivers. IS481 was positive in 15 251 
(3.3%; 95% CI 1.8-5.3%) of the caregivers, 10 in mothers of children with confirmed B. 252 
pertussis infection, table 2. All IS481 positive specimens were negative for the hIS1001 B. 253 
holmesii locus.  254 
 255 
Caregivers with detected nasal B. pertussis were all mothers of enrolled children and all slept in 256 
the same bedroom with the child. No association was noted between presence of maternal 257 
symptoms and confirmed B. pertussis infection [4/171 (2.3%) symptomatic versus 11/289 258 
(3.8%) asymptomatic; p=0.392]. There was no difference in the duration of symptoms between 259 
caregivers with confirmed pertussis and those without: median 3 (IQR 2.5-5) days and 2 (IQR 2-260 
5) days respectively; p=0.513. B. pertussis was detected in 6 (5.4%) of HIV infected caregivers 261 




Effect of risk factors  264 
Unadjusted and adjusted effects of factors on risk of pertussis disease in children are 265 
shown in Table 3. 266 
Table 3: Risk factors for confirmed Bordetella pertussis infection in study children 
     
    Relative Risk (95% Confidence Interval) 
Risk factor  Risk  n/N (%)  Crude   Adjusted* 
Age  
 
    
≥ 2 months old  26/419 (6.2)  1  1 
< 2 months old  6/41 (14.6)  2.36 (1.03-5.40)  2.37 (1.03-5.42) 
       
Nutritional status           
Normal  19/351 (5.4)  1  1 
Mild under-nutrition  8/64 (12.5)  2.31 (1.06-5.05)  2.27 (1.01-5.09) 
Moderate under-nutrition  5/33 (15.2)  2.80 (1.12-7.02)  2.70 (1.13-6.45) 
Severe under-nutrition  0/12 (0.0)  NA  NA 
             
HIV status        
Unexposed uninfected   19/349 (5.4)  1  1 
Exposed uninfected  10/92 (10.9)  2.00 (0.96-4.15)  3.53 (1.04-12.01) 
Infected  3/19 (15.8)  2.90 (0.94-8.96)  4.35 (1.24-15.29) 
        
Pertussis vaccine doses            
None  5/28 (17.9)  1  1 
One  4/57 (7.0)  0.49 (0.11-1.35)  0.39 (0.11-1.33) 
Two  5/58 (6.9)  0.47 (0.14-1.51)  0.33 (0.09-1.19) 
Three and more  19/308 (6.2)  0.33 (0.13-0.81)  0.28 (0.10-0.75) 
        
Caregiver B. pertussis            
PCR negative  22/455 (4.9)  1  1 
PCR positive  10/15 (66.7)  13.48 (7.84-23.21)  13.82 (7.76-24.62) 
        
Home cigarette smoking            
No home smoker  21/298 (7.0)  1  1 
Home smoker  11/162 (6.8)  0.96 (0.48-1.95)  0.98 (0.49-1.98) 
        
Bio-fuel use            
No bio-fuel  29/442 (6.6)  1  1 
Use of bio-fuel  3/18 (16.7)  2.54 (0.85-7.57)   2.40 (0.73-7.91) 
       
n/N (%) = stratum specific proportion and percent. * Multivariable models adjusted for age, sex, HIV status, socio-
economic status, breast-feeding and number of household members with cough. Risk ratio 95% confidence intervals 




Clinical features of children with and without pertussis were similar except for fever 268 
which was present in 274 (64.0%) of children without pertussis compared to 14 269 
(43.8%) in children with pertussis; p=0.022. LRTI cases with confirmed B. pertussis 270 
had a median age of 8 months (IQR 2-21), similar to LRTI cases without pertussis [8 271 
months (IQR 4-18)]; p=0.43). However, the risk of pertussis was significantly 272 
increased in young infants less than two months of age; 14.6% versus 6.2%; aRR 2.37 273 
(95% CI 1.03-5.42). 274 
 275 
No association was found between household air pollution or smoking and risk of pertussis 276 
was identified even after adjusting for potential confounders.  277 
 278 
Both HIV exposure and HIV infection were independently associated with an increased 279 
risk of confirmed B. pertussis infection with aRR 3.53 (1.04-12.01) and 4.35(1.24-280 
15.29) respectively. The risk of B. pertussis declined with each extra dose of pertussis 281 
vaccine independent of age, although the reduction only became significant after completion 282 
of the 3-dose primary vaccine schedule; aRR 0.28 (95% CI 0.10-0.75).  283 
 284 
Mild and moderate under-nutrition were also associated with an increased risk of pertussis in the 285 
adjusted model, however no cases occurred in severely under-nourished children, table 3.  286 
 287 
Detection of maternal nasal B. pertussis was most strongly associated with an increased 288 
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risk of pertussis in the children with aRR 13.82(7.76-24.62). HIV infected caregivers were 289 
more likely to have children with confirmed pertussis infection with 13/111 (11.7%) compared 290 




This study reports important, novel findings of significant increased risk of pertussis in 295 
children exposed to HIV in utero and in children with HIV infection as well as in children 296 
with poor nutritional status.  In addition, the highest risk of pertussis-associated LRTI in 297 
hospitalised African children was in those whose mothers had B. pertussis detected in 298 
nasopharyngeal specimens, with more than 13 fold increased risk.  This study also confirms 299 
known factors, namely, incomplete primary vaccination and early infancy as important 300 
risks for pertussis in an LMIC setting. 301 
 302 
Sub-Saharan Africa, where this study was conducted, carries a high burden of HIV, 303 
including a large number of infected or exposed children. In the current study, after 304 
adjusting for potential confounding, HIV-infected children had a four-fold increase in 305 
the risk of pertussis, possibly due to reduced vaccine effectiveness due to both poor 306 
responses to vaccination as well as low persistence of immunoglobulin following 307 
vaccination.[8, 9] This increased risk may also reflect increased parental susceptibility. A 308 
study Nigerian study showed a 20-fold risk of pertussis in adolescents not yet initiated 309 
on anti-retroviral therapy.[26] Other recent studies have reported an increased risk of 310 
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pertussis in HIV infected individuals.[27-30]The quality and duration of immunity to 311 
pertussis in HIV infected children once they are started on antiretroviral therapy is 312 
uncertain.[31] The small number of HIV-infected children in our study made it 313 
impossible for us to investigate these aspects.  314 
  315 
HIV-exposed, but uninfected, children are increasingly emerging as a group more 316 
susceptible to developing disease compared to unexposed children, due to successful 317 
implementation of prevention of mother to child transmission strategies with a 318 
reduction in vertically transmitted HIV.[32] This study identifies HIV exposure in 319 
utero as a significant important risk factor for pertussis, consistent with other reports 320 
that suggested an increased risk in infants, even if the findings were not significant. In 321 
our study a quarter of the mothers were HIV infected. The increased risk in HIV 322 
exposed uninfected children seems related to reduced immunoglobulin levels 323 
passively transmitted from the mother, increased exposure to pertussis in a HIV-324 
household as well as possible impaired responses to vaccination that are not yet 325 
clearly understood.[10, 11]  326 
 327 
The high risk of pertussis-associated LRTI in children whose mothers had 328 
nasopharyngeal B. pertussis is consistent with studies showing that most infants 329 
acquire pertussis from an older sibling or parent.[14] Consequently, attempts to protect 330 
young infants have advocated cocooning, which involves vaccinating household 331 
members, as well as antenatal and postnatal vaccination of mothers of neonates. 332 
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Whereas cocooning does not seem cost-effective, antenatal vaccination of mothers has 333 
shown promising protection for infants with no added risk to either the mother or the 334 
pregnancy.[33-37]. In our study, the risk of pertussis may be partially explained by the 335 
high proportion of HIV infected caregivers who exhibited a higher risk for 336 
nasopharyngeal carriage compared to HIV uninfected caregivers (5.4% vs 2.6%) 337 
although these findings were not statistically significant most likely due to small 338 
numbers. 339 
 340 
The risk of B. pertussis infection independently decreased with each extra dose of 341 
vaccine received, but as observed in other studies, statistically significant reduction 342 
was only seen with completion of at least three doses.[38, 39]  This highlights the great 343 
risk pertussis poses to children in LMIC who, according to WHO, largely receive 344 
incomplete vaccination.[40, 41] This risk is further increased by the high incidence of 345 
endemic childhood malnutrition.[42] 346 
 347 
The study is limited by low frequencies of pertussis in some subgroups. Even when the 348 
study possessed sufficient power to demonstrate statistically significant risk, the estimated 349 
magnitude had low precision in some instances. A further limitation is that the study was 350 
done in children hospitalised with LRTI so the generalizability of the results to children with 351 






There is an urgent need for interventions in LMICs to address modifiable risk factors for 356 
pertussis. Such interventions should include nutritional support and immunisation.  357 
Immunisation programs should be strengthened to ensure high levels of coverage for children 358 
with at least three vaccine doses and include catch-up immunisation for missed doses.  A key 359 
consideration is to prioritise vaccination of pregnant women, particularly those who are 360 
HIV infected, as maternal infection is the greatest risk for disease in infants.[43] 361 
 362 
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Multiple potential pathogens are frequently co-detected among children with lower 34 
respiratory tract infection (LRTI). Evidence indicates that Bordetella pertussis has an 35 
important role in the aetiology of LRTI. We aimed to study the association between B. 36 
pertussis and other respiratory pathogens in children hospitalised with severe LRTI, 37 
and to assess clinical relevance of co-detection. Nasopharyngeal (NP) swabs and 38 
induced sputa (IS) were tested with a B. pertussis specific PCR; additionally, IS was 39 
tested for other pathogens using a multiplex PCR. We included 454 children, median 40 
age 8 months (IQR 4-18), 31 (7%) of whom tested positive for B. pertussis. Children 41 
with B. pertussis had more bacterial pathogens detected (3 versus 2; P<0.001). While 42 
B. pertussis showed no association with most pathogens, it was independently 43 
associated with Chlamydia pneumoniae, Mycoplasma pneumoniae and parainfluenza 44 
viruses with adjusted risk ratios of 4.01 (1.03-15.64), 4.17 (1.42-12.27) and 2.13 (1.03-45 
4.55), respectively. There was a consistent increased risk of severe disease with B. 46 
pertussis. Patterns indicated even higher risks when B. pertussis was co-detected with 47 
any of the three organisms although not statistically significant. Improving vaccine 48 
coverage against B. pertussis would impact not only the incidence of pertussis but also 49 






















Lower respiratory tract infection (LRTI) is responsible for a large burden of morbidity 70 
and mortality in children each year. [1] Current understanding is that the aetiology of 71 
LRTI may frequently be polymicrobial, with various combinations of viral and 72 
bacterial pathogens implicated in the pathogenesis.[2-5] Bordetella pertussis, the 73 
organism that causes whooping cough, is one of the organisms strongly associated 74 
with LRTI in children, however the role of other organisms in the pathogenesis of 75 
LRTI is not well-understood. [4]  76 
 77 
Effective vaccines against B. pertussis have been available since the 1940’s. Initially 78 
these were of the whole cell type (wP) but have since the 1990’s been superseded by 79 
acellular vaccines (aP) mainly in high income countries.[6] The introduction and wide 80 
use of vaccines have markedly reduced the burden of pertussis over the last six 81 
decades, but there is strong evidence that pertussis has resurged all over the world in 82 
recent years, bringing into focus B. pertussis as an important respiratory pathogen in 83 
the aetiology of respiratory illness, including LRTI.[7, 8] 84 
 85 
Although the presence of B. pertussis has been described together with other 86 
organisms that are potential co-pathogens in individuals with LRTI, most studies have 87 
focused on the role of viruses in respiratory tract co-infections.[9] As a result, 88 
potential interactions between  B. pertussis and other organisms remain poorly 89 
understood.[10-12] The organism, B. pertussis, produces several toxins that aid the 90 
organism in evading the immune system, assisting it to establish infection on the 91 
respiratory epithelium.[13, 14]  92 
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We hypothesise that the conditions produced by B. pertussis toxins not only create a 93 
conducive environment for B. pertussis itself but may facilitate the colonisation or 94 
infection of the respiratory tract epithelium by other bacteria or viruses. In this study, 95 
we aimed to investigate whether the detection of B. pertussis in children hospitalised 96 
for LRTI was associated with co-detection of other potential respiratory pathogens. 97 
We also explore whether there was an association between co-detection and clinical 98 




Recruitment and specimen collection 103 
 104 
Methods for sampling as well as inclusion criteria have been described 105 
elsewhere.[15] Briefly, the study recruited inpatient children seen at a referral 106 
hospital, Red Cross War Memorial Children’s Hospital (RCH) in Cape Town, 107 
South Africa over a one-year period (September 2012 to September 2013). 108 
Children were recruited if they presented with cough and WHO defined age 109 
specific tachypnoea, or apnoea, and were ill enough to warrant admission. Only children 110 
whose legal guardians were present to give written consent were enrolment.  111 
Being in contact with the health care services in the preceding two weeks was an 112 
exclusion criterion. 113 
 114 
To assess the severity of respiratory symptoms, the presence of chest indrawing was 115 
noted. In addition, all children had pulse oximetry to assess for oxygen saturation. 116 
A cut-off of <94% was used to define hypoxaemia in children at sea level.[16-18]  117 
A detailed history of the current illness was collected, and participants underwent 118 
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testing for HIV infection. The diagnosis of HIV infection was made for children 119 
less than 18 months of age if they tested positive for two HIV PCR tests (COBAS 120 
AmpliPrep/COBAS Taqman HIV-1, Roche Molecular Diagnostics, Pleasanton, 121 
CA). For children above 18 months of age, HIV infection was diagnosed on the 122 
basis of two positive ELISA tests using two different assays (Architect HIV 123 
Ag/Ab Combo, Abbott Diagnostics, Wiesbaden; and Enzygnost Anti-HIV 1/2 124 
Plus, Siemens/Dade Behring, Erlange sequentially).  125 
 126 
All children had anthropometry (weight and height), performed at enrolment by 127 
trained study staff. Nutritional status was classified using WHO weight for age z-128 
scores (WAZ). Children were classified as moderate to severely malnourished if 129 
their weight for age fell below -2 z-scores.   130 
 131 
The children’s vaccination status was sourced from their handheld clinic booklets. The 132 
primary schedule according to the South African Expanded Program on 133 
Immunisation, in addition to other vaccines, contains an acellular (aP) vaccine against 134 
B. pertussis combined with that against Haemophilus influenzae type b at 6, 10 and 14 135 
weeks (with a booster at 18 months), and vaccination with 13-valent pneumococcal 136 
conjugate (PCV13) vaccine at 6 and 10 weeks of age (with a booster at 9 months) 137 
.[19] 138 
 139 
A nasopharyngeal (NP) swab was collected first after which an induced sputum (IS) 140 
specimen was collected on enrolment as previously described.[20] Molecular 141 
diagnostic testing was carried out on batched specimens as described below. No 142 




Laboratory methods 145 
 146 
Diagnosis of Bordetella pertussis  147 
To diagnose Bordetella pertussis infection, PCR specific for IS481 for Bordetella 148 
species was conducted on both NP and IS specimens with a validated commercial kit 149 
(Roche LightMix®, Basel) using previously published primers.[21] Bordetella 150 
holmesii (defined as IS481 + and hIS1001 +) infection was excluded by further 151 
testing all IS481 positive specimens for the presence of insertion site hIS1001.[22]  152 
 153 
Diagnosis of co-infections 154 
The FTDResp 33 multiplex real-time PCR assay (Fast-Track Diagnostics, Esch-sur-155 
Alzet, Luxembourg) was used to identify presence of a range of viruses and bacteria 156 
as well as Pneumocystis jirovecii on IS. As the study was designed specifically to 157 
study the epidemiology of pertussis in this population, for the analysis, B. pertussis 158 
results from LightMix® for B. pertussis (rather than those from FTDResp 33) 159 
were used as our assessment indicated that the assay had better sensitivity for B. 160 
pertussis than Fast-Track, although both employ the same targets.  161 
 162 
 163 
Statistical analysis 164 
 165 
We used percentages to depict proportions of study participants with organisms 166 
detected from respiratory specimens. Continuous data were tested for normality 167 
and summarized as medians with interquartile ranges (IQR) or means and 168 
standard deviations (SD) as appropriate. The difference in total numbers of organisms 169 
detected in participants with and without confirmed B. pertussis was compared using 170 
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Student’s t-test. χ2 or Fisher’s exact tests were used to assess the strength of association 171 
between infection with B. pertussis and each co-pathogen. All associations at a two-tailed 172 
p<0.1 were further analysed adjusted for sex, age and HIV status as potential 173 
confounders. Generalised linear modelling using Poisson regression with robust 174 
error variance was used to estimate adjusted relative risks (aRR) and their 95% 175 
confidence intervals in a multivariable analysis. Severity of clinical disease and 176 
outcomes were further analysed stratified by a combination pertussis status and organisms 177 
showing strong association with pertussis. Continuous data were tested for normality and 178 
comparisons between groups were made with the appropriate test for parametric or non-179 
parametric data as indicated. Statistical significance was set at a two-side P<0.05. All 180 
analyses were carried out using Stata Statistical Software Release 13 (StataCorp 181 
LP, College Station, TX). 182 
 183 
Statement on ethics approval 184 
Prior approval for the study was obtained from the Human Research Ethics 185 
Committee of the Faculty of Health Sciences of the University of Cape Town; 186 
reference: 371/2011. Written informed consent was sought and received from the 187 
parent or legal guardian of each child in order for the child to participate in the 188 
study. All methods were carried out in accordance with the relevant guidelines 189 











Baseline data 199 
Four hundred and sixty children were enrolled. Six children, including four whose IS 200 
could not be collected and two whose IS were lost prior to processing during transportation 201 
or storage, were excluded, providing 454 participants with sufficient data for analysis, of 202 
which 253 (55.7%) were male. 203 
 204 
The median age of the children was 8 (IQR 4 -18) months. HIV infection was 205 
confirmed in 19 (4.2%) of the children. Nine children (2.0%) did not have their 206 
immunisation records with them. Of the 445 (98.0%) with known vaccination 207 
status, 321(72.1%) were up to date with pertussis and Haemophilus influenzae type 208 
b vaccine doses for age, while 427 (96.0%) had received at least one dose of the 209 
combination. Similarly, 312 (70.1%) were up to date with PCV13 doses for age 210 
with 385 (86.5%) having received at least one dose of the vaccine. Baseline 211 








Table 1: Baseline characteristics of study participants  
Baseline character  N=454 
   
Age   
Median (IQR) months  8 (4-18) 
   
  n (%) 
Male sex  253 (55.7.) 
   
Pertussis/H. influenza type b vaccines 
doses          
  
0  31 (6.8) 
1  59 (13.0) 
2  61 (13.4) 
≥ 3  294 (64.8) 
Unknown  9 (2.0) 
   
PVC13 vaccine doses   
0  60 (13.2) 
1  108 (23.8) 
2  139 (30.6) 
3  138 (30.4) 
Unknown  9 (2.0) 
   
HIV infected  19 (4.2) 
   
Nutritional status   
Normal  384 (90.8) 
WAZ  ≤ -2  39 (9.2) 
   
Pre-hospital antibiotic   
Yes  153 (36.2) 
No  270 (63.8) 
   
Oxygen saturation < 94% in room air  70 (15.4) 
Chest indrawing  380 (83.7) 
   
Confirmed Bordetella pertussis  31(6.8) 
   
WAZ=World Health Organization weight for age Z-score < -2 
 218 
Confirmed Bordetella pertussis infection 219 
PCR for insertion site IS481 was positive in 16 NP specimens and 25 IS specimens 220 
on LightMix®. Ten participants had a positive PCR on both NP and IS specimens, 221 
therefore 31 (6.8%; 95% CI 4.7-9.6%) participants were confirmed as having B. 222 
pertussis infection. The B. holmesii insertion site hIS1001, was not identified in 223 
any of the IS481 positive specimens.  Only 10 (2.2%) samples, all also found to be 224 
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positive on LightMix®, were positive for B. pertussis on Fast-Track testing of IS 225 
samples. 226 
 227 
The median age of children with confirmed B. pertussis was 8 (IQR 2-22) months 228 
while those testing negative had a median age of 8 (IQR 4-18) months; P=0.559. 229 
 230 
General description of PCR detected pathogens 231 
In most participants (n=412; 90.7%) both a viral and bacterial organism were co-232 
detected from the IS specimen.  Four hundred and forty-one (97.1%) participants had 233 
at least one virus identified from an IS specimen. There were 29 (6.4%) participants in 234 
whose specimens only a viral pathogen was detected with no bacterial pathogens detected.  In 235 
421 (92.7%) at least one bacterial species was identified. There were 9 (2.0%) participants in 236 
whose specimens only a bacterial pathogen was detected with no viral pathogens detected. 237 
Four (0.9%) of the 454 children did not have any organism (including B. pertussis) 238 
identified from their IS specimen.   239 
 240 
For all participants with confirmed B. pertussis infection, a minimum of two 241 
organisms were identified. The average number of viruses detected in children with 242 
and without confirmed pertussis were 2.5 (SD 1.4) and 2.3 (SD 1.3) respectively; 243 
P=0.665. Children with confirmed pertussis had on average 3.0 (SD 1.6) different 244 
bacterial species detected while those without had 2.0 (SD 1.1); P<0.001. When both 245 
bacterial and viral organisms were considered, the average number identified in 246 
pertussis positive participants was 5.5 (SD 2.0) and 4.4 (SD 1.9) in the pertussis 247 





















































































Figure 1. Distribution of number of bacteria (a) , viruses (b) and bacteria + viruses (c) identified on polymerase 
chain reaction (PCR)  in participants with and without Bordetella pertussis 






















































The prevalence of specific organisms identified on IS in participants with and without 250 
confirmed pertussis is shown in descending order of frequency in Table 2. 251 
 252 
 253 
Co-detection of Bordetella pertussis with specific organisms  254 
Overall, Moraxella catarrhalis was the commonest bacterium identified with 295 255 
(65.0%) samples testing PCR positive for the organism. Mycoplasma pneumoniae 256 
showed association with B. pertussis infection (P=0.025) while Chlamydia 257 
pneumoniae displayed weak evidence of association with B. pertussis (P=0.076). No 258 
other bacteria were significantly associated with confirmed pertussis. Table 2.  259 
Cytomegalovirus was the commonest virus, identified in 253 (55.7%) of the 260 
participants. Parainfluenza viruses (1, 2, 3 &4) were weakly associated (P=0.052) 261 
with the presence of B. pertussis, while Respiratory Syncytial Virus (RSV) was 262 
Table 2: Association between Bordetella pertussis and other organisms isolated on IS (N=454) 
    Bordetella pertussis PCR n (%) 
Pathogen¶  Total n (%)  Positive n=31  Negative n=423  P value# 
Viral organisms         
Cytomegalovirus  253 (55.7)  17 (54.8)  236 (55.8)  0.918 
Rhinovirus  222 (48.9)  17 (54.8)  205 (48.5)  0.493 
Respiratory Syncytial 
Virus 
 135 (30.7)  5 (16.1)  130 (30.7)  0.086 
Adenovirus  117 (25.8)  9 (29.0)  108 (25.5)  0.667 
Bocavirus  80 (17.6)  8 (25.8)  72 (17.0)  0.215 
Enterovirus-parechovirus  80 (17.6)  7 (22.6)  73 (17.3)  0.453 
Parainfluenza (1,2,3 4)  75 (16.5)  9 (29.0)  66 (15.6)  0.052 
Metapneumovirus A & B  45 (9.9)  1 (3.2)  44 (10.4)  0.345 
Coronavirus 
(43,63,229,hku) 
 35 (7.7)  3 (9.7)  32 (7.6)  0.723 
Influenza (A, B, C)  28 (6.2)  0 (0.0)  28 (6.6)  0.244 
Bacterial organisms         
Moraxella catarrhalis  295 (65.0)  18 (58.1)  277 (65.5)  0.403 
Streptococcus pneumoniae  240 (52.9)  17 (54.8)  223 (52.7)  0.819 
Haemophilus influenzae  231 (50.9)  18 (58.1)  213 (50.4)  0.407 
Staphylococcus aureus  136 (30.0)  9 (29.0)  127 (30.0)  0.907 
Haemophilus influenzae B  16 (3.5)  2 (6.5)  14 (3.3)  0.299 
Mycoplasma pneumoniae  10 (2.2)  3 (9.7)  7 (1.7)  0.025 
Chlamydia pneumoniae  7 (1.2)  2 (6.5)  5 (1.2)  0.076 
Fungal organism             
Pneumocystis jirovecii  98(21.6)  8 (25.8)  90 (21.3)  0.554 
IS=induced sputum. # Two-sided Fisher’s exact or Chi Square tests P-values; Bold Typeface = P < 0.1 
¶ Organisms shown in descending order of total frequency for each pathogen group 
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weakly associated with the absence of B. pertussis (p=0.086). The other viruses did 263 
not show any association with B. pertussis infection. Table 2. Pneumocystis jirovecii 264 
was detected in 8 (25.8%) and 98 (21.6%) of participants with and without confirmed 265 
pertussis, respectively, P=0.554). 266 
  267 
After adjusting for potential confounding, two bacterial pathogens, namely C. 268 
pneumoniae (aRR 4.01 (95% CI 1.03-15.64) and M. pneumoniae (aRR 4.17 (95% CI 269 
1.42-12.27) remained independently associated with confirmed B. pertussis infection. 270 
Parainfluenza viruses (aRR 2.13 (95% CI 1.03-4.55) was the one group of viruses that 271 
showed significant independent association with confirmed pertussis.  Lack of strong 272 
association between the absence of B. pertussis and RSV remained unchanged after 273 
adjusting for potential confounding. Table 3.  274 
 275 
Table 3. Risk of lower respiratory co-infection in children with confirmed Bordetella pertussis infection 
Co-infection  Bordetella pertussis PCR n (%)  RR (95% Confidence interval) 
  Positive n=31 Negative n=423  .              Crude              .   .          Adjusted#       . 
Chlamydia pneumoniae  2 (6.5) 5 (1.2)  4.40 (1.29-14.98) 4.01 (1.03-15.64) 
Mycoplasma pneumoniae  3 (9.7) 7 (1.7)  4.75 (1.73-13.11) 4.17 (1.42-12.27) 
Parainfluenza (1,2,3,4)  2 (6.5) 4 (1.0)  2.07 (0.99-4.31) 2.13 (1.03-4.55) 
Respiratory syncytial virus  5 (16.1) 130 (30.7)  0.45 (0.18-1.16) 0.45 (0.17-1.20) 
RR = Relative risk; # Multivariable model adjusted for age in months, sex and HIV status; confidence intervals not 
overlapping the null value of 1 are shown in bold typeface. 
 276 
Clinical presentation and outcome 277 
 278 
Only three (9.7%) of the 31 B. pertussis PCR positive cases were diagnosed clinically 279 
with pertussis. All 454 participants were discharged from hospital with no in-hospital 280 
deaths occurring in both the B. pertussis PCR positive and negative groups. Twelve 281 
(2.4%) children required a High Dependency Unit or Paediatric Intensive Care Unit 282 
admission; slightly higher frequency in children with confirmed B. pertussis with 283 
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two out of 31 (6.5%) and 10 out of 423 (2.4%) in the positive and negative groups 284 
respectively; P=0.194. Due to the small numbers, no further analysis was possible. 285 
Hypoxaemia as indicated by oxygen saturation of <94% was noted in 70 (15.4%) 286 
children while chest indrawing was noted in 380 (83.7%). In general, children with 287 
confirmed pertussis showed higher frequencies of chest indrawing with 28 (90.3%) 288 
out of 31 compared to 352 (83.2%) of the 423 (P=0.449) without pertussis. 289 
Similarly, there were 9 (29.0%) out of 31 compared to 61(14.4%) out of 423 290 
(P=0.039) showing hypoxaemia in children with and without B. pertussis, 291 
respectively. 292 
 293 
The same pattern was noted with the two bacterial organisms whose detection was strongly 294 
associated with B. pertussis. Figure 2. A higher risk of severe disease was seen when B. 295 
pertussis was detected with each organism than when B. pertussis or each of the bacteria 296 
was detected on its own.  No hypoxaemia was noted in any of the C. pneumoniae positive 297 
children who did not have B. pertussis. With parainfluenza viruses, this pattern was noted 298 
only with respect to hypoxaemia but not with chest indrawing. The small sample sizes of 299 
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Figure 2. Proportion of children with hypoxaemia and chest indrawing by presence of  co-detected organisms 
that were strongly associated with pertussis
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The median length of hospital stay was similar in children with confirmed B. 304 
pertussis [2 (IQR 1- 5) days] and children testing negative [2 (IQR 1-4) days]; 305 
P=0.522. The co-detection of organisms independently associated with pertussis 306 
did not have an effect on the length of hospital stay.  307 
 308 
Discussion 309 
This study demonstrates a high prevalence of bacteria and viruses involved in LRTI in 310 
children requiring hospitalisation for severe disease. The study also shows that only a 311 
few of these organisms are specifically associated with B. pertussis co-detection. The 312 
detection of B. pertussis was however strongly associated with a higher number of co-313 
detected potential respiratory pathogens, specifically bacterial organisms. Although 314 
most of the studied potential respiratory pathogens did not show association with the 315 
presence of B. pertussis, three, namely C. pneumoniae, M. pneumoniae and 316 
parainfluenza viruses, were independently associated with being co-detected with B. 317 
pertussis. In addition, the study shows some evidence, albeit weak, that the co-318 
detection of B. pertussis, together with these three organisms may be a risk for severe 319 
illness. 320 
 321 
The finding of other pathogens in a respiratory tract specimen together with B. 322 
pertussis is not by itself remarkable. As noted earlier, several studies have shown that 323 
multiple potential pathogens are frequently identified from children with respiratory 324 
infections, including pertussis.[4, 23] What is of interest, however, is the finding of 325 
higher numbers of potential pathogens, in particular bacterial, significantly associated 326 
with the presence of confirmed B. pertussis; and the association of specific organisms 327 




Participants with B. pertussis had more organisms detected in their sputum samples, 330 
compared to those without. This association was significant for bacterial pathogens, a 331 
finding which had an impact also on association with overall total number of all 332 
detected organisms. In addition, patients with B. pertussis had a fourfold increase in 333 
the risk for detection of either C. pneumoniae or M. pneumoniae, as well as twice the 334 
risk to detect parainfluenza viruses.  335 
 336 
In this study, although the number of viruses associated with B. pertussis was 337 
marginally higher, this finding was not of statistical significance. This is in keeping 338 
with findings of other studies that show little association between B. pertussis and 339 
viral infections.[24] Specifically, our study showed a negative correlation between B. 340 
pertussis and RSV although this finding was also not of statistical significance. This 341 
pattern was however in keeping with published literature where a negative association 342 
was noted between RSV and pertussis or between pertussis and bronchiolitis, a disease 343 
mainly attributable to RSV.[25, 26] We did however, find independent association 344 
between detection of parainfluenza viruses and the presence of B. pertussis. 345 
 346 
Children with pertussis generally showed more severe clinical illness (hypoxaemia, 347 
chest-indrawing and need for high dependency care). Although these findings were 348 
not all statistically significant due to the small numbers, the pattern was consistent. 349 
Children who had both strongly associated organisms and B. pertussis detected 350 
showed additional risk of severe disease, again without statistical significance. It is of 351 
note that the three organisms independently associated with B. pertussis are associated 352 
with ‘atypical’ or interstitial pneumonia which commonly presents with impaired 353 
oxygenation. There was no difference in mortality (study registered no deaths) and 354 
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length of hospital stay. 355 
 356 
There is evidence associating B. pertussis with pneumonia in children. [4] Although 357 
the first vaccine specifically targeting pneumonia was only introduced with the 358 
registration of a vaccine against Haemophilus influenzae b in 1985, the decline in 359 
pneumonia-associated mortality in the United States was noted three decades 360 
earlier.[27] This decline can not be fully explained by the improvement in quality of 361 
health care alone, and may in part be explained by the rapid decline in reported 362 
pertussis cases following the introduction of DPT in the 1940s. The decline in 363 
pneumonia-associated mortality mirrors that of pertussis over the period. 364 
 365 
Due to the small sample size, our study was limited both in exploring the effect of 366 
other factors such as HIV infection and in its ability to establish strong evidence for 367 
some associations, even where patterns suggested a correlation. In some instances, in 368 
which strong association was demonstrated, the precision of the estimated risk was 369 
low due to the same limited sample size. In addition, the study is limited only to the 370 
organisms included in the multiplex PCR, noting also that distinguishing between 371 
benign colonisation and pathological infection from PCR detection of an organism in 372 
the respiratory tract remains a challenge. [3] As such these findings must be 373 
interpreted with caution. 374 
 375 
Further well powered studies or creative metanalytical systematic reviews are 376 
required, to study this phenomenon further.  377 
 378 
Partial and waning immunity, especially in individuals vaccinated with acellular 379 
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pertussis (aP) vaccines, has been shown to lead to pertussis not presenting in a 380 
classical manner.[28-30] This atypical nature of presentation may lead to the 381 
diagnosis being missed unless a high index of suspicion is maintained. South Africa, 382 
where this study was conducted, changed from wP to aP containing vaccines in early 383 
2009. [19]  384 
 385 
Less than 10% of children with confirmed B. pertussis in this study were clinically 386 
suspected of having possible pertussis, which highlights the need for laboratory 387 
support in the diagnosis of the disease. Where the diagnosis needs confirmation, the 388 
use of an additional IS specimen seems to improve detection rates.[4, 15]  389 
 390 
As we have shown previously, isolation of B. pertussis in this cohort of children was 391 
strongly associated with incomplete primary vaccination.[15] Improving vaccine 392 
coverage for pertussis remains the most affordable and effective tool to decrease the 393 
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Introduction: Diagnosis of pertussis is challenging especially in infants.  Most 33 
low and middle-income countries (LMIC) lack resources for laboratory confirmation, 34 
relying largely on clinical diagnosis alone for both case management and surveillance. 35 
This necessitates robust clinical case definitions. 36 
Objectives: This study assesses the accuracy of clinical case definitions with and 37 
without lymphocytosis in diagnosing pertussis in children with severe lower 38 
respiratory tract infection (LRTI) in a LMIC setting. 39 
Methods: Children hospitalised with severe LRTI in a South African hospital were 40 
prospectively enrolled and evaluated for pertussis using PCR on respiratory 41 
samples.  Clinical signs and differential white cell counts were recorded. 42 
Sensitivity and specificity of pertussis clinical diagnosis using WHO and Global 43 
Pertussis Initiative (GPI) criteria; and with addition of lymphocytosis were 44 
assessed with PCR as the reference standard.  45 
Results: 458 children <10 years were enrolled. Bordetella pertussis infection was 46 
confirmed in 32 (7.0%). For WHO criteria, sensitivity was 78.1% (95% CI 60.7– 47 
89.2%) and specificity 15.5% (95% CI 12.4 –19.3%); for GPI sensitivity was 34.4% 48 
(95% CI 20.1– 52.1) and specificity 64.8% (95% CI 60.1 – 69.2%). Area under the 49 
curve (AUC) on receiver operating character (ROC) analysis was 0.58 (95% CI 0.46-50 
0.70 for WHO criteria, and 0.72 (95% CI 0.56-0.88) for GPI with highest likelihood 51 
ratios of 5.33 and 4.42 respectively. Diagnostic accuracy was highest between five and 52 
seven days of symptoms for both criteria. Lymphocytosis had sensitivity of 31.3% 53 
(95% CI 17.5 - 49.3%) and specificity of 70.7% (95% CI 66.1-74.8%) and showed a 54 
marginal impact on improving clinical criteria. 55 
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Conclusion: Clinical criteria lack accuracy for diagnosis and surveillance of 56 
pertussis. Non-outbreak settings should consider shorter durations in clinical 57 
criteria. New recommendations still fall short of what is required for a viable 58 
clinical screening test which means the need to improve access to laboratory 59 
diagnostic support remains crucial. 60 
 61 
Introduction  62 
 63 
Pertussis has resurged globally over the last decade. Waning immunity change in 64 
primary schedule to acellular vaccines and improvement in diagnostics have been 65 
given as possible explanations. [1, 2] A large proportion of reported cases have not 66 
shown the classic presentation of a prolonged spasmodic cough with inspiratory 67 
whoop and post tussive vomiting.[3] In response, some high income countries (HICs) 68 
have modified their case definitions to suit local diagnostic and surveillance criteria; 69 
usually this includes reducing duration of cough symptoms to lower than the two 70 
weeks historically recommended as the minimum cut-off time.[4] 71 
 72 
The World Health Organization (WHO) developed criteria for clinically defining 73 
cases of pertussis. These include presence of a cough for at least 14 days 74 
characterized by one of paroxysms, inspiratory whoop or post-tussive vomiting, table 75 
1.[5] Apart from reduction by a week in the duration of cough from more than 21 76 
days, very little has changed over the last three decades in the WHO case definition of 77 
pertussis.[6] 78 
 79 
Acknowledging shortcomings of WHO clinical case definition, the Global Pertussis 80 
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Initiative (GPI), following a Roundtable discussion in 2010, recommended changes to 81 
improve diagnostic sensitivity and specificity for pertussis. In addition to clinical 82 
features found in WHO criteria, the GPI suggests adding presence of coryza, apnoea, 83 
seizures or cyanosis as well as absence of fever, and shortens duration of symptoms to 84 
7 days. GPI clinical features vary by age categories: less than four months of age, four 85 
months to nine years and 10 years and above, table 1.[4] 86 
 87 
Although culture, ELISA and direct fluorescent antigen testing can all be used to 88 
confirm pertussis, polymerase chain reaction (PCR) has gained favour as the most 89 
practical confirmatory method with an acceptable level of sensitivity and 90 
specificity.[7, 8] In contrast to HICs which have access to laboratory resources to 91 
validate clinical suspicion, most low and middle-income countries (LMICs) lack 92 
resources for laboratory confirmation, relying largely on clinical diagnosis alone.[9] It 93 
is therefore imperative to have a robust clinical definition in these settings. 94 
 95 
Pertussis is commonly associated with leukocytosis, with an increase in lymphocytes. 96 
[10] In the absence of resources for confirming pertussis, clinicians have also used 97 
Table 1: Clinical features for diagnosis of pertussis cases  
  
 
World Health Organization  Global Pertussis Initiative 
§ A case diagnosed as pertussis by a physician, OR 
 
§ Cough or illness in a person without or with only minimal fever AND: 
§ A person with a cough lasting ≥2 weeks with ≥1 
of the following: symptoms: 
 
0 – 3 months  4 months to 9 years 
 Cough and coryza PLUS any of  Paroxysmal cough PLUS any of 
     
 
   
• Paroxysms (i.e., fits) of coughing 
 
• Whoop  • Whoop 
• Inspiratory “whooping”  
 
• Apnoea  • Apnoea  
• Post-tussive vomiting (i.e., vomiting  
 
• Post-tussive emesis   • Post-tussive emesis 
         immediately after coughing) without  
 
• Cyanosis   • Worsening of symptoms at night 
                          other apparent cause 
 
• Seizure  • Seizure 
  • Pneumonia  • Pneumonia   
• Close exposure to an adolescent or 
adult (usually a family member) 
with a prolonged afebrile cough 
illness 
 • Close exposure to an adolescent or 
adult (usually a family member) with 
a prolonged afebrile cough illness 
Adapted from World Health Organization & Cherry et al (2012)[4, 5] NB. Global Pertussis Initiative criteria for individuals older than 9 years not shown 
 
138 
lymphocytosis to support a clinical diagnosis.[11] 98 
 99 
Here we investigate the sensitivity and specificity of clinical criteria recommended by 100 
WHO and GPI to diagnose pertussis with PCR as the diagnostic reference standard, in 101 
a LMIC. The analysis includes assessment of the impact of duration of symptoms on 102 
sensitivity and specificity for both sets of diagnostic criteria. Secondarily, we assess 103 
the impact of adding lymphocytosis to clinical criteria to improve diagnostic 104 
accuracy. WHO criteria were selected as they represent the reference criteria used by 105 
most countries and they also form the basis for pertussis clinical criteria adopted with 106 
some amendments by most national health administrations. The GPI was used as a 107 
comparator as it represents the most radical proposal to changes to the WHO criteria 108 
independent of national context. 109 
 110 
Materials and Methods 111 
 112 
A prospective study was conducted from September 2012 to September 2013, to 113 
investigate the incidence of pertussis in children hospitalised for severe lower 114 
respiratory tract infection (LRTI), or with apnoea, at a tertiary hospital in South 115 
Africa. Children were included if they presented with WHO defined severe LRTI or 116 
apnoea and had not been in touch with the health care services in the preceding two 117 
weeks after written informed consent was received from the parent or legal guardian. 118 
A nasopharyngeal swab and an induced sputum specimen were taken from each child 119 
and sent to the laboratory for culture and pertussis PCR.   120 
 121 
The duration and character of cough, especially presence of paroxysms, inspiratory 122 
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whoop, or post-tussive vomiting; as well as presence of apnoea, cyanosis, seizures 123 
and fever were recorded. In addition, any prior exposure to antibiotics including 124 
macrolides and cotrimoxazole were noted.  125 
 126 
A blood cell count was done including white cell count with a differential. An 127 
absolute count of more than 9000 cells/μL or 7000 cells/μL was used to define 128 
lymphocytosis in infancy or in children 12 months and older respectively, according 129 
to local laboratory guidelines. 130 
 131 
Pertussis PCR 132 
PCR targeting the IS481 common Bordetella insertion site and IS1001 for Bordetella 133 
parapertussis was done after which specimens testing positive for the former were 134 
further tested with PCR for hIS1001 to exclude Bordetella holmesii which shares the 135 
same IS481 insertion site. IS481+/ hIS1001- samples were classified as confirmed 136 
Bordetella pertussis infection. The methods and epidemiological findings of this 137 
study have been published elsewhere.[12] Only assessment of  Bordetella pertussis 138 
was included in the current analysis to allow for comparison with other studies. 139 
 140 
Analysis of data 141 
 142 
Data were analysed using STATA statistical package version 14 (StataCorp, College 143 
Street, Texas).  144 
 145 
Proportions were summarized as percentages with a 95% interval of confidence, as 146 
indicated. Age in months and duration of symptoms in days were summarized using 147 
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medians and interquartile ranges.  148 
 149 
The Wilcoxon rank sum test was used to test the difference between continuous 150 
variables while the χ2 or Fisher’s exact tests were used to compare proportions of 151 
categorical variables as appropriate. Where hypothesis testing was undertaken the P-152 
value was set at a two-tailed p<0.05 as a cut-off point of statistical significance 153 
Proportions of cases conforming to positive and negative clinical case definitions 154 
were compared with PCR, the reference standard, to respectively estimate sensitivity 155 
and specificity of using clinical signs in the diagnosis of pertussis. Clinical features, 156 
chosen to conform to WHO and GPI recommendations (Table 1), were assessed with 157 
and without taking duration of symptoms into consideration in this analysis. 158 
 159 
As our sample did not include older individuals, the analysis was restricted to children 160 
less than 10 years of age who presented with respiratory illness and underwent 161 
confirmatory diagnostic testing for pertussis.   162 
 163 
Although GPI criteria do not include duration, for comparison, both WHO and GPI 164 
criteria were additionally assessed for sensitivity and specificity at different durations 165 
of symptoms. A receiver operating character (ROC) analysis was done to determine 166 
area under the curve (AUC) with PCR as diagnostic reference standard.  Finally, the 167 
utility of adding lymphocytosis to WHO and GPI criteria was analysed. 168 
 169 
Our data allowed us to stratify analysis to reflect only two of the GPI suggested age 170 






Four hundred and fifty-eight children were enrolled with a median age of 8 (IQR 4-175 
17) months; 132 (28.8%) were younger than 4 months of age. HIV infection was 176 
confirmed in 19 (4.2%) while 92 (20.1%) were exposed to HIV in utero but tested 177 
negative for HIV infection. Forty-five children (9.8%) were classified as moderately 178 
to severely malnourished using WHO criteria. Table 2.  179 
Table 2: Baseline characteristics of study participants (N=458) 
  
 
n (%)   
PCR confirmed cases 32 (7.0) 
Lymphocytosis 135 (29.5) 
Age group  
0 - 3 months 132 (28.8) 
4 months – 9 years 372 (71.2) 
Sex  
Female 200 (43.7) 
Pertussis vaccine doses 
 
0 28 (6.1) 
1 57 (12.4) 
2 58 (12.6) 
≥ 3 308 (67.2) 
Unknown 7 (1.5) 
HIV status  
 
Infected 19 (4.1) 
Exposed uninfected 92 (20.1) 
  
Nutritional status  






PCR= polymerase chain reaction, # As per World Health Organization 
criteria of weight for age Z score less than -2 
 180 
A total of 32 (7.0%, 95% CI 4.8 – 9.7%) cases were confirmed to have Bordetella 181 
pertussis on PCR, including 13 (9.9%) of the 132 infants younger than four months 182 
and 19 (5.8%) of 326 in the older age group. One of the PCR confirmed cases was 183 
also positive on culture. Lymphocytosis was found in 135 (29.5%) of which the two 184 
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age groups had 33/132 (25.0%) and 102/326 (31.3%) respectively. Clinical features of 185 
PCR positive and negative cases were similar across age groups, table 2. Only 3 (9%) 186 
of the 32 PCR positive participants were suspected to have pertussis by the attending 187 
clinicians while 12 (2%) of the PCR negative participants were diagnosed with 188 
pertussis; P=0.079. 189 
 190 
The median duration of symptoms was 3 (IQR 2-5) days. Paroxysmal cough was 191 
reported as a presenting feature in 398 (69.9%) children; similar in confirmed 192 
pertussis cases and those with negative PCR under four months of age with 8/13 (61.5 193 
%) and 79/119 (66.4%) respectively; p=0.726. Similarly, paroxysmal cough was 194 
found in 15/19 (79.0%) participants four months to nine years old with confirmed 195 
pertussis compared to 218/326 (71.0%) with negative PCR; P=0.837. The other 196 
presenting clinical features are shown in Table 3. 197 
 198 
Table 3: Clinical presentation of children by Bordetella pertussis PCR status N=458 
 
  Clinical Feature  PCR+[n (%)]  PCR- [n (%)] P Value 
       
       n=13  n=119  
         































   Absence of fever  3(23.1)  33(27.7) 1.000         
 
     n=19  n=307  
         
































109(35.5) 0.728    





         
PCR= polymerase chain reaction 
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Of the clinical features recommended by WHO for diagnosing pertussis, presence of 199 
paroxysms had the highest sensitivity (61.5% 0 to 3 months and 78.9% 4 months to 9 200 
years, respectively) while inspiratory whoop gave the highest specificity (68.9% % 0 201 
to 3 months and 76.2% 4 months to 9 years, respectively) of any single feature on its 202 
own, figure 1. Overall, when the whole group was considered, the use of any feature 203 
suggested by WHO had sensitivity of 78.1% (95% CI 60.7– 89.2%) while GPI 204 
suggested clinical features had sensitivity of 34.4% (95% CI 20.1– 52.1%). 205 
Specificity was 15.5% (95% CI 12.4 –19.3%) and 64.8% (95% CI 60.1 – 69.2%) for 206 
WHO and GPI, respectively. Figure 1. 207 
208 
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When ROC analysis was undertaken on duration of symptoms, GPI recommended 210 
features had AUC of 0.72 (95% CI 0.56-0.88) while those suggested by WHO had 211 
AUC of 0.58 (95% CI 0.46-0.70). The AUC was greater in younger infants than in the 212 
older age group for both WHO and GPI criteria. Figure 2.  213 
 214 
Figure 2. Receiver operating characteristics (ROC) curves for duration of symptoms  215 
 216 
 217 
Specificity increased for both WHO and GPI criteria as duration of symptoms 218 
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decline in sensitivity occurred earlier and steeper when using WHO clinical criteria 220 
than when GPI criteria were utilized. Sensitivity was 12.0% and 27.3% at ³14-day 221 
duration for WHO and GPI criteria respectively, while specificity was 94.0% and 222 
90.7% respectively for WHO and GPI criteria at a similar duration cut-off.  223 
In general, sensitivity declined, and specificity increased with increase in duration of 224 
symptoms. When any symptom was considered, the highest combination of sensitivity 225 
and specificity with the use of GPI clinical features was seen between five and seven 226 
days with sensitivity ranging between 63.6% and 72.7% and specificity ranging 227 
between 62.0% and 76.7%. Criteria recommended by WHO showed their highest 228 
combination of sensitivity and specificity between three and five days duration of 229 
symptoms with sensitivity ranging between 40.0% and 72.0%, and specificity ranging 230 
between 34.3% and 69.6%. Figure 3. The highest likelihood ratio for sensitivity was 231 
seen in the young infant group. This ranged between 1.00 and 5.33 using WHO based 232 
criteria and between 0.96 and 4.42 when GPI based criteria were applied. 233 
 234 
Figure 3. Sensitivity and specificity of clinical features in the diagnosis of pertussis with 235 
changing duration  236 
  237 


























WHO= World Health Organization; GPI = Global Pertussis Initiative
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Lymphocytosis when used alone had a sensitivity of 31.3% (95% CI 17.5 -    49.3%) 238 
and a specificity of 70.7% (95% CI .66.1-74.8%) compared to PCR. The sensitivity 239 
and specificity when lymphocytosis was combined with WHO clinical criteria were 240 
36.0% (95% CI 19.6 - 56.4%) and 75.6% (95% CI 63.7- 84.8%) for the whole group, 241 
respectively; while combining GPI criteria with lymphocytosis gave sensitivity and 242 
specificity of 45.5% (95% CI 19.2 - 74.5%) and 71.4% (95% CI 65.7- 76.4%), 243 
respectively. Age stratified sensitivity and specificity of lymphocytosis when 244 
combined with WHO and GPI criteria is shown in Figure 4. 245 
 246 
Figure 4. Sensitivity and specificity of lymphocytosis in the diagnosis of pertussis 247 
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Pertussis remains difficult to diagnose clinically with certainty as demonstrated by 250 
low sensitivity and specificity using current clinical case definitions. Adding 251 
lymphocytosis had a marginal impact in improving the diagnosis of pertussis in cases 252 
preselected with the use of WHO and GPI clinical criteria. In addition, the low 253 
sensitivity was across age groups. 254 
 255 
The overall sensitivity and specificity of clinical features were generally low 256 
irrespective of whether WHO or GPI diagnostic criteria were used. Criteria 257 
recommended by WHO showed better sensitivity than those suggested by the GPI 258 
when duration of symptoms was not considered, but the latter showed better 259 
specificity. Paroxysmal cough and post-tussive vomiting as standalone clinical 260 
features, gave the best sensitivity for both sets of criteria. The highest likelihood ratios 261 
of just above five and four for WHO and GPI based criteria, respectively, are too low 262 
to make for a functional diagnostic tool for clinical practice. 263 
 264 
A systematic review conducted on the use of symptoms in the diagnosis of pertussis 265 
concluded that the presence of whooping or post-tussive vomiting could be used to 266 
make a possible diagnosis of pertussis in adults while the absence of paroxysmal 267 
cough would possibly exclude it.[13] This study concluded that post-tussive vomiting 268 
was less helpful as a clinical diagnostic test in children. However, when Cornia et al 269 
analysed the likelihood ratios of clinical features used in the same systematic review, 270 
they found all positive likelihood ratios to be less than 2, significantly lower than a 271 
threshold regarded robust enough for clinical use.[14] A similar likelihood was 272 
observed when data from other systematic reviews on sensitivity of clinical signs in 273 
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the diagnosis of pertussis were analysed.[15, 16]  274 
 275 
In our study, when duration was added to clinical features, GPI criteria had overall 276 
better diagnostic accuracy compared to WHO as indicated by the higher AUC (0.72 277 
versus 0.58). For both criteria, duration based diagnostic accuracy was better in young 278 
infants than in older infants and children (AUC 0.71 vs. 0.51 and AUC 0.74 vs. 0.68 279 
for WHO and GPI, respectively). Increase in the duration of symptoms reduced the 280 
sensitivity of clinical diagnosis in both sets of criteria, while the opposite was noted 281 
with respect to specificity. The best combinations of sensitivity and specificity (60% 282 
to 70% for both sets of criteria) were seen between five- and seven-days duration of 283 
symptoms. This suggests that suspected cases of pertussis are more likely to be 284 
correctly classified as positive or negative in children with this symptom duration. 285 
However, early diagnosis is desirable for effective treatment and to prevent 286 
transmission 287 
 288 
An Iranian study reported 95% sensitivity and 15% specificity using a 14 day cut-off 289 
with at least one WHO clinical criterion in a cohort of children and adolescents 6 to 290 
14 years of age.[17] Duration of symptoms equal to or longer than 14 days gave a 291 
specificity of 63% and sensitivity  of 93% in outbreak settings in one American 292 
study.[18] A recently published Serbian study testing diagnostic of GPI criteria in 293 
individuals older than 3 months reported sensitivity ranging between 5% and 76% in 294 
the 4 months to 9 year old group and between 2% and 73% in the older group; while 295 
for both groups specificity ranged between 50% and 100%.[19] For each clinical 296 
feature evaluated, there was an inverse relationship between sensitivity and 297 
specificity. All the studies mentioned here seem to have selected participants on the 298 
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bases of clinical criteria some of which were later tested for their sensitivity, which 299 
may explain the observed high sensitivity in some. 300 
 301 
Adding lymphocytosis to our analysis marginally improved the diagnostic sensitivity 302 
of suspected cases screened with either criteria but showed a specificity higher than 303 
70% for both. The increase in sensitivity was higher in younger infants than in older 304 
children for both WHO and GPI when lymphocytosis was added to the criteria. This 305 
suggests that although lymphocytosis may be less useful in confirming the diagnosis 306 
of pertussis, when used age stratification should be considered. Very high lymphocyte 307 
counts have been shown to predict the severity and likelihood of dying in infants with 308 
pertussis; and therefore, should best be utilized for this role in the management of 309 
pertussis rather than diagnosis.[10, 20] 310 
 311 
The difficulty involved in the diagnosis of pertussis has major implications for clinical 312 
management, infection control, surveillance and the conduct of pertussis vaccine 313 
trials. Missed diagnoses of pertussis due to low sensitivity affects both appropriate 314 
clinical intervention in the index patient and contacts as well as appropriate reporting 315 
and surveillance. In addition, low sensitivity undermines optimizing of preventive 316 
measures including immunisation. On the other hand, over diagnosis of pertussis may 317 
lead to overtreatment and inappropriate use of resources. Overall, diagnostic 318 
shortcomings have serious economic implications, particularly in poor resourced 319 
settings. Clinical and surveillance practice favours higher sensitivity at the expense of 320 
specificity, but low specificity has a huge impact on the estimated efficacy of 321 
pertussis vaccines.[6] There may be a need to develop context specific definitions of 322 
pertussis rather than attempting to come with one for all settings.   323 
 
150 
Our study was limited by a small sample size as well as the use of a single laboratory 324 
confirmation method performed at a single point in the course of the illness. As the 325 
diagnostic sensitivity of PCR is not constant throughout the course of illness, a 326 
negative result at a single point does not necessarily exclude infection with B. 327 
pertussis.[9, 21] We were also unable to assess the impact of HIV on clinical criteria 328 
as the sample size was not sufficient to make such an analysis. In addition, as our 329 
study population consisted of children with severe disease requiring hospitalisation, 330 
these findings may not be generalisable to children with less severe disease. 331 
 332 
While acknowledging the observed poor diagnostic accuracy of clinical criteria, the 333 
slight improvement observed with use of GPI criteria should encourage development 334 
of screening criteria. Screening with a high sensitivity (but acceptably low specificity) 335 
triage algorithm before laboratory testing would potentially reduce the waste of 336 
testing patients that are likely to return a negative result, while increasing the 337 
sensitivity of confirmatory PCR. Finding such screening criteria will require well-338 
designed, prospective studies specifically investigating clinical diagnosis of pertussis. 339 
Such studies should ideally employ different laboratory diagnostic methods with 340 
testing at multiple periods in the course of the illness and include appropriate controls 341 
to allow estimation of specificity. A majority of published studies exploring 342 
sensitivity and specificity of pertussis clinical diagnosis are done in participants 343 
included on clinical suspicion of pertussis. Involving only suspected cases of pertussis 344 
to assess diagnostic accuracy of the same features on which the sample was selected 345 






Ultimately, in the absence of laboratory confirmation, confident diagnosis of 350 
pertussis on clinical grounds is difficult even for experienced physicians, 351 
especially when cases do not have the classical presentation. In our study, only 9% 352 
of confirmed cases were suspected to have pertussis, substantially underestimating 353 
pertussis as a possible cause of severe respiratory illness in our cohort. There is no 354 
obvious substitute for pertussis laboratory confirmation, and more effort is needed 355 
to increase this resource in LMIC settings where most pertussis is speculated to 356 
occur.[3, 23] In the current presence of limited resources, it would seem prudent to 357 
consider using modified case definitions, such as the one suggested by the GPI.[24] It 358 
is clear that longer durations of symptoms in a number of criteria used all over the 359 
world - including the ones suggested by WHO and the Centre for Disease control - 360 
greatly undermine sensitivity.[5, 25] Due consideration must be given to abandon these 361 
in favour of shorter durations of five to seven days used in conjunction with age-362 
stratified criteria, even if this is at the expense of over-diagnosing pertussis.  363 
 364 
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Highlights and Conclusions 1 
 2 
The thesis aimed to explore the full spectrum of pertussis in children who require 3 
hospitalisation for lower respiratory tract infection (LRTI). This included descriptions 4 
of prevalence, risk factors, clinical presentation, and to describe other organism 5 
associated with pertussis. I have used primary data supported by a comprehensive 6 
literature review - both structured as part of each chapter and formally as a systematic 7 
review - to come to some unambiguous conclusions about the burden of pertussis as 8 
seen in this group of children with severe illness. 9 
The systematic review highlights the high mortality and case fatality rate in infants 10 
secondary to persistently high prevalence of pertussis in low and middle-income 11 
countries (LMIC). In addition, the systematic review is able, for the first time to 12 
provide consolidated evidence showing that both HIV exposed but uninfected 13 
children and HIV infected individuals are at a higher risk of acquiring pertussis and 14 
having worse outcomes. This is an important finding especially for countries in Sub-15 
Saharan Africa, that carry the greatest burden of HIV. 16 
Data from the systematic review is supported by the primary data that show that 17 
pertussis is quite common in South African children hospitalised with LRTI. 18 
Almost 10% of children had laboratory confirmed pertussis. The data suggests that 19 
one of the reasons for severity of disease, such that hospitalisation is required, 20 
may very well be the significant association between pertussis and bacteria and 21 
viruses that tend to cause interstitial pneumonia - a condition that is known to 22 
typically lead to hypoxaemia. 23 





not clinically recognised by the attending clinicians. This should not be too surprising 25 
as this thesis shows the futility of using clinical features to confidently diagnose 26 
pertussis. Part of the aim of this study was to try find features that would improve 27 
clinical diagnosis of pertussis. It becomes however, the conclusion of this thesis, 28 
that there is currently no obvious substitute for pertussis laboratory confirmation in 29 
non-outbreak settings. 30 
 31 
This highlights the need for laboratory support for confirming pertussis. The findings 32 
in this thesis show that laboratory confirmation can be further enhanced by testing an 33 
induced sputum in addition to a nasopharyngeal specimen; a novel finding of the 34 
thesis. Both the primary study and the systematic review concur that the only 35 
useful test in this instance is polymerase chain reaction (PCR) as culture, the 36 
supposed diagnostic gold standard, and serology, do not have the requisite 37 
sensitivity and convenience to be of practical value. 38 
In addition to confirming the increased risk of pertussis in children exposed to HIV in 39 
utero and in children with HIV infection – a finding that was novel at the time – the 40 
primary data of the thesis also shows poor nutritional status as a major risk.  Detection 41 
of Bordetella pertussis in nasopharyngeal specimens of mothers, was independently 42 
associated with a more than 10-fold increased risk of pertussis in their children.  The 43 
thesis also confirms incomplete primary vaccination and early infancy as important 44 
risk factors for pertussis. 45 
 46 
Both the primary study and the systematic review indicate an urgent need to 47 
strengthen immunisation programs to prioritise vaccination of pregnant women, 48 





In conclusion, I would like to list the recommendations of the Global Pertussis 50 
Initiative (GPI) for the African continent.[1] I got involved with the GPI as a result 51 
of this doctoral project. These recommendations mirror the conclusions and 52 
recommendations of this thesis. Table 1. 53 
 54 
Table 1. Summary of GPI recommendations for African countries 
§ Public health and laboratory-confirmed pertussis surveillance should be improved both at regional and national levels to better 
understand the pertussis burden and to help healthcare authorities and policy makers make informed decisions. 
§ More research on pertussis aetiology, disease pattern and vaccine development is needed to prevent pertussis. 
§ Pertussis vaccination coverage should be improved through education and better outreach programs in rural areas. 
§ Based on the available resources, infants and toddlers should be prioritized for vaccination followed by pregnant women and other risk groups. 
§ Better disease and treatment awareness should be advocated to help prevent pertussis. 
From Muloiwa et al. Pertussis in Africa: Findings and recommendations of the Global Pertussis Initiative (GPI)[1] 
 55 
Seventy-five years after the introduction of effective vaccination against pertussis 56 
as a public health strategy, pertussis is still with us and causing severe disease. 57 
This thesis does more than just highlight the problem, pointing also to some 58 
potential targets for public health policy to prioritise in order to reduce the disease 59 




1. Muloiwa R, Wolter N, Mupere E, Tan T, Chitkara AJ, Forsyth KD, et al. 64 
Pertussis in Africa: Findings and recommendations of the Global Pertussis 65 
Initiative (GPI). Vaccine. 2018;36(18):2385-93. Epub 2018/04/01. doi: 66 
10.1016/j.vaccine.2018.03.025.  67 
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Informed Consent form for parents and guardians 
Pertussis in children hospitalised with Lower Respiratory Tract Infection 
You and your child are invited to participate in a study on an illness called pertussis 
(whooping cough).  
Whooping cough is  common in children but may also  occur in  adults. It is caused by a 
germ.This infection may cause the child to have a severe cough. A vaccine (immunization) 
is available to prevent this infection, and your child may have been given some or all of the 
doses of the vaccine at the clinic,  
The aim of this study is to understand why some children get pertussis and to develop better 
ways of diagnosing this infection.  
All children admitted into our ward (S11) with a chest infection can participate in this study. 
You and your child may choose to participate or not. This will not affect the care that you or 
your child receives.Your child will have all the usual tests for a chest infection including, a 
chest x-ray, blood culture, HIV test (if the result is not yet known), and sputum tests for 
tuberculosis (TB) if they are needed, Your child will receive usual care whether or not you 
choose to participate in this study. 
 Study investigations 
You and  your  child  will  have  extra  tests  done  to look for the cause of the chest infection. 
These are:  
• Two samples of mucus from the nose will be taken as well as a mucus sample from
the chest. These will be sent to the laboratory to be tested for pertussis as well as
for other infections that may cause cough and chest infection.
• A small amount of blood (about a teaspoon full) will be taken from your child to store
for new tests in the future to diagnose this infection.
• You as the caregiver will have a sample of mucus taken from your nose. This will be
sent to the laboratory and stored to test for pertussis, (if your child’s specimen is
found to have pertussis).
• After two weeks, you will be contacted over the phone to see how your child and
other household members are doing.
Side Effects and Risks 
The cotton wool swabbing is a bit uncomfortable but it is not dangerous. 
Appendix A
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Benefits 
If you and your child participate in this research, your child will have the benefit of extra tests 
to look for the cause of cough and chest infection. This may improve treatment as it may 
indicate a specific treatment to be used. Should your child have pertussis other family 
members in the family will be offered treatment to protect them against this infection. 
Reimbursements 
The research will not cost you anything.You will not be given any money or gifts to take part 
in this research. 
Confidentiality 
The information that we collect from this research project will be kept confidential. Any study 
information about you and your child will have a number on it instead of a name. Only the 
researchers will know what you and your child’s number is.  
Who to Contact 
If you have any questions you may ask them now or later, even after the study has started. If 
you wish to ask questions later, you may contact any of the study staff or 
Dr Rudzani Muloiwa 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road 
Rondebosch, 7700 
Tel: 021 658 5111/5445E-mail: Rudzani.muloiwa@uct.ac.za 
This proposal has been reviewed and approved bythe Human Research Ethics 
Committee of the University of Cape Town, which is a committee whose task it is to 
make sure that research participants are protected from harm.  If you wish to find 
about more about the ethics committee, contact  
Mrs LameesEmjedi 
Research Ethics Committee 
E 52 Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone: +27 21 406 6338 
Fax: 27 21 406 6411  
Email: nosi.tsama@uct.ac.za  and shuretta.thomas@uct.ac.za 
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PART II: Certificate of Consent 
Storage of samples 
If any of the blood or mucus samples my child has provided for this research project is 
unused or leftover when the project is completed  
  I give my permission for my child’s samples to be stored and used in future 
research of any type which has been properly approved  
  I give permission for my child’s samples to be stored and used in future research 
but only for research on Pertussis.  
  I give permission for my child’s samples to be stored and used in future research 
except for research about _________________________________.  
OR   I wish my child’s samples to be destroyed immediately. 
AND 
  I want my child’s identity to be removed from my child’s samples. 
  I want my child’s identity to be kept with my child’s samples. 
I have read the foregoing information, or it has been read to me. I have had the opportunity 
to ask questions about it and any questions that I have asked have been answered to my 
satisfaction.  I consent voluntarily for my child and myself to participate in this research. 
Print Name of Parent/Guardian_______________________________________ 




A literate witness must sign (if possible, this person should be selected by the 
Parent/Guardian and should have no connection to the research team). Parents/Guardians 
who are illiterate should include their thumb-print as well.   
I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has 
given consent freely.  
Print name of witness__________________________ AND Thumbprint of Parent/Guardian 
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Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to the best 
of my ability made sure that the participant understands that the following will be done: 
1. Nasopharyngeal swabs will be done on the child and on the caregiver.
2. An induced sputum will be collected from the child.
3. Specimens will be analysed for Bordetella pertussis and other respiratory tract infections.
4. Samples may be stored for possible future analysis.
I confirm that the Parent/Guardian was given an opportunity to ask questions about the 
study, and all the questions asked by the Parent/Guardian have been answered correctly 
and to the best of my ability. I confirm that the Parent/Guardian has not been coerced into 
giving consent, and the consent has been given freely and voluntarily.  
 A copy of this information and consent form has been provided to the Parent/Guardian. 
Name of Researcher/person taking the consent       _____________________________ 






Signature removed to avoid exposure online
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 CASE REPORT FORM 
CRF Draft 1: 5 September 2012 
STUDY TITLE 
Pertussis in children hospitalised with Lower Respiratory Tract infection (LRTI) 
Study reference number: 371/2011 
CLINICAL TRIAL SITE/UNIT: Red Cross War Memorial Children’s Hospital 
Department of Paediatrics 
University of Cape Town 
Klipfontein Road 
Rondebosch, 7700 
PRINCIPAL INVESTIGATOR: Rudzani Muloiwa 
Patient’s Name Hospital sticker 
Subject Study  Number: 
I am confident that the information supplied in this case record form is complete and 
accurate data.  I confirm that the study was conducted in accordance with the protocol 
and any protocol amendments and that written informed consent was obtained prior 
to the study. 
Investigator’s Signature: 
Date of signature: 
d d m m y y y y 
Appendix C
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Parent contact details& Inclusion criteria 
Care giver's First and Middle Names:    ________________________________ 
Care giver's Last Name:        ________________________________ 
Home Address   (If different from child’s address)  
 __________________________________________ 
  __________________________________________ 
  __________________________________________ 
Home Telephone Number: ______________________ 
Work Telephone Number: ______________________ 
Cellular Telephone Number: ______________________ 
Alternate contact details 
1. Name _________________________________ Relationship __________________
Home Telephone Number:  ______________________ 
Work Telephone Number: ______________________ 
Cellular Telephone Number: ______________________ 
Inclusion Criteria Yes No* 
1 Is the subject a child aged 13 years or younger? 
2 Has the subject’s parent/legal guardian willingly given written informed consent? 
3 Has the subject been admitted for LRTI or apnoea? 
*If any inclusion criteria are ticked ‘No’ then the patient is not eligible for the study.
Exclusion Criteria Yes*  No 
1 Is child too ill to be enrolled? 
2 Has the child been admitted for more than 72 hours? 
*If any exclusion criteria are ticked ‘Yes’ then the patient is not eligible for the study.
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1. Parent Interview Form
Staff initials: __ __ __      Date completed: __ __ /__ __ / 20 __ __ 
Pertussis study number:  __ __ __ __: __ __ __ 
A. GENERAL: Complete all questions
1. Are you the primary caregiver for 
this child? 
 Yes  No 





 Father       
 Other relative 
 Other: _____________ 
3. During the first 4 months of life, how 
was your child fed?  
 Breast milk 
 Formula (never breastfed) 
 Breast milk and formula 
 Unknown 
4. If older than 4 months: how is your 
child being fed at present? (In 
addition to solids)    
 Breast milk 
 Formula 
 Unknown 
 Breast milk and formula 
 Other: ______________ 
 Not applicable 
5. What is your house made of?  Bricks 
 Tin/iron sheeting 
 Unknown 
 Mud/traditional  
 Other: ______________
6. How many people sleep in the same 
room as the child (not counting the 
child)? 
_____ people  Unknown 
7. Do you use any of the following for 
heating and/or cooking in the 





 Gas  
 Paraffin 
 Other: _____________
8. What is the main source of water in 
the household? 
 In-door tap water 
 River water 
 Other: _____________ 
 Borehole  
 Outdoor/communal tap 
 Unknown 
9. What type of toilet do you have at the 
house? 
 Flush toilet 
 Bucket system 
 Other: _____________ 
Pit latrine 
 None/ Outdoors 
 Unknown 
10. Does the person who usually cares 
for the child smoke inside the house?  Yes               No  Unknown 
11. Does anyone else smoke inside the 
house?  Yes               No  Unknown 
12. Does your child attend a nursery or 
crèche?(at least 2 other children for at 
least 4 hours per day, 3 days per week)  
 Yes               No  Unknown 
13. What is the highest level of education 
the mother has completed? 
 No School 
 Higher education 
 Unknown 
 Schooling: highest grade 
completed ___ ___  
B. MEDICAL HISTORY
14. Did your child have any of the following symptoms during the current 
illness? 
14.1 Fever  Yes  No  Unknown 
14.1.1 If yes: Duration ______ days  Unknown 
 (skip to 14.2 if No or 
Unknown) 
14.2 Cough  Yes  No  Unknown 
14.2.1 If yes: Duration ______ days  Unknown 
 (skip to 14.3 if No or 
Unknown) 
14.2.2            Night time cough  Yes  No  Unknown 
14.2.3            Paroxysms of cough  Yes  No  Unknown 
14.2.4            Whooping cough  Yes  No  Unknown 
14.2.5  Vomiting after cough  Yes  No  Unknown 
14.2.6            Facial cyanosis  Yes  No  Unknown 
14.2.7           Barking cough  Yes  No  Unknown 
14.2.8            Normal state between cough  Yes  No  Unknown 
14.3 Apnoea (stopping breathing)  Yes  No  Unknown 
14.4 Loss of weight  Yes  No  Unknown 
14.5 Fits (seizures)  Yes  No  Unknown 
14.6 Presence of any of these symptoms  Runny nose  Wheeze 
 Sneezing  None 
 Fast breathing 
 Unknown 
15.  Did you seek health care prior to this 
hospitalization? 
 Yes  No  Unknown (skip to 16 if No or 
Unknown) 
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1. Parent Interview Form – (continue) 
 
15.1  If Yes, did you go to:  Clinic  
 General practitioner 
 Traditional healer 
 Other: ______________ 
16.  Did the child receive an antibiotic 
before coming to the hospital?  
If Yes, name of antibiotic 
 Yes, oral antibiotic  Unknown  
 Yes, injection  No 
___________________  Unknown  
(skip to 17 if No or 
Unknown) 
16.1  If Yes, number of days on antibiotics?  
_____ days   Unknown 
 
 
17.  Does your child take cotrimoxazole 
(bactrim)? 
 Yes         No  Unknown 
 
(skip to 18 if No or 
Unknown) 
17.1  If Yes, for how long? _____ months or ____ weeks  Unknown 
18.  Has any one at home been coughing 
for more than two weeks? 
If yes, how many people? 
Relationship with coughing person/s 
 Yes  No  Unknown  
 






19.  Has your child been in contact with 
an adult known to have TB in the 
past 6 months? 
 Yes         No  Unknown 
 
(skip to 20 if No or 
Unknown) 
19.1 If Yes, is the person with TB 
currently on treatment? 
 Yes         No  Unknown 
 
 
20  Is your child currently receiving INH 
prophylaxis 
 Yes         No  Unknown (skip to 21 if No or 
Unknown) 
20.1 If Yes, about how long has your child 
been taking it?   
_____ months or ____ weeks 
 Unknown 
 
21 Has the child ever been admitted to 
hospital? (Before this admission) 
 Yes         No  Unknown 
 
(skip to 22 if No or 
Unknown) 
21.1 If Yes,   
21.2 How long ago was the last 
admission? 




21.3 Number of previous hospitalizations 
(not including current illness):  
 1-2          3-5 
 >5   Unknown 
       
 
21.4 Were any of these previous 
admissions for apnoea?  
 
 Yes         No  Unknown 
 
21.5 Were any of these previous 
admissions for a chest infection? 
 
 Yes         No  Unknown 
 
22  Has your child ever been diagnosed 
with one of the following chronic 
medical conditions? (before this 
admission)  
 
 TB Disease:      If yes: 
 
 Asthma 
 Heart problem 
 Pertussis/Whooping cough 
 Other lung problems 
 Cerebral palsy 
 Malnutrition 
 Kidney problem 
 Other  
 None known 
 On treatment   
 Completed treatment    








23 Did the child’s mother have an HIV 
test during pregnancy? 
 Yes  No   Unknown 
 
(skip to 24 if No 
or Unknown) 
23.1 If Yes, what was the latest result?  Positive  Negative  Unknown  
24 Has the child ever been tested for 
HIV? 
 Yes  No   Unknown 
 
(skip to end if No / 
Unknown) 
24.1 If Yes, What was the result?   Positive  Negative  Unknown (skip to end if Neg 
/ Unknown) 
25 Is the child currently receiving 
Antiretroviral Therapy (ART)? 
 Yes  No  Unknown (skip to end if No / 
Unknown) 
25.1 For how long has the child taken ART? ______  months           Unknown 
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2. RTHC / Vaccination History        
      Staff initials: __ __ __                                     Date completed: __ __ /__ __ / 20 __ __      
Pertussis study number: __ __ __ __: __ __ __ 
1.  Does the child have a road to health card 
available? 
 
 Yes (Skip to 2)      No 
 
1.1  If No, Has the child ever received any 
vaccines other than the vaccines he or she 
received at birth? 
 




Copy the following information from the card, if no RTHC available, ask person completing interview 
2.  Date of Birth (dd/mm/yy) __ __ / __ __ / 20__ __  Unknown 
2.1  If DOB unknown, enter age in months: __________  
3.  Is the child failing to thrive/crossing centiles  Yes                       No  Unsure 
4.  Birth weight ___ . ___ ___ kg  Unknown 
5.  Gestational age ___ ___ weeks  Unknown 
5.1  If gestational age unknown  Term    
 Premature (<37 weeks) 
 Unknown 
  
If the RTHC is available, please complete  No RTHC available  
6.  Vaccine  Date given (dd/mm/yyyy)   
6.1  BCG  __ __ / __ __ / 2 0 __ __    Not given  
6.2  OPV 0 __ __ / __ __ / 2 0 __ __    Not given  
  1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
  3 __ __ / __ __ / 2 0 __ __    Not given  
  4 __ __ / __ __ / 2 0 __ __    Not given  
6.3 PENTAXIM           LOCATION GIVEN -  (i.e.Health facility where the child received vaccine) 
6.3   1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
  3 __ __ / __ __ / 2 0 __ __    Not given  
  4 __ __ / __ __ / 2 0 __ __    Not given  
 OR    
 DTP/HIB 1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
  3 __ __ / __ __ / 2 0 __ __    Not given  
 DTP 4 __ __ / __ __ / 2 0 __ __    Not given  
6.4  PCV       7      13     Unknown 1 __ __ / __ __ / 2 0 __ __    Not given  
        7      13     Unknown 2 __ __ / __ __ / 2 0 __ __    Not given  
        7      13     Unknown 3 __ __ / __ __ / 2 0 __ __    Not given  
6.5  ROTAVIRUS 1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
6.6  MEASLES  1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
7.  INFLUENZA 1 __ __ / __ __ / 2 0 __ __    Not given  
  2 __ __ / __ __ / 2 0 __ __    Not given  
8.  OTHER: ______________  __ __ / __ __ / 2 0 __ __  
9.  Did the child have any of the 
following within 6 weeks before or 
after any of the vaccines in 6.3? 
 
If yes, which vaccines? Enter 1- 4 
  
 Steroid use 
 Immunoglobulin therapy 
 Other: _________________ 
_____________ 
 
 Measles  
 None  
 Unknown 
10.  Has the child received Vitamin A in 
the previous six months? 
  















3. Medical Records             
  Staff initials: __ __ __                                     Date completed: __ __ /__ __ / 20 __ __      
 
 The following questions relate to the current admission. Information should be obtained from clinical 
records or measured (e.g. weight and temperature) if not available in records. Temperature, heart rate and 
respiratory rate should be the maximum recorded within 24 hours of admission 
Pertussis study number:  __ __ __ __: __ __ __ 
1.  Sex  Male   Female 
2.  Date of admission  ___ ___ / ___ ___ / 2 0 ___ ___ (dd/mm/yyyy) 
3.  Time of admission ___ ___ : ___ ___  Am      Pm       Unknown 
4.  Race  Asian/Indian     Black      White  Coloured 
5.  Admission height/length __ __ _ , __ cm      
6.  Admission weight __ __ . __  kg          
7.  Mid upper arm circumference (MUAC) __ __  , __ cm 
8.  Head Circumference __ __  , __ cm 
9.  Temperature  __ __ . __  °C  
10.  Heart rate ___ ___ ___ beats / min    Not recorded 
11.  Respiratory rate ___ ___ ___ breaths / min    Not recorded 
12.  Oxygen saturation ___ ___ ___ %    Room air ___ ___ ___ %  On oxygen 
  Not recorded 
13.  Presence of oedema  Yes    No                    Not recorded 
14.  Did the child receive any of: 
Bronchodilators 
Antibiotics 
If Yes, name(s) of antibiotic(s) 
 
 Yes    No 
 Yes    No 
_______________________________________________ 
 
15.  HIV Stage of the child 1       2       3      4   Not Applicable 
  
16.  Lower chest wall indrawing: Yes     No      Not recorded 
17.  Crackles/crepitations Yes     No      Not recorded 
18.  Wheezing Yes     No      Not recorded 
19.  Clubbing Yes     No      Not recorded 
   Outcome Summary – to be obtained on all participants when discharged. 
20.  Did child receive supplemental oxygen Yes   No   Not recorded 
21.  Admission to a High Care unit or ICU 
 
If admitted to above, number of days 
 ICU          High Care       None           Unknown 
 
ICU days: ____     High Care days:  ____          Unknown 
22.  Assisted ventilation 
If Yes, Duration 
            Type of support 
            Number of days 
Yes      No   Not recorded 
______ days    Not recorded 
CPAP              IPPV   
_____ days               _____ days             Not recorded 
23.  Outcome of child  Discharged  Refused Hospital Treatment (RHT)  
 Died    Transferred to another hospital 
24.  Date of discharge/ death/ transfer/RHT  ___ ___ / ___ ___ / 2 0 ___ ___ (dd/mm/yyyy) 
25.  If discharged, on what treatment was 
child discharged? (mark all that apply)
  
 Antibiotics, specify:______________________________ 
 Bronchodilators         Inhaled steroids     
 Anti TB treatment   Other, specify ____________  
26.  Discharge diagnosis (mark all that 
apply)  
 Bronchopneumonia    Bronchiolitis     
 Lobar Pneumonia   Tuberculosis  
 Pertussis                            Pneumocystis pneumonia    
 Chronic lung disease  Sepsis        
 Underweight/Kwashiorkor/Marasmus  
 Not recorded                  Other, specify_____________ 
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4. Care-Giver Information             
 
  Staff initials: __ __ __                                     Date completed: __ __ /__ __ / 20 __ __      
 
 
Pertussis study number:  __ __ __ __: __ __ __ 
1.  Sex  Male   Female 
2.  Date of birth  ___ ___ / ___ ___ / 19 ___ ___ (dd/mm/yyyy) 
3.  What is your relationship to child  Mother 
 Grandparent  
 Caregiver  
 Father        
 Other relative 
 Other: _____________ 
4.  Race  Asian/Indian     Black      White  Coloured 
5.  Do you sleep in the same room as 
child?  Yes                        No 
6.  Do you smoke? 
If Yes, do you smoke inside the 
house? 
 Yes                        No (skip to next question if No) 
 Yes                        No 
 Did you experience any of these symptoms before or during the course of the child’s illness? 
7.  Fever?  Yes                        No                       Unknown 
8.  Wheezing?  Yes                        No                       Unknown 
9.  Runny or congested nose?  Yes                        No                       Unknown 
10.  Cough? 
 
If Yes, duration? 
 Yes                        No                       Unknown 
                                             (skip to 11 if No or Unknown) 
_____ days  _____ weeks  ____  months            Unknown 
10.1            Night time cough  Yes  No  Unknown 
10.2            Paroxysms of cough  Yes  No  Unknown 
10.3            Whooping cough  Yes  No  Unknown 
10.4            Vomiting after cough  Yes  No  Unknown 
10.5            Barking cough  Yes  No  Unknown 
10.6            Normal state between cough  Yes  No  Unknown 
10.7 Did you receive any of the following: 
Bronchodilators 
Antibiotics 
              If Yes, Name of antibiotic 
 
 Yes    No 
 Yes    No 
_________________________________ 
 
11.  Have you ever been diagnosed with 
one of the following chronic medical 
conditions?  
 TB Disease:                   If yes:     On treatment   
                                                           Completed 
treatment    
                                                           Defaulted  
 Asthma 
 Other lung problems 
 Pertussis/Whooping cough 
 Heart problems 
 None 
 Other, Specify _________________________ 
12.  Have you ever had an HIV test?  Yes        No                 (skip to end if No) 
13.  If Yes, what was the result of the latest 
test? 
 Positive  Negative        (skip to end if Negative) 
14.  Are you currently receiving 
Antiretroviral Therapy (ART)?  
 Yes  No                  (skip to 14.2 if No) 
14.1 If Yes, how long have you received it? __________  months 
14.2 Most recent CD4 count 
Date __ __ / __ __ / 20 __ __ 
______           Unknown 
14.3 Most recent viral load 
Date __ __ / __ __ / 20 __ __ 
______           Unknown   
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5. Investigations & Results Form      
Staff initials: __ __ __                                     Date completed: __ __ / __ __ / 2 0 __ __      
Pertussis study number: __ __ __ __: __ __ __ 
 Questions 1 and 2 to be completed for all participants 
1.  HIV testing               Not done (skip to 2) 
 Test Date of test Result 
1.1   ELISA – child __ __ / __ __ / 2 0 __ __  Reactive  Non reactive 
1.2   ELISA - mother __ __ / __ __ / 2 0 __ __  Reactive  Non reactive 
1.3   PCR - child __ __ / __ __ / 2 0 __ __  Positive   Negative 
1.4   Most recent CD4 count - child  __ __ / __ __ / 2 0 __ __ __ __ __ __  Absolute CD4 
__ __.__  % of lymphocytes 
1.5   Most recent viral load - child: __ __ / __ __ / 2 0 __ __ __ __ __ __ __ __ copies/ml 
 >750 000 
2.  Micro/Virology results -  Obtained in the first 48 hours of admission       Not done (skip to 3) 
 Lab number Date of test Site Organism 
2.1   __ __ / __ __ / 2 0 __ __   
2.2   __ __ / __ __ / 2 0 __ __   
2.3   __ __ / __ __ / 2 0 __ __   
2.4   __ __ / __ __ / 2 0 __ __   
  
  
3.  CRP (C-reactive protein) (<72 hrs of admission)                        Not done  (skip to 4) 
 Date __ __ / __ __ / 2 0 __ __ Time__ __ : __ __     Am  Pm  
 Not recorded 
Result___ ___ ___  mg/l 
 
3.1  Haematology Result  
3.1 Haemoglobin   ___________  
3.2 Platelets   ___________  
3.3 White cell count   ___________ (Total)  
4. Differential count Lymphocytes     Absolute  ______  Percentage ______ 
4.1   Neutrophils        Absolute  ______ Percentage ______ 
4.2   Monocytes         Absolute  ______ Percentage ______ 
4.3   Bands                 Absolute  ______ Percentage ______ 
4.4   Other                  Absolute  ______ Percentage ______ 
5.  STUDY SPECIMENS TAKEN 
 
Date __ __ / __ __ / 2 0 __ __ 
 
 NP Swab for culture       NP Swab for PCR (Child) 
 Induced sputum              NP Swab for PCR (Care-Giver) 
6.  TB Results        Not done (skip to 6) 
 Date Specimen Result –AFB smear Culture requested 
6.1 __ __ / __ __ / 2 0 __ __  Induced sputum 
 Gastric Washings 
 Not recorded 
  Positive  
  Negative 
 
 Yes   
 No     
7. Other (skip to 8 if not done) 
 Test Date of test Result 
7.1  Albumin __ __ / __ __ / 2 0 __ __ ___ ___ . ___ g/dL 
7.2  Total protein __ __ / __ __ / 2 0 __ __ ___ ___ . ___ g/dL 
7.3  Chemistry __ __ / __ __ / 2 0 __ __ Na ____  K ____  Urea ____   Creatine ____ 
8. Radiology  
8.1  Date of chest x-ray __ __ / __ __ / 2 0 __ __ 
        
8.2  X-ray findings  Normal 
 Pleural effusion 
 Cavitations 
 Sub-optimal quality 
 Interstitial infiltrate                                             
 Consolidation or air bronchograms  
 Lobar consolidation  
 Other   _________________________  
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